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ABSTRACT 
Daniel James Crona: Identification and validation of germline variations that associate with 
overall survival in metastatic renal cell carcinoma patients treated with sorafenib 
(Under the direction of Federico Innocenti) 
 
 
Sorafenib is a potent inhibitor of multiple oncogenic, stromal and angiogenic receptor 
tyrosine kinases. Germline variants in VEGF-pathway genes and in sorafenib pharmacology 
genes might associate with prognosis and/or sorafenib efficacy in metastatic renal cell 
carcinoma (mRCC patients). A total of 295 mRCC patients from the phase III TARGET trial 
were genotyped using candidate germline variants from 56 candidate genes implicated in 
angiogenesis, sorafenib pharmacology and/or RCC prognosis/pathogenesis. Seven variants 
that significantly associated with overall survival (OS) in mRCC patients treated with 
sorafenib, and an additional two variants associated with OS in a combined analysis of both 
treatment arms.  
Statistical associations between genetic variants and outcomes in cancer studies 
should be supported with molecular mechanistic evidence of variant function to aid in 
biomarker validation. Variants identified in Aim 1 that significantly associated with OS were 
analyzed using in silico bioinformatic tools to prioritize in vitro validation assays.  Cell 
viability assays validated one non-synonymous variant in FLT-4, and dual reporter gene 
luciferase assays validated two intronic VEGFA variants in three different cell lines.  
Novel pathways and targets of sorafenib activity remain to be identified. Primary 
mouse embryonic fibroblasts (MEFs) from 32 inbred strains were profiled for sorafenib 
iv 
cytotoxicity utilizing high content imaging and simultaneous evaluation of cell health 
parameters (cell viability, membrane permeability, mitochondrial membrane potential, and 
cytochrome C release). One quantitative locus (QTL) on chromosome 9, which reached 
genome-wide significance and significantly associated with cytochrome C release, was 
identified. A total of nine genes, expressed in MEF cells at mRNA level, were present in this 
QTL. A second QTL associated with cell viability was also identified. A total of 13 candidate 
genes, expressed in MEF cells at mRNA level, were present in this QTL. In the future, 
functional validation of candidate genes under these two identified QTLs, using knockdown 
and overexpression approaches, will be conducted in MEF and human cell lines.
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CHAPTER 1: RENAL CELL CARCINOMA: 
ANGIOGENESIS, VEGF-PATHWAY INHIBITORS AND BIOMARKERS 
 
1.1 Overview 
Cancers of the kidney and renal pelvis account for approximately 2-3% of all adult 
malignancies, and have increased in overall incidence over the past few decades.  The most 
common subtype of kidney cancer arises from the renal parenchyma in the proximal tubules 
of the kidney and is classified as renal cell carcinoma (RCC). Approximately 30% of RCC 
patients will present initially with metastatic disease, and another 30% will relapse after 
surgical resection of their primary tumor. RCC responds poorly to standard cytotoxic 
chemotherapy and, prior to advent of targeted multikinase inhibitor therapies, interleukin-2 
(IL-2) and interferon-α (INF-α) were the only systemic therapies commonly used for the 
treatment of advanced or metastatic RCC (mRCC).  
However, over the past decade the treatment landscape for mRCC has changed 
dramatically due to the U.S. Food and Drug Administration (FDA) approval of multiple 
agents that target tumorigenic and angiogenic pathways. The approval of seven agents, which 
target angiogenic and/or oncogenic signaling pathways, has helped increase median survival 
time amongst mRCC patients.  Nevertheless, despite these major advancements, most 
patients experience disease progression while on treatment and mRCC is eventually their 
cause of death. 
Sorafenib is a multikinase inhibitor with potent activity against angiogenic, 
oncogenic, and stromal kinases, as well as the RAF/MEK/ERK signaling pathway, which 
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leads to inhibition of tumor proliferation and angiogenesis. Data from the pivotal phase III 
randomized, placebo-controlled, multicenter Treatment Approaches in Renal Cancer Global 
Evaluation Trial (TARGET) confirmed a significant overall survival (OS) and progression-
free survival (PFS) benefit. These data led to its U.S. FDA approval in December 2005 for 
the treatment of patients with advanced or metastatic RCC.  
 Despite the recent U.S. FDA approval of several additional multikinase inhibitors for 
the treatment of mRCC, there is a clear unmet need to identify and validate prognostic and 
predictive biomarkers that associate with improved survival. Because anti-angiogenic 
multikinase inhibitors target, in addition to the tumor itself, non-malignant endothelial cells 
and tumor microenvironment, germline DNA variations likely affect the treatment efficacy 
and/or toxicity profiles of these drugs. In addition, because RCC is a highly vascularized 
tumor type and considerable interindividual variability in response to sorafenib is observed 
clinically, identification and validation of germline genetic variants that associate with 
sorafenib response may help determine which patients should be treated with sorafenib. In a 
crowded landscape of targeted agents for the treatment of mRCC, identification of predictive 
pharmacogenetic variants could certainly impact clinician treatment decisions and improve 
patient outcomes.  
 Additionally, the identification of novel prognostic markers may provide insight into 
RCC pathogenesis/prognosis, or identify patients who would benefit from more intensive 
therapies and/or monitoring. Germline single-nucleotide polymorphisms (SNPs) in 
angiogenesis pathway genes have associated with patient outcome in numerous tumor types, 
but the results are often inconsistent across studies and rarely validated. Furthermore, 
previous candidate gene pharmacogenetic studies of oral multikinase inhibitors have each 
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only interrogated a small number of candidate genes or SNPs. Moreover, for the variants 
identified in these studies, little information regarding their effects on angiogenesis, at the 
molecular and cellular level, is available.  
 This research stems from the hypothesis that germline genetic variants in mRCC 
patients will help explain the interindividual differences in sorafenib response and patient 
survival. This hypothesis will be addressed through three aims, described in detail below. 
The overall goal of this dissertation research is to identify and validate predictive germline 
genetic markers of sorafenib efficacy, and prognostic germline genetic markers that associate 
with RCC pathogenesis and/or prognosis. 
 
1.2 Renal Cell Carcinoma 
Cancers of the kidney and renal pelvis account for approximately 2-3% of all adult 
tumors, and the overall incidence has increased over the past few decades.1,2 Renal cell 
carcinomas (RCC) arise from the epithelia that lines the renal tubules, and at least 85-90% of 
all malignancies arising in the kidney and renal pelvis can be classified as RCC.3 The most 
common histological subtype of RCC is clear-cell RCC (70-80% of all cases of RCC).4-6 
Clear-cell RCC often presents as a single solid tumor located at the periphery of the renal 
parenchyma, and is defined by its optically clear cytoplasm, with nested clusters of cells 
surrounded by a dense endothelial network.7,8  
Worldwide, RCC is the ninth most common type of cancer, with an estimated 
incidence of approximately 337,860 newly diagnosed cases and approximately 143,406 
deaths in 2012.9 In the U.S., RCC is the seventh most common cancer among men, and ninth 
most common cancer among women. It constitutes approximately 3.9% of all new cancers, 
with a median age of 64 years at diagnosis.10 The American Cancer Society estimated that 
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approximately 63,920 new RCC cases were diagnosed, and 13,860 deaths (8,900 men and 
4,960 women) occurred due to RCC in the U.S. in 2014.1  
Median overall survival rates for RCC have improved over the past two decades, 
which could be attributed to improved screening and early detection of smaller tumors, the 
use of cytoreductive nephrectomy prior to the use of systemic therapy in advanced disease, 
and/or the U.S. FDA approval of multiple agents that target angiogenic and oncogenic 
signaling pathways. The 5-year and 10-year relative survival rates for kidney cancer are 72% 
and 62%, respectively. A majority of RCC cases are diagnosed at an early stage when disease 
is localized (64%), and the 5-year relative survival rate for these patients is 92%. Overall, the 
5-year survival for all patients with RCC is 74%, and as high as 96% when patients present 
with stage I disease.11,12 However, approximately 30% of RCC patients will present initially 
with metastatic disease, and an additional 30-50% of RCC patients, initially thought to be 
curable through nephrectomy, will relapse.13-16 The median survival time for patients with 
metastatic disease is 10-12 months,17 the 5-year survival rate for these patients is 
approximately 23%, and the 10-year survival is only 12.3%.2,10,12 
 
1.3 Renal Cell Carcinoma and Angiogenesis 
RCC arises from a series of mutations and selection events in cells of the proximal 
tubules of the nephron. These events ultimately result in the formation of cells that possess 
characteristics that are consistent with the hallmarks of cancer: unregulated cellular 
proliferation, growth in a hypoxic environment, recruitment of pro-angiogenic factors, 
evasion of anti-apoptotic signaling, invasion of basement membrane, and ultimately distant 
metastases.18  
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A seminal event in the pathogenesis of clear-cell RCC is loss of function of the von 
Hippel-Lindau (VHL) tumor suppressor gene. VHL was identified in 1993,19 contains three 
exons, and is located on the short arm of chromosome 3 (3p25). Germline inheritance of 
mutated or deleted VHL alleles is the primary etiology for inherited clear-cell RCC.  In 
addition, at least 75% of sporadic clear-cell RCC cases also occur as a consequence of 
aberrant VHL function.18-21 Indeed, biallelic gene inactivation of VHL is a hallmark event that 
promotes clear-cell RCC tumor development, and it classically conforms to the Knudson 2-
hit carcinogenesis model in cases of sporadic clear-cell RCC.22 A deletion of one VHL allele 
results in a loss of heterozygosity in more than 90% of cases of sporadic clear-cell RCC.23 
Subsequently, the second allele can be inactivated through additional gene mutations,24 or 
through gene silencing secondary to hypermethylation.25,26 In contrast to inherited clear-cell 
RCC, both the first and second “hits” occur as a result of somatic mutations, rather than 
germline mutations.20 
VHL is an upstream mediator of a family of transcription factors, known as hypoxia 
inducible factors. Under normoxic conditions, VHL marks hypoxia inducible factor-1α (HIF-
1α) for ubiquitination and proteasomal degradation.27 Ultimately, dysfunctional VHL protein 
prevents HIF-1α degradation, which allows HIF-1α to translocate into the nucleus to 
facilitate transcription of pro-angiogenic and mitogenic factors (including vascular 
endothelial growth factor [VEGF], transforming growth factor beta [TGF-β], and platelet 
derived growth factor [PDGF]). RCC is often associated with up-regulated activity of distal 
HIF-1α effectors (VEGFA, VEGFRs, TGF-β [and its receptor, EGFR], PDGF, and PDGFRs) 
and the RAF/MEK/ERK signaling pathway (Figure 1.1).18,28,29 Because angiogenesis is so 
central to the pathophysiology of RCC, there is clear rationale for administering multikinase 
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inhibitors that target distal HIF-1α effectors, primarily pro-angiogenic effectors in the VEGF-
pathway, to patients with mRCC.  
 
1.4 The Treatment of Advanced or Metastatic Renal Cell Carcinoma 
RCC responds poorly to traditional cytotoxic chemotherapy. While multiple agents 
(e.g. gemcitabine, vinblastine, and 5-fluorouracil) have been tested in patients with mRCC, 
response rates are extremely poor (4% to 6%).3,30 One main mechanism of resistance to 
traditional chemotherapy could be related to the expression of MDR1, which encodes for the 
P-glycoprotein (Pgp) drug efflux transporter, in the proximal tubules of the kidney.3 Prior to 
2005, pharmacotherapeutic options for mRCC patients were limited to immunotherapies (IL-
2 and INF-α). However, IL-2 and/or INF-α are highly toxic to patients, only a subset of RCC 
patients adequately respond to these therapies,31 and prognosis for patients with mRCC 
receiving immunotherapy was poor with less than 10% achieving durable and complete 
remissions.5 
Over the past decade the treatment landscape for mRCC has changed dramatically 
due to the U.S. FDA approval of multiple agents that target tumorigenic and angiogenic 
pathways. The approval of seven agents (Figure 1.2), which target angiogenic and/or 
oncogenic signaling pathways (notably, inhibitors of the VEGF-pathway and the mammalian 
target of rapamycin [mTOR] pathway) based on the pathophysiology of the disease (Figure 
1.1), has helped increase median survival time amongst mRCC patients.2,32-38 
Ultimately, 5-year survival rates for RCC patients with advanced disease have 
improved from 7.3% during 1992-1995 to 12.3% during 2004-2010,2 which is likely to be at 
least partially attributable to the approval of multiple oral multikinase inhibitors that all have 
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a positive impact on patient overall survival. Nevertheless, despite these major 
advancements, most patients experience disease progression while on treatment and mRCC is 
eventually their cause of death.7  In 2014, it was estimated that over 13,000 patients in the 
U.S. died from RCC,2 and these statistics highlight the need for mRCC treatment 
optimization.   
 
1.5 Sorafenib  
Sorafenib tosylate (Nexavar; Bayer HealthCare Pharmaceuticals Corporation, Wayne, 
NJ; Onyx Pharmaceuticals, South San Francisco, CA) is an orally administered biaryl urea 
agent that is also a potent multikinase inhibitor. The chemical name of sorafenib is 4-[4-[[4-
chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-
carboxamide (Figure 1.3).  It has a broad spectrum of activity in angiogenic, oncogenic, and 
stromal kinases, as well as the RAF/MEK/ERK signaling pathway. Sorafenib was originally 
developed as a RAF kinase inhibitor, but was subsequently shown to effectively inhibit 
VEGFR-1, -2 and -3, PDGFR-β, FMS-like tyrosine kinase-3 (FLT-3), fibroblast growth 
factor receptor-1 (FGFR-1), RAF-1, BRAF (wild-type and mutant BRAFV600E), and c-KIT 
(cellular homolog of the feline sarcoma viral oncogene v-kit) receptor tyrosine kinases in 
multiple tumor cell lines (Table 1.1).39-42 Sorafenib also exhibited broad-spectrum, dose-
dependent inhibitory activity in multiple mouse xenograft models, including: breast, colon, 
lung, thyroid, and kidney tumors, as well as melanoma.39,41 The anti-proliferative effects of 
sorafenib are largely dependent on the inhibition of oncogenic signaling pathways that 
regulate tumor proliferation.41 Sorafenib has also been shown to induce apoptosis in 
numerous cell lines.41 While the mechanisms underlying its pro-apoptotic effects are not well 
understood, one proposed hypothesis revolves around sorafenib’s ability to inhibit 
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phosphorylation of initiation factor eIF4E combined with the loss of the anti-apoptotic 
myeloid leukemia-1 (MCL-1) protein.43 Dynamic contrast-enhanced magnetic resonance 
imaging (MRI) in RCC patients revealed that sorafenib also significantly altered vascular 
permeability and tumor perfusion.44 
 Data from four dose-escalation phase I trials revealed that sorafenib was relatively 
safe at its maximum tolerated dose (MTD) of 400 mg twice daily (BID).45-48 However, there 
was also a high degree of interpatient variability in the sorafenib pharmacokinetic profile for 
patients enrolled on these trials. The mean elimination half-life of sorafenib is approximately 
25–48 hours. Multiple dosing at the MTD for seven days resulted in sorafenib accumulation 
levels 2.5- to 7-fold higher than when a single dose was administered.40,47 Steady-state 
concentrations of sorafenib were reached after seven days of dosing, and no additional 
accumulation observed after steady-state was reached.48 In the non-continuous trials, the 
mean peak plasma concentration (Cmax) and area under the concentration–time curve (AUC) 
values were substantially greater on the last day than they were after sorafenib administration 
on the first day.49 And, at 200 mg BID and at the MTD of 400 mg BID, the interpatient 
variability (%CV) in sorafenib exposure (measured by its AUC) ranged from 5 to 83%, and 
from 33 to 88% for sorafenib Cmax.49,50 Fortunately, even with this wide interpatient 
variability in sorafenib pharmacokinetics, there was not an observed association between 
increased sorafenib exposure and increased toxicities (notably: fatigue, diarrhea and 
dermatologic toxicities).49  
Sorafenib metabolism is mediated through two parallel pathways: pyridine N-oxide 
oxidation catalyzed by cytochrome P450 (CYP) 3A4, and through glucuronide conjugation 
by uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A9. At steady state, the most 
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prevalent circulating analyte detected in the plasma is parent sorafenib (70-85%); however, 
the main pyridine N-oxide is still detected at high levels, and has been shown to be as potent 
as the parent drug.40,51 In patients with mild or moderate hepatic dysfunction (Child Pugh A 
and Child Pugh B) who received sorafenib twice daily at the MTD, AUC values for the N-
oxide metabolite were 23-65% lower than for patients without hepatic impairment.52  
As a target of glucuronide conjugation, sorafenib is believed to undergo extensive 
enterohepatic recirculation, as evidenced by occurrence of observable double peaks in the 
concentration–time profiles among patients treated with sorafenib. This is supported by 
population pharmacokinetic modeling, which adequately described sorafenib disposition 
when accounting for enterohepatic recirculation in the model.50 Sorafenib is highly bound to 
plasma proteins (99.5%), and because of its lipophilic characteristics, it is widely distributed 
to tissues. However, recent studies have also shown that sorafenib also undergoes OCT1, 
OATP1B1, and OATP1B3-mediated active transport.53,54  
Data from a phase II randomized discontinuation trial showed that sorafenib 
significantly improved PFS in mRCC patients.55 Data from the pivotal phase III randomized, 
placebo-controlled, multicenter TARGET confirmed a significant PFS benefit, and showed a 
trend towards an OS benefit in patients with mRCC treated with sorafenib. Median PFS was 
significantly improved for patients treated with sorafenib,33 and final survival analyses 
revealed improved OS for patients treated with sorafenib.56 Based on these clinical trial data, 
the U.S. FDA approved sorafenib in December 2005 as the first anti-angiogenic multikinase 
inhibitor for the treatment of mRCC.  
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1.6 Renal Cell Carcinoma Biomarkers 
The development and approval of oral multikinase inhibitors, such as sorafenib, that 
target the angiogenesis and the VEGF-pathway have improved overall survival for many 
patients with mRCC. However, there is a significant interindividual variability when it comes 
to the benefit of these medications. And, the overall response rate, defined generally as the 
proportion of patients with reduction in tumor burden of a predefined amount, only ranged 
from 10-44% in patients that received front-line VEGF-pathway inhibitor therapy.33,36,37,57 
The identification of prognostic and predictive biomarkers is an important next step in the 
evolution of mRCC treatment, and will help clinicians prioritize the use and sequence of the 
seven targeted agents approved over the past decade.  
Prognostic biomarkers are used to evaluate phenotypes, which correlate with survival 
outcomes, independent of treatment.12,58 Clinical prognostic biomarkers have been used 
extensively to estimate RCC prognosis. The Memorial Sloan Kettering Cancer Center 
(MSKCC) risk criteria score for estimating survival has been incorporated into routine 
clinical practice, and categorizes mRCC patients into low, intermediate and high risk 
categories. The MSKCC risk score examined five prognostic factors (serum hemoglobin 
levels, corrected serum calcium levels, serum lactate dehydrogenase (LDH) levels, interval 
between diagnosis and the start of treatment, and Karnofsky performance status) in mRCC 
patients.59,60 More recently, newer prognostic models have been developed subsequent to the 
U.S. FDA approval of VEGF-targeting agents.61,62 And, additional histological, molecular 
(e.g. circulating tumor cells, serum amyloid A protein, C-reactive protein, HIF-1α, 
phosphatidylinositol-4,5-bisphosphate 3-kinase [PI3K], etc.), and more recently genetic 
biomarkers have also been investigated as measures of prognosis.12 
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Predictive biomarkers are used to predict the clinical benefit and/or response to 
medications, and can be followed throughout the course of treatment.12,58 No clinically 
validated biomarkers for RCC are utilized. However, types of predictive molecular 
biomarkers have been investigated, including: circulating biomarkers (e.g. VEGFA, 
sVEGFR2 and sVEGFR3), cytokine angiogenic factors (e.g. baseline IL-6 and elevated 
LDH), tissue-based biomarkers (e.g. VHL mutations), and factors in the mTOR pathway (e.g. 
elevated phosphor-S6 expression, and elevated phosphorylated protein kinase B [pAKT] 
expression).58 In addition, single nucleotide polymorphisms (SNPs) that associate with 
differences in pharmacokinetics/pharmacodynamics, and that associate with differences in 
survival have been postulated to be predictive biomarkers of mRCC treatments.63-68   
To date, mRCC remains incurable, despite the approval of several targeted therapies, 
and there is a clear unmet need to identify and validate markers that associate with improved 
survival. And, despite the U.S. FDA approval of multiple VEGF pathway inhibitors that have 
become the mainstay for pharmacotherapeutic treatment of mRCC, many unanswered 
questions remain regarding the choice of drug for an individual patient, the timing of and 
dose at treatment initiation, and the optimal sequencing of these agents for an individual 
patient. But, there are currently no validated molecular/genetic prognostic or predictive 
biomarkers that have been incorporated into routine clinical practice to help answer these 
questions and help clinician decision making. The identification, validation and clinical 
implementation of novel prognostic and predictive biomarkers are important towards 
optimizing mRCC therapies, and could certainly help ascertain which patients would receive 
the greatest clinical benefit from sorafenib.  
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1.7 Purpose of the Research 
Despite the recent U.S. FDA approval of several multikinase inhibitors for the 
treatment of mRCC, there is a clear unmet need to identify and validate prognostic and 
predictive markers that associate with improved survival. Because anti-angiogenic 
multikinase inhibitors target, in addition to the tumor itself, non-malignant endothelial cells 
and tumor microenvironment, germline variations likely affect the treatment efficacy and/or 
toxicity profiles of these drugs. In addition, because RCC is a highly vascularized tumor type 
and considerable interindividual variability in response to sorafenib is observed clinically, 
identification and validation of germline genetic variants that associate with sorafenib 
response may help determine which patients should be treated with sorafenib. In a crowded 
landscape of targeted agents for the treatment of mRCC, identification of predictive 
pharmacogenetic variants will certainly impact clinician treatment decisions.  
 Additionally, the identification of novel prognostic markers may provide insight into 
RCC pathogenesis/prognosis, or identify patients who would benefit from more intensive 
therapies and/or monitoring. Germline single-nucleotide polymorphisms (SNPs) in 
angiogenesis pathway genes have associated with patient outcomes in numerous tumor types, 
but the results are often inconsistent across studies and results are rarely validated. 
Furthermore, previous candidate gene pharmacogenetic studies of oral multikinase inhibitors 
have interrogated small numbers of candidate genes or SNPs. Moreover, for the variants 
identified in these studies, little information regarding their effects on angiogenesis, at the 
molecular and cellular level, is available. 
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1.8 Specific Aims 
The central hypothesis of this research is that identification and validation of germline 
genetic variants in mRCC patients will help explain the interindividual differences in 
sorafenib response and OS. This hypothesis will be addressed through three aims, described 
in detail below. The overall goal of these studies is to identify and validate predictive 
germline genetic markers of sorafenib efficacy and/or pharmacology, and prognostic 
germline genetic markers that associate with RCC pathogenesis and/or prognosis.  
 
Aim 1. To genotype candidate SNPs from 56 candidate genes, using available genomic 
DNA from TARGET patients, and test associations with OS.  
Hypothesis: Germline variants in genes related to RCC prognosis/pathogenesis, the 
angiogenesis pathway and/or sorafenib pharmacology will associate with OS in patients with 
mRCC enrolled on the phase III TARGET trial.  
Significance: The oral multikinase inhibitor sorafenib helped revolutionize the treatment of 
mRCC, but mRCC remains incurable, even for patients with stage IV disease who have been 
treated with sorafenib.69 In addition, wide interindividual variation in response to sorafenib 
clinically, coupled with the recent U.S. FDA approval of three additional oral anti-angiogenic 
multikinase inhibitors, has revealed an unmet need in the treatment of mRCC. Identification 
of predictive markers of sorafenib response may help identify a subpopulation of mRCC 
patients who will benefit most from sorafenib therapy, while identification of novel 
prognostic markers will provide clinicians and researchers with insights concerning the 
tumor biology of mRCC and identify patients that may require more intensive therapies 
and/or monitoring. 
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Rationale: Anti-angiogenic multikinase inhibitors target tumor cells, host endothelial cells, 
pericytes, and even the tumor microenvironment rather than simply targeting the tumor cell 
alone. Therefore, germline variation is likely an important determinant of drug response in 
multikinase inhibitors.70 Identification and validation of germline genetic variants that 
significantly associate with survival will help identify patients who are optimal candidates for 
sorafenib therapy.   
 
Aim 2. To validate functionality of germline variants (identified in Aim 1) that associate 
with OS in TARGET patients. 
Hypothesis: Functional validation of germline variants that significantly associate with OS 
in TARGET patients can help elucidate the molecular effects of these variants on RCC 
pathogenesis/prognosis, angiogenesis and/or sorafenib pharmacology. 
Significance: Findings from pharmacogenetic and pharmacogenomic studies (both candidate 
gene and genome wide association studies [GWAS]) continue to provide a plethora of 
information about genetic variation that underlies both disease pathology and responses to 
pharmacotherapy. However, a clear understanding of the molecular effects of candidate 
variants (selected from significant associations between genotype and clinical phenotypes) is 
often absent. Since a tagging SNP approach was employed to select SNPs for genotyping 
TARGET patient DNA, it is imperative that the causal variant(s) is identified. Therefore, it is 
important that a series of validation assays characterize the effect(s) of the variant on 
signaling pathways and/or drug response. Essential steps in the functional validation process, 
aside from genotyping and imputation, include: in silico analyses to identify and prioritize 
putatively functional variants, and in vitro validation of predicted molecular effects to 
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provide a basic explanation of the mechanistic processes that underlie the genotype-
phenotype associations. Validation of these germline variants (in the absence of, or in 
conjunction with replicative genotyping in an independent, external cohort) is essential to 
their translation into potentially useful biomarkers that will inform treatment decisions 
concerning sorafenib therapy for mRCC patients.  
Rationale: Many significant genotype-phenotype associations, derived from multikinase 
inhibitor pharmacogenetic studies, lack validation.63-68 Information regarding the molecular 
effects, which underlie disease pathogenesis and/or response to therapy, is direly needed. 
Therefore, a sequential in silico  in vitro approach to validate germline variants of interest 
(garnered from Aim 1) will be employed. Functional validation of genetic variants that reveal 
significant associations with clinical phenotypes and drug response can increase the validity 
of the observed associations.71,72 Elucidation of the molecular effects of variants will help 
translate the genotype-phenotype associations derived from pharmacogenetic studies into 
clinically useful biomarkers. 
 
Aim 3. To use in vitro cell models to discover novel candidate genes and signaling 
pathways related to sorafenib cytotoxicity 
Hypothesis: Differential cell health and response data (e.g. EC50 or IC50 values) from 32 
MEF cells lines treated with sorafenib, can be used in GWAS to identify candidate genes 
associated with sorafenib response, which will ultimately lead to the discovery of novel 
genes for future pharmacogenetic testing in patients treated with sorafenib.   
Significance: Aim 1 identified germline variants that significantly associate with OS through 
a candidate gene/candidate SNP approach. Since this approach leverages existing knowledge 
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about mRCC pathogenesis/prognosis, angiogenesis and/or sorafenib pharmacology, there is 
little chance that novel and previously unidentified signaling pathways or candidate genes 
will be discovered. This aim will use a cellular genetics approach, using high-content cellular 
imaging and genetic mapping, and will help discover novel genes and pathways involved 
with sorafenib cytotoxicity and provide a better understanding of the variability observed 
with this phenotype. 
Rationale: Previous studies have shown that GWAS mapping can be successfully performed 
in a panel of diverse inbred strains of mice to identify genetic loci that contain candidate 
genes that modulate both single gene and polygenic traits.73-76 But to date, there have been 
few examples of animal GWAS pharmacogenetics, and even those that have been published 
have not analyzed the contribution of genetics to multikinase inhibitor (e.g. sorafenib) 
cytotoxicity.77,78 The use of genetically well-characterized inbred mouse strains provides a 
viable model system to analyze the genetic basis for cytotoxicity variability.  Mouse 
embryonic fibroblasts (MEFs) from 32 inbred mouse strains are used for this high-throughput 
cellular genetics approach for four main reasons: they retain the exact genetic composition of 
the mouse strain from which they are isolated, selection of over 30 strains increases the 
likelihood of detecting genetic differences that underlie differences in sorafenib response, 
technological advances (e.g. high-content imaging) have allowed for better characterization 
of cellular phenotypes, and technological advances (e.g. siRNA loss of function and cDNA 
over-expression in vitro techniques) have allowed for functional validation of genetic loci. 
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TABLES 
Table 1.1. Sorafenib inhibits angiogenic kinases and RAF/MEK/ERK pathway 
oncogenic kinases. Table adapted from Wilhelm, et al. Cancer Res. 2004;64:7099-7109. 
Abbreviations: BRAF, v-Raf murine sarcoma viral oncogene homolog B; c-KIT, v-Kit 
Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; c-MET, MET proto-oncogene, 
receptor tyrosine kinase; CDK1, cyclin dependent kinase 1; EGFR, epidermal growth factor 
receptor, ERK, extracellular-signal-regulated kinase; FGFR-1, fibroblast growth factor 
receptor-1; FLT-3, fms-related tyrosine kinase 3; HER-2, human epidermal growth factor 
receptor 2; IC50, half maximal inhibitory concentration; IGFR, insulin growth factor receptor 
; MEK, ; mitogen-activated protein kinase kinase; PDGFR- β, platelet derived growth factor 
receptor β; PIM-1, proviral integration site 1; PKA, protein kinase A; PKB, protein kinase B; 
PKC, protein kinase C; RAF, rapidly accelerated fibrosarcoma; SD, standard deviation; 
VEGFR, vascular endothelial growth factor receptor. 
Molecular Target Biochemical Activity Sorafenib IC50 (mmol/L) ± SD 
VEGFR-1 NA 
VEGFR-2 90 ± 15 
mVEGFR-2 15 ±  6 
mVEGFR-3 20 ±  6 
RAF-1 6 ±  3 
BRAF WT 22 ±  6 
BRAFV600E 38 ±  9 
FGFR-1 580 ±  100 
mPDGFR-β 57 ±  20 
c-KIT 68 ±  21 
FLT-3 58 ±  20 
IC50 >10,000 mmol/L: ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-MET, PKB, 
PKA, CDK1/CyclinB, PKC-α, PKC-γ,  and PIM-1 
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FIGURES 
Figure 1.1. Overview of the RCC pathway with VEGF and therapeutic targets. Under 
normoxic conditions and with normal VHL function, the VHL protein is an integral part of 
the E3 ubiquitin ligase complex that marks HIF-1α for proteasomal degradation. Under 
hypoxic conditions and/or mutated VHL, HIF-1α is allowed to accumulate, which leads to 
the accumulation of HIF-1α transcription factors. HIF-1α can also accumulate secondary to 
activation of mTOR by PI3K/AKT signaling. Activated HIF-1α translocate to the nucleus 
and promotes transcription of pro-angiogenic genes, such as VEGF and PDGF. 
Transcriptional activation of these genes subsequently leads to the production of pro-
angiogenic ligands that are released and able to bind to receptors present on the surface of the 
tumor cells, as well as on the surface host endothelial cells and/or pericytes. Activation of 
these receptors leads to increased migration, proliferation, and permeability of host 
vasculature. Bevacizumab is an inhibitor of the VEGFA ligand. Axitinib, pazopanib, 
sorafenib, and sunitinib are inhibitors of VEGFRs. Everolimus and temsirolimus are 
inhibitors of mTOR. Adapted from Rini BI, et al. Lancet Oncol. 2009;373:1119-1132. 
Abbreviations: AKT (also known as PKB), protein kinase B; HIF, hypoxia-inducible factor; 
mTOR, mammalian target of rapamycin; PDGF, platelet-derived growth factor; PDGFR, 
platelet-derived growth factor receptor; PI3K, phosphoinositide-3 kinase; TGF, transforming 
growth factor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial 
growth factor receptor; VHL, von-Hippel Landau. 
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Figure 1.2.  First and second line therapy recommendations for relapsed or Stage IV 
and surgically unresectable RCC. Per NCCN kidney cancer guidelines version 3.2015 
(http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf), predictors of poor RCC 
prognosis include: lactate dehydrogenase >1.5 the upper limit of normal, hemoglobin level 
less than the lower limit of normal, corrected calcium >10.5 mg/dL (2.5 mmol/L), interval 
less than one year from original diagnosis until initiation of systemic therapy, Karnofsky 
performance score ≤70, ≥2 metastatic sites. Abbreviations: IFN, interferon; IL, interleukin; 
NCCN, National Comprehensive Cancer Network; PS, performance status RANKL, ligand 
of receptor activator of nuclear factor-κB; XRT, external radiation therapy. 
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Figure 1.3. Chemical structure of sorafenib 
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CHAPTER 2: TARGET TRIAL PATIENTS: IDENTIFICATION OF PREDICTIVE 
AND PROGNOSTIC GERMLINE VARIANTS ASSOCIATED  
WITH OVERALL SURVIVAL 
 
2.1 Overview 
Background:  
Sorafenib is a potent inhibitor of multiple oncogenic, stromal and angiogenic receptor 
tyrosine kinases. Germline variants in VEGF-pathway genes and in sorafenib pharmacology 
genes might associate with prognosis and/or sorafenib efficacy in mRCC patients. The 
primary objective of this aim was to identify novel germline genetic markers associated with 
OS in mRCC patients from the phase III TARGET trial. The secondary objective of this aim 
was to determine if the variants associated with OS also associated with PFS.   
 
Methods:  
A total of 295 mRCC patients from the phase III TARGET trial were genotyped using 
1,536 germline SNP variants from 56 candidate genes implicated in angiogenesis, sorafenib 
pharmacology and/or RCC prognosis/pathogenesis. Patients were either treated with 
sorafenib (n=155) or randomized to placebo (n=140). Directly genotyped variants were 
enriched through imputation, and imputation garnered an additional 10,097 germline variants 
(SNPs and insertions/deletions) for analyses. Germline variants were first tested for 
association with OS using the log rank test, and then in a multivariate analysis with clinical 
covariates using the Cox proportional hazards (PH) model. False discovery rate (FDR) was 
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used to correct for multiple comparisons for all variant-OS associations, from the 
multivariate model, with a p-value ≤0.05. Significant variants (p≤0.05 and q≥0.1) were then 
tested for associations with PFS using the log rank test and a multivariate Cox PH model.  
Germline variant effects are summarized using median OS, median PFS hazard ratios with 
95% confidence intervals, p-values and FDR q-values.  
 
Results: 
Genomic DNA form 295 patients enrolled on the phase III TARGET trial were used 
in this study. A total of 11,117 germline variants (1,020 directly genotyped and 10,097 
imputed variants) were used in the final analyses. The primary aim of the study was to 
determine if these variants significantly associated with OS. The secondary analysis of this 
study was to prospectively test whether variants that associated with OS also associated with 
PFS. This analysis identified five predictive variants that significantly associated with OS in 
mRCC patients treated with sorafenib (rs1885657 in VEGFA, rs3816375 in ITGAV, 
rs6719561 3’ of UGT1A9, rs8047917 in WWOX, and rs200809375 3’ of NRP-1), and an 
additional two possibly prognostic variants that associated with OS in a combined analysis of 
both treatment arms (rs307826 and rs3024987). PFS was correlated with OS among the 
genotyped patients, and five of the variants significantly associated with PFS as well. 
 
Conclusions:  
The identification of these seven variants is a key first step towards discovering and 
validating novel predictive and prognostic biomarkers to be used clinically in the treatment 
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of mRCC patients.  While these associations are novel and encouraging findings, they require 
functional laboratory validation and/or replication.  
 
2.2 Introduction 
Sorafenib tosylate (sorafenib, Nexavar®) was the first small-molecule, oral, VEGF-
pathway inhibitor approved by the U.S. FDA for the treatment of advanced and mRCC.  
Sorafenib is a potent multikinase inhibitor of numerous angiogenic, oncogenic, and stromal 
kinases. These include VEGFR2 and VEGFR3, PDGFR-β, FGFR-1, FLT-3, c-KIT, and 
genes that are part of the mitogen-activated protein kinase (MAPK) signaling cascade 
(including RAF-1 and BRAF).1-4  
The approval of sorafenib in mRCC was based upon the results from a randomized 
discontinuation phase II trial, and the phase III TARGET trial. In the phase II trial, sorafenib 
significantly improved PFS in mRCC patients (24 vs. 6 weeks; p=0.0087).5 The phase III 
TARGET trial was a double-blind randomized, placebo-controlled, multicenter study of 903 
patients with advanced RCC who had failed previous systemic cytokine therapy (Figure 2.1).  
Data from an interim analysis of this pivotal phase III trial demonstrated a significant PFS 
benefit (5.5 vs. 2.8 months; HR=0.44, 95% CI 0.35-0.55; p<0.01). Based on these data, 
patients who progressed while receiving placebo were allowed to cross-over and receive 
open-label sorafenib. At the time of the interim analysis, data also revealed a trend toward 
improved OS for patients on sorafenib (14.7 months in the placebo arm, but had not been 
reached in the sorafenib arm at the time of interim analyses; HR=0.72, 95% CI 0.54-0.94; 
p=0.02); however, this result was not significant based on an a priori selected threshold for 
significance.6 Final survival analyses, where cross-over patients censored, revealed improved 
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OS for patients treated with sorafenib (17.8 vs.14.3 months; HR=0.78, 95% CI 0.62-0.97; 
p=0.029).7 Currently, sorafenib is used in the second-line setting after progression on an 
initial first-line therapy (Figure 2.2).1,8-10 However, in select patients (e.g. patients with 
adequate organ function and performance status, or even the elderly), sorafenib can be 
utilized as a first-line option.10 Several clinical trials focused on sorafenib have revealed a 
high degree of interindividual variability in sorafenib pharmacokinetics.11-15 Considerable 
interindividual variability in response to sorafenib is also observed clinically.5-7 
The MSKCC risk score (a score comprised of serum hemoglobin levels, corrected 
serum calcium levels, serum LDH levels, interval between diagnosis and the start of 
treatment, and Karnofsky performance status) was developed to help clinicians predict 
outcomes in patients with mRCC.16-18 In the era of VEGF-targeting agents, additional 
prognostic scores have also been validated.19,20 And, studies have analyzed how baseline 
soluble protein levels also associate with outcomes in these patients.21 Studies have also 
found a correlation between circulating VEGF levels and mRCC prognosis, but results 
remain inconclusive because results have not been replicated. Plasma VEGF levels, as well 
as soluble VEGFR2 levels, have also been examined as predictive markers of treatment 
response. But again, the correlations were weak, and have not been validated.22,23 Additional 
potential predictive biomarkers, such as cytokine angiogenic factors (e.g. baseline IL-6 and 
elevated LDH), tissue-based biomarkers (e.g. VHL mutations), and factors in the mTOR 
pathway (e.g. elevated phosphor-S6 expression, and elevated pAKT expression), have also 
been investigated, but have not been validated and are not used clinically.24 
New recommendations have also begun to emerge, which are designed to help 
optimize sequencing of VEGF-pathway inhibitors, for patients likely to benefit from several 
32 
lines of treatment.10 However, currently, there are still no validated molecular biomarkers to 
provide insights into mRCC prognosis, and no validated predictive biomarkers used routinely 
in clinic to help providers identify which patients will benefit most from a specific VEGF-
pathway multikinase inhibitor (e.g. sorafenib). To date, only a small number of studies have 
been conducted that attempt to identify predictive pharmacogenetic variants, and none of 
them have been validated (e.g. in the laboratory and/or though replication). Finally, none of 
the previous pharmacogenetic studies have been conducted in a population of mRCC patients 
treated with sorafenib.25-29  
RCC is a highly vascularized malignancy, due to molecular mechanisms abrogating 
the activity of the von VHL tumor suppressor gene, resulting in increased production of key 
growth factors integral to angiogenesis, including: VEGF, PDGF, TGF-α, and FGF.30-34 
Collectively, increased growth factor production results in epithelial cell proliferation in the 
tumor microenvironment, and dysregulated angiogenic signaling that results in induction of 
tumor angiogenesis and proliferation.2,31,35,36 Sorafenib has been shown to inhibit angiogenic 
and non-angiogenic targets in multiple RCC models.37-39  
Sorafenib affects tumor vascular endothelium,40 the tumor microenvironment,41 and 
as a VEGF-pathway inhibitor it also has effects on the host vascular endothelium and 
pericytes.42,43 Because RCC is dependent on angiogenesis and the VEGF pathway, it is a 
pathway that is a viable target for pharmacotherapy.44,45 And, because angiogenesis is 
primarily a host-mediated process,46 there is excellent rationale for investigating germline 
variants as predictors of sorafenib efficacy and/or as markers with prognostic significance.  
In this study, comprehensive assessments of the common germline DNA variants in 
genes related to the sorafenib pharmacology, angiogenesis and/or RCC 
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prognosis/pathogenesis were performed. Identification of germline variants that significantly 
associate with OS should help clarify which patients will benefit most from sorafenib. The 
primary objective of this Aim was to identify germline genetic markers that associate with 
OS. The secondary objective of the study was to prospectively analyze how the variants that 
associated with OS are also related to differences in PFS.  
 
2.3 Patients, Materials and Methods 
2.3.1 Patients and the TARGET Trial 
TARGET was a multinational, double-blind, randomized, phase III trial that enrolled 
patients with unresectable or metastatic clear cell RCC, and who had received prior systemic 
cytokine therapy (n=903). Patients were randomized 1:1 to receive continuous treatment with 
either 400 mg sorafenib orally twice daily (n=451), or matched placebo (n=452). Patients 
remained on study until disease progression or discontinuation due to intolerable toxicity or 
death (Figure 1.1). Baseline characteristics for patients from the entire TARGET population 
were compared to those TARGET patients who consented for genotyping (Table 2.1). 
The primary endpoint of TARGET was OS, defined as the time from the date of 
randomization until the date of death. The OS data used in these analyses were collected 
before patients in the placebo arm were permitted to cross over to receive open-label 
sorafenib. PFS was measured from the date of randomization until the date of progression. 
Disease progression was determined based on computed tomography (CT) or MRI, clinical 
progression, or death, with the use of the Response Evaluation Criteria in Solid Tumors 
(RECIST).47 Investigators and independent radiologists who were unaware of the study-
group assignments assessed PFS.6  
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Patient DNA collected from the peripheral blood from 295 patients (n=155 on 
sorafenib and n=140 on placebo) was used for genotyping.  All patients provided written 
informed consent to participate in both the main TARGET trial and this pharmacogenetic 
study. The studies were conducted in accordance with the Declaration of Helsinki, and the 
study was approved by the institutional review board at each center.  
 
2.3.2 Gene Selection 
Fifty-six candidate genes were selected based on five main criteria. These candidate 
genes were selected because they are either important to angiogenesis, the VEGF pathway 
and the function of the host and tumor endothelium (AKT1, CRK, EPO, FGF2, FGFR1, 
FLT1,  FLT-4, FRS2, GRB2, ITGAV, ITGB5, KDR, KRAS, MAP2K4, MAP2K6, MAPK1, 
MAPK3, MAPK10, MAPK11, MAPK14, NOS3, NRAS, NRP-1, PGF, PIK3C2A, PIK3C2B, 
PIK3R5, PRKCA, PRKCE, PXLDC2, RAF1, VEGFA, and VEGFB),  are targets of sorafenib 
not directly linked with angiogenesis (KIT and RET), are associated with pericyte survival 
(PDGFRα, PDGFRβ), are related to sorafenib pharmacology and toxicity (BGLAP, CDH13, 
CYP3A4, EXPH5, PMF1, STK39, UGT1A9, and WNK1), have been associated with RCC 
pathogenesis (EGFR, EPAS1, HIF1α, TGFα, and VHL), or have been associated with 
prognosis (CA9, IL8, IL17A, IL17F, STAT3, and WWOX). 
 
2.3.3 Variant Selection 
From these candidate genes, 1,536 common germline SNP variants were selected for 
genotyping. Variant selection consisted of four step-wise procedures. First, SNP variants 
with minor allele frequency (MAF) >0.05 in European Americans, identified from data 
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obtained through a sequencing initiative of VEGF-pathway genes conducted by the National 
Heart, Lung and Blood Institute’s  DNA Resequencing and Genotyping Service 
(http://rsng.nhlbi.nih.gov/scripts/index.cfm),48 and then from data from both 1000 Genomes 
(www.1000genomes.org) and HapMapIII,(www.hapmap.org) were selected. Second, 
variants not identified in Step 1 were selected based on dbSNP 
(http://www.ncbi.nlm.nih.gov/snp) annotation that predicted functionality (e.g. the variant 
creates or is located in: stop codon, missense, frameshift, insertion/deletion, 5’ or 3’ UTR, 
and/or a 5’ or 3’ splice site). Third, variants that were not identified in Steps 1-2 were 
selected if they were known to be expression quantitative trait loci (eQTL) in lymphoblastoid 
cell lines according to the SNP and CNV Annotation (SCAN) database.49 Fourth, variants 
that were not previously identified in Steps 1-3 were selected based on already published 
variant-phenotype associations in the literature. Redundancy was minimized by excluding 
variants if they were in high linkage disequilibrium (LD) with (r2≥0.80) other identified 
variants.  
 
2.3.4 Illumina GoldenGate Genotyping 
The GoldenGate Assay (BeadArray technology) was selected as the platform on 
which to conduct the genotyping. Briefly, the GoldenGate Assay is designed for large scale 
genotyping of biallelic markers such as SNP variants, and was selected because it allows for 
a custom-built panel of 1,536 germline variants.50,51 It consists of an initial allele-specific 
extension reaction followed by polymerase chain reaction (PCR) amplification, and allows 
for a high degree of multiplexing during the extension and amplification steps. In the 
GoldenGate Assay, allele-specific primers are hybridized to genomic DNA. The ligated 
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product then undergoes PCR amplification, and the amplified PCR products are then 
captured on beads carrying complementary target sequences for the SNP variant. 
Fluorescence signals from the extension and amplification steps are then read, and clustering 
for each individual variant is displayed in a scatter plot with the signal intensity on the y-axis 
and a signal intensity ratio on the x-axis (Figure 2.3). 
Germline DNA was extracted from peripheral blood samples (FlexiGene DNA kit; 
Qiagen, Valencia, CA, USA). DNA concentrations were quantified by NanoDrop at the 
University of Chicago, and then Pico Green (Invitrogen, Carlsbad, CA) was used at the 
University of North Carolina Mammalian Genotyping Core to assess DNA quality and 
quantity. Genotypes were called using Illumina GenomeStudio software v2011. Variants 
were excluded from final analyses if there was evidence of a genotype call rate <97.5%, a 
MAF <1% across the cohort, or if they deviated from Hardy–Weinberg equilibrium (HWE; 
p<0.0001). GenTrain scores were derived from the Illumina GenomeStudio scatter plots to 
measure of variant detection reliability based on genotypic clustering distributions (Figure 
2.3).52 GenTrain scores <0.4 were removed and considered examples of poor clustering. For 
all significant variant-OS associations, clustering was manually inspected.  
 
2.3.5 Imputation Procedures 
Using the directly genotyped SNP variants genotypes at additional loci were imputed 
within a 5 Mb window of a gene center, and variants located within 25 kb of the gene 
transcription start and stop sites were retained for final analyses. Sample phasing and 
imputation were carried out using Impute2 version 2.30.53,54 Phased reference haplotypes, 
based on 1,092 individuals from the 1000 Genomes Project (http://www.1000genomes.org; 
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2010 low-coverage whole-genome and 2011 high-coverage whole-exome sequence data 
freezes), were used. Only variants with information scores >0.90 and expected MAF >0.02 
were retained. Genotypes were assigned their most likely genotype if their posterior 
probabilities ≥0.90, but were otherwise excluded to diminish the chance of type I error. 
 
2.3.6 Polymerase Chain Reaction  
Four SNP variants (rs1885657 and rs3024987 in VEGFA, rs8047917 in WWOX and 
rs307826 in FLT-4) were selected for follow-up confirmatory genotyping by TaqMan® SNP 
genotyping assays (Applied Biosystems, Foster City, CA, USA). TaqMan® assays were 
performed on two directly genotyped variants (rs1885657 and rs307826) to confirm Illumina 
Genome Studio genotyping calls, and were performed on two additional variants (rs3024987 
and rs8047917) confirm Impute2 imputation calls. Each of the TaqMan® genotyping assays 
were carried out per the manufacturer’s instruction using a CFX384 Real-Time System (Bio-
Rad, Hercules, CA, USA) and allelic discrimination results were visualized on Bio-Rad CFX 
Manager software, version 1.6 (Bio-Rad).  
For each assay, 120 ng of TARGET patient DNA were loaded onto 384-well plates 
with TaqMan® Genotyping Mastermix (Applied Biosystems, Foster City, CA, USA) 
containing VIC and FAM reporter dyes. Briefly, the VIC reporter dye is linked to the 5’ end 
of the allele 1 probe, while the FAM reporter dye is linked to the 5’ end of the allele 2 probe. 
Fluorescence signal of the two reporter dyes, generated during PCR amplification, 
distinguishes variant alleles. For rs1885657, sense 5’-GAGAGAAGCCCCTGTCACC-3’ and 
antisense 5’-GCTGTGCTTTAGCTCTCGTG-3’ primers were used. For rs307826, sense 5’-
CCTGCCTGTATCCCTGACC-3’ and antisense 5’-GGAGAGAGAGGCCATTACTGC-3’ 
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primers were used. For rs3024987, sense 5’-GTCCCCTTTCCTCCTTGG-3’ and antisense 
5’-GGAGTTGGTGAGAGCTGGAG-3’ were used. For rs8047917, sense 5’-
CTGTGGGCTTGACTTGTCC-3’ and antisense 5’-CCATCTCCATGCAGTTAAGC-3’ 
were used. The cycling conditions were: an initial 10 minute step at 95°C for AmpliTaq Gold 
enzyme activation, followed by 40 cycles that alternated between a denaturation step for 15 
seconds at 95°C and an annealing/extension step at 60°C for one minute.   
Sanger-based DNA sequencing, using 3730xl Genetic Analyzers (Applied 
Biosystems) and performed at the UNC Mammalian Genotyping Core, was used to validate 
representative samples and determine thresholds for allelic discrimination. Analysis of the 
sequencing data, to confirm PCR thresholding prior to comparison against either Illumina 
Genome Studio or Impute2 genotype calls, was performed using Sequencher software, 
version 5.1 (Gene Codes Corporation, Ann Arbor, MI, USA). Comparison of PCR and 
sequencing to either Illumina Genome Studio or Impute2 calls was performed using MS 
Excel software (Microsoft, Redmond, WA, USA).  
 
2.3.7 Statistical Analyses 
The primary objective of this Aim was to identify germline genetic markers that 
associate with OS (Figure 2.1). To do so, univariate log rank tests and a multivariate Cox PH 
model were employed for each association. First, the effects of directly genotyped and 
imputed germline variants on OS were assessed using three separate log rank tests.  The first 
was performed to analyze differences in OS by a germline variant among patients in the 
sorafenib arm only, the second was performed for the same reason but only among the 
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patients in the placebo group only, and the third was performed using both the placebo and 
sorafenib arms from TARGET.  
Second, a multivariate Cox PH model was used to analyze the genotype-phenotype 
relationships for each variant while accounting for the effects of appropriate clinical 
covariates included in the model. Country, sex, age, race, Eastern Cooperative Oncology 
Group (ECOG) PS, time since RCC diagnosis, previous systemic IL-2 or INF administration, 
MSKCC prognostic score, number of metastatic sites, evidence of spread of distant 
metastasis to liver or lung, and treatment arm (sorafenib or placebo) were all covariates that 
were considered.  First, a Chi-squared test of homogeneity was used for categorical variables 
when testing for differences in the covariate between treatment groups (country, race, ECOG 
PS, previous IL-2 or INF use, MSKCC prognostic score, and liver or lung metastases). 
Linear regression, with treatment as the independent variable, was used for quantitative 
variables (age, time since diagnosis, and number of metastatic sites). Associations between 
OS or PFS and potential covariates were then assessed using a likelihood ratio test applied to 
a Cox PH model. Third, potential covariates that remained significant (p≤0.05) after the 
previous likelihood ratio test were then tested, conditioned on one another, in a multivariate 
Cox PH model. Only variants that were conditionally significant (p≤0.05) were included in 
the final OS and PFS multivariate models. The results for these tests are provided in Tables 
2.2 and 2.3. 
All germline variant-OS associations were tested without a priori assuming any 
genetic model (i.e. did not assume an additive, dominant or recessive genetic model). FDR q-
values were generated to account for multiple testing, and to ensure that type I error was 
limited so that spurious associations could be avoided.55 FDR was employed in lieu of 
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correcting the family-wise error rate (e.g. Bonferroni correction) to account better for the 
correlation among tests induced by LD between germline variants. Variants were deemed 
significant if their multivariate model p-value was ≤0.05 and if their FDR q-value was ≤0.1.  
Correlation analyses were conducted to ascertain if a significant relationship between 
OS and PFS existed among the TARGET genotyped patients. If the assumptions of 
normalized distributions were satisfied, a Pearson product moment correlation (Pearson’s r) 
test was employed. If not, then a Spearman rank order correlation (Spearman’s rho) test was 
used. For variants considered to be significantly associated with OS (p-value ≤0.05 and q-
value ≤0.1), prospective testing was conducted to determine if there was also an association 
with PFS. As described above, univariate log rank tests were conducted followed by 
multivariate Cox PH models. Variant-PFS associations were considered significant if p-value 
≤0.05. Because these associations were exploratory in nature, a correction for multiple 
testing was not applied.  
All hazard ratios (HRs) and 95% confidence intervals (CIs) for each variant-OS and 
variant-PFS association were derived from the OS and PFS multivariate models, 
respectively. All analyses were conducted in R software,56  and confirmed using SAS 
software, version 9.2 (SAS, Cary, NC, USA). GraphPad Prism® version 5.03 (GraphPad 
Software, Inc., La Jolla, CA, USA) software was also used in analyses and in the creation of 
all figures.  
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2.4 Results 
2.4.1 Patient Characteristics 
The genotyped patients used in this study were representative of the overall TARGET 
population. Baseline characteristics for those patients who consented for genotyping were 
similar to characteristics from the overall TARGET population (Table 2.1). In addition, OS 
was similar between the two groups (Figure 2.4). In the entire TARGET population, patients 
treated with sorafenib achieved a median OS of 175 days, compared with 162 days for the 
patients administered placebo. Among the genotyped TARGET patients, those treated with 
sorafenib achieved a median OS of 190 days, compared with 178 days for the patients 
administered placebo. PFS was also similar between the two groups (Figure 2.5). In the 
entire TARGET population, patients treated with sorafenib achieved a median PFS of 123 
days, compared with 50 days for the patients administered placebo. Among the genotyped 
TARGET patients, those treated with sorafenib achieved a median PFS of 125 days, 
compared with 46 days for the patients administered placebo. These comparisons provided 
confidence that the subgroup of genotyped patients (n=295) were representative of the entire 
TARGET cohort (n=903).  
 
2.4.2 Genotyping 
The first round of GoldenGate genotyping, consisting of four total plates, was 
conducted at the University of Chicago. Among the TARGET patients who consented for 
genotyping and DNA was obtained (n=334), 68 failed the initial genotyping. Systematic 
assay error was assumed to be the reason underlying such a high failure rate because 56 of 
the 68 total failures came from plate 4 (with the remaining 12 failure divided evenly from 
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plates 1-3). As a result, a second round of GoldenGate genotyping was conducted at the 
University of North Carolina’s Mammalian Genotyping Core. Prior to the second round of 
genotyping, Pico Green was performed on all failed DNA samples and on all positive control 
DNA samples to quantify the total amount and assess the quality of the DNA. A total of 29 
additional patients (21 were form the original failed plate 4) had sufficient genotype calls and 
were included in the final analyses. Genotype calls for samples included as positive controls 
from plates 1-3 (n=7) in the second round of genotyping at the University of North Carolina 
were found to be in 100% concordance with the original genotype calls from the University 
of Chicago.  
From the original 1,536 SNP variants that were directly genotyped, 416 were 
excluded. They were excluded if there was evidence of a genotype call rate below 97.5% 
(n=209), MAF <1% (n=123), HWE p<0.0001 (n=77), a combination of failing both MAF 
and HWE criteria (n=1), and poor clustering determined by an Illumina GenTrain score <0.4 
(n=6). An additional 100 directly genotyped variants were excluded from the final analyses 
because they were not concordant between the two genotyping cores. Imputation was then 
conducted to enrich the directly genotyped variants.  After quality control pruning, a total of 
11,117 variants (1,020 directly genotyped SNP variants, and 10,097 imputed SNPs and 
insertion or deletions [indels]) were included to test associations between genotype and OS 
(Figure 2.6). 
 
2.4.3 Confirmation of Genotyping and Imputation Calls 
As an additional quality control measure, TaqMan® assays were performed on two 
directly genotyped variants (rs1885657 in VEGFA and rs307826 in FLT-4) and two imputed 
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variants (rs3024987 in VEGFA and rs8047917 in WWOX) that were significantly associated 
with differences in OS (Figure 2.7A-2.7D). These assays were performed to confirm the 
accuracy of the calls for both the directly genotyped variants performed on the Illumina 
GoldenGate Assay, and the imputed variants gained through Impute2 analyses. Results from 
these assays revealed a very high concordance between TaqMan® assays and either the 
Illumina GoldenGate Assay or Impute2 analyses. For rs1885657, there was greater than 96% 
concordance between TaqMan and Illumina GoldenGate genotyping. Among the 11 calls that 
were discordant, eight were due to failed genotyping on the TaqMan® assay (no call was 
returned). The remaining three discordant results were called homozygous wild type (WT) on 
the Illumina GoldenGate platform, but were called heterozygous by TaqMan®. For 
rs3024987, there was 99% concordance between the TaqMan® assay calls and results from 
Impute2. In this case, all three of the discordant calls were due to failed genotyping on the 
TaqMan® assay. For rs307826 and rs8047917, 100% concordance was observed. These data 
provided a high level of confidence in both the Illumina GoldenGate Assay genotyping calls 
and GenomeStudio clustering algorithm, and the Impute2 results.  
 
2.4.4 Multivariate Model Covariates 
Multiple clinical covariates that could conceivably influence OS and/or PFS were 
examined based on their potential affect variant-OS or variant-PFS associations. These 
included country, sex, age (years), race, ECOG PS, previous interleukin or interferon use, 
MSKCC prognostic score, number of metastatic sites, and evidence of spread of distant 
metastasis to liver or lung, and treatment arm (sorafenib or placebo). For OS, number of 
metastatic sites and the MSKCC prognostic risk score were included in its final multivariate 
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model (Table 2.2). For PFS, time since diagnosis and patient age were included in its final 
multivariate model (Table 2.3).  
 
2.4.5 Germline variants associated with OS 
Seven variants that associated with OS in either the patients solely from the sorafenib 
arm, or from a combined analysis of both treatment arms, were identified and deemed 
significant by an a priori established criteria (p-value ≤0.05 and FDR q≤0.1). Five germline 
variants within genes were identified. Two variants (rs1885657 and rs3024987) were in 
intronic regions of VEGFA, rs3816375 was in an intronic region in ITGAV, rs8047917 was in 
an intronic region of WWOX, and rs307826 was in a coding region of FLT-4. In addition, two 
intergenic variants (rs200809375 and rs6719561) were found to be in close proximity to 
NRP-1 and UGT1A9, respectively (Table 2.4).  
Three intragenic variants that associated with differences in OS in sorafenib-treated 
patients (rs1885657 in VEGFA, rs3816375 in ITGAV, and rs8047917 in WWOX) were 
identified. For rs1885657, patients with the TT or TC genotypes had a 17-fold decrease in 
risk of death, when compared to patients with the CC genotype (HR=17.32; 95% CI, 5.69 to 
52.73; p=1.39x 10-4; q=0.076; median OS 175 v 409 days) (Figure 2.8). For rs3816375, 
patients with the AA or AG genotype had a 6-fold decreased risk of death, when compared to 
patients with the GG genotype (HR =5.88; 95% CI, 2.11-16.39; p=4.87x10-4; q=0.051; 
median OS 281 v 409 days) (Figure 2.9). And for rs8047917, patients with the TT genotype 
had a 4-fold decreased risk of death, when compared to patients with the TA genotype 
(HR=4.06; 95% CI, 1.88 to 8.78; p=3.27x10-4; q=0.076) (Figure 2.10).  
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Two additional intergenic variants that associated with differences in OS for patients 
treated with sorafenib (SNP rs6719561 located 1.8 kB 3′ of UGT1A9 and 606 bp 5′ of 
HEATR7B1 and short indel rs200809375 located 7.5 kb 3′ of NRP-1) were identified. For 
rs6719561, patients with the CC or CT genotype had a nearly 4-fold decreased risk of death, 
when compared to those with the TT genotype (HR =3.82; 95% CI, 1.56 to 9.52; p=3.27x10-
4; q=0.076; median OS 195 v 216 days) (Figure 2.11).  For rs200809375, patients without the 
insertion had a nearly 6-fold decreased risk of death, when compared to patients with at least 
one copy of the ATG insertion (HR=6.77; 95% CI, 2.62 to 17.5; p=2.65x10-4; q=0.076; 
median OS 374 v 281 days) (Figure 2.12). 
Finally, two intragenic variants, which associated with OS in a combined analysis of 
both treatment arms (SNP rs307826 in FLT-4 and SNP rs3024987 in VEGFA), were 
identified. For rs307826, patients with the AA or AG genotypes had a nearly 14-fold 
decreased risk of death, when compared to patients with the GG genotype (HR=13.79; 95% 
CI 3.04 to 62.61; p=1.24 x 10-4; q=0.088; median OS 93 v 210 days) (Figure 2.13). For 
rs3024987, patients with the CC genotype had a 3-fold decreased risk of death when 
compared to patients with the CT genotype (HR=2.98; 95% CI, 1.66 to 5.37; p=8.80x10-4; 
q=0.088; median OS 190 vs 210 days) (Figure 2.14). Decreased median OS was observed for 
patients with the CT genotype, when compared with those with the CC genotype, in patients 
from only the sorafenib (p=0.019) and in the patients from only the placebo arm (p=0.004), 
but these results were not deemed significant based q-values ≥0.1 (q=0.301 and q=0.371, 
respectively). This variant is in moderate LD with rs1885657 (r2=0.61).  
Unless specified above, none of the variant-OS associations observed in the sorafenib 
arm were also significant (p≤0.05 and q≤0.1) in analyses when the treatment arms were 
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combined. Similarly, neither of the significant variant-OS associations observed in the 
combined arm analyses was significant in the sorafenib arm alone. Finally, no associations 
between germline variants and OS among patients from the placebo arm met the criteria for 
significance (p≤0.05 and q≤0.1).  
 
2.4.6 OS Variant Associations with PFS 
PFS was correlated with OS in non-censored patients from the entire TARGET cohort 
(Figure 2.15A; Spearman ρ=0.5083, p<0.0001), genotyped TARGET patients (Figure 2.15B; 
Pearson r=0.4681, p=0.0001), genotyped TARGET patients treated with sorafenib (Figure 
2.15C; Pearson r = 0.4778, p=0.0076), and genotyped TARGET patients treated with placebo 
(Figure 2.15D; Pearson r=0.4701, p=0.0076). 
In this secondary endpoint, variants that significantly associated with OS were 
examined prospectively to test their associations with PFS. Among the five original variants 
that associated with OS in the sorafenib arm, rs1885657, rs6719561 and rs8047917 also 
significantly associated with PFS (p≤0.05). For rs1885657, patients from the sorafenib arm 
with the TT or TC genotypes had a four-fold decreased risk of disease progression, when 
compared to patients with the CC genotype (Figure 2.16; HR=4.00, 95% CI 1.57-10.21; 
p=0.0037). For rs6719561, patients from the sorafenib arm with the CC or CT genotypes had 
a nearly two-fold decreased risk of disease progression, when compared to patients with the 
TT genotype (Figure 2.17; HR=1.94, CI 1.00-3.76; p=0.05). For rs8047917, patients from the 
sorafenib arm with the TT genotypes had a 77% decreased risk of disease progression, when 
compared to patients with the TA genotype (Figure 2.17; HR=1.77, 95% CI 1.03-3.04; 
p=0.0389). Variant rs3816375 did not significantly associate with PFS.  
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Among the two variants that associated with OS in analyses when the treatment arms 
were combined, only rs307826 significantly associated with PFS (p≤0.05). For rs307826, 
patients with the AA and AG alleles decreased risk of disease progression, when compared to 
patients with the GG genotype (Figure 2.18; HR=2.92, 95% CI 1.19-7.19; p=0.0193). Also, 
rs307826 was associated with PFS among the patients from the sorafenib arm. Sorafenib-
treated patients with the AA or AG alleles, had a nearly 9-fold decreased risk of disease 
progression (Figure 2.18; HR=8.62, 95% CI 1.98-37.04, p=0.0041). Variant rs3024987 did 
not significantly associate with PFS.  
Two variants, rs200809375 and rs3816375, did not significantly associate with PFS 
in the sorafenib arm, nor in the combined arms. Similar to OS, none of the five variants 
significantly associated with PFS in the placebo arm.  
 
2.5 Discussion 
To date, this study represents the most comprehensive sorafenib pharmacogenetic 
study in mRCC patients, and the first to associate germline variants with OS and PFS. And, 
by analyzing 11,117 variants in 56 genes, it is the most comprehensive candidate gene 
pharmacogenetic study involving any of the four VEGF-pathway inhibitors approved by the 
U.S. FDA for the treatment of mRCC (axitinib, pazopanib, sorafenib and sunitinib). A 
candidate gene-candidate variant approach was selected in this case, instead of genome-wide 
studies or next generation sequencing approaches, based on how patients were consented for 
correlative studies during the TARGET trial.  
The primary objective of this Aim was to identify germline genetic markers that 
associate with OS. The secondary objective of the study was to prospectively analyze how 
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the variants that associated with OS are also related to differences in PFS. Germline variants 
were examined in this study, and they are appropriate for pharmacogenetic studies because 
germline DNA has significant advantages over other nucleotide and protein biomarkers in 
that it is inherited, fixed, and relatively insensitive to time and environmental factors.26 And, 
because angiogenesis is primarily a host-mediated process,46 there is excellent rationale for 
investigating germline variants as predictors of sorafenib efficacy and/or as markers with 
prognostic significance. 
In the TARGET study, OS was the primary endpoint and PFS was a secondary 
endpoint. In this study, OS was also used as the phenotype for the primary objective of this 
Aim. In the TARGET trial, sorafenib was used as monotherapy, and because there were no 
U.S. FDA approved VEGF-pathway multikinase inhibitors for the treatment of mRCC prior 
to sorafenib, OS results would not be confounded by concomitant and/or subsequent 
therapies. OS still remains the gold standard endpoint in clinical trials because OS is not a 
surrogate endpoint, and improved OS demonstrates a direct clinical benefit to the patient. 
Therefore, the identification of predictive and/or prognostic biomarkers that help provide a 
direct clinical benefit to mRCC patients, and help guide provider decision-making, is of the 
utmost importance. However, PFS was used as a phenotype for the secondary objective of 
this Aim. PFS has been shown to be a credible endpoint in oncology trials,57 and can be a 
valuable surrogate endpoint for OS. With the recent U.S. FDA approval of multiple treatment 
options for patients with mRCC, a clear understanding of how each treatment impacts PFS 
(to ultimately extend OS for patients) will be crucial towards clarifying how these treatments 
are sequenced.  
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For the purposes of this Aim, it is important to distinguish between a prognostic and a 
predictive variant. Simply, a prognostic variant is one that is objectively measurable and is 
associated with clinical outcome in the absence of active therapy, or with the administration 
of standard of care or best supportive care medications. Essentially, this type of variant 
provides valuable information about the patient’s overall cancer outcome.58 The TARGET 
placebo patients provide the ideal scenario for evaluating the prognostic significance of 
germline variants in relation to OS and PFS. In this study, germline variants that exhibit 
similar OS and/or PFS effects in both treatment arms, where it is evident that there is not an 
association being driven by the effects of sorafenib, could be prognostic. Conversely, a 
predictive variant is one that is associated with response or lack of response, and provides 
information on the likely benefit of a particular therapy.58 The sorafenib-treated TARGET 
patients are ideal for analyzing the interplay between germline variants, and sorafenib 
efficacy. In this study, germline variants that associate with the effects of OS and/or PFS, 
where the effects appear to be driven by sorafenib only, could be predictive.  
VEGFA encodes for VEGFA (also known simply as VEGF), which has been shown 
to be a major driver of angiogenesis, in multiple preclinical models, through its interactions 
with VEGFR1-3.59 Previously, baseline circulating VEGFA levels were shown to be 
prognostic for mRCC OS,7 and circulating VEGF-165 (the predominant isoform) has also 
been shown to associate with tumor stage/grade and poorer prognosis.60 More recently, 
VEGF-pathway multikinase inhibitor pharmacogenetic studies have shown that VEGFA SNP 
variants (e.g. rs699947, rs833061, rs2010963, and rs3025039) associated with differences in 
OS and/or PFS for patients treated with sunitinib or pazopanib.26,61,62 In this study, rs1885657 
(not in LD with the aforementioned variants) significantly associated with sorafenib efficacy 
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in TARGET patients. For sorafenib-treated patients with the CC genotype, this SNP 
associated with significantly worse OS and PFS and could be a predictive biomarker of 
sorafenib efficacy. A plausible hypothesis to explain these associations is that since 
rs1885657 is located in an intronic region of the VEGFA, two copies of the C allele resulted 
in altered transcription factor binding that ultimately caused VEGFA overexpression. 
Ultimately, increased VEGFA expression could have led to increased transcription and 
translation of VEGFA, which increased the pro-angiogenic capability of the ligand and 
overwhelmed sorafenib’s ability to effectively inhibit angiogenesis. In turn, increased 
angiogenesis, as a result of VEGFA overexpression, could have led to a greater risk of 
disease progression and death in patients with the CC genotype. These results are certainly 
compelling; however, the dramatic effects on OS and PFS observed in the sorafenib-treated 
patients could be driven by a low number of uncensored patients with the CC genotype 
(n=5). Therefore, these results require validation in the laboratory and/or in an independent 
replication cohort of mRCC patients treated with sorafenib.  
VEGFA variant rs3024987 was also found to significantly associate with poorer OS in 
TARGET patients. When both treatment arms were combined, patients with only one copy of 
the T allele experienced significantly shorter OS. This variant is also in an intronic region in 
VEGFA, is in moderate LD with rs1885657 (r2=0.61), and also likely altered transcription 
factor binding, which led to increased VEGFA expression. This variant significantly 
associated with OS in an analysis where treatment arms were combined, and associations 
with OS were not significant (p-value ≤0.05 and q-value ≤0.1) in either the sorafenib or the 
placebo arm alone. However, there appears to be an effect in both treatment arms. The 
association between rs3024987 and OS trended towards significance in the sorafenib arm 
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(p=0.019) and the placebo arm (p=0.004), and each of the individual study arm Kaplan-
Meier plots revealed a noticeable divergence in the OS curves for patients with the CC 
genotype versus those with the CT genotype. Therefore, rs3024987 could be prognostic of 
survival in mRCC patients. 
FLT-4 encodes for VEGFR3, a transmembrane kinase receptor that has been 
traditionally linked to lymphangiogenesis.63 But, VEGFR3 is also expressed in tumor 
vasculature.64 Moreover, inhibition of VEGFR3 can suppress vascular network formation,65 
and preclinical models have suggested that VEGFR3 could possibly be more relevant than 
VEGFR2 (a primary driver of angiogenic signaling, and a main target for the VEGF-pathway 
inhibitors used to treat mRCC) for the development of metastases.66 In this study, rs307826 
was associated with decreased survival. In a combined analysis of both study arms, patients 
with the GG genotype were at higher risk for both disease progression and death. 
Interestingly, sorafenib-treated patients with the GG genotype were also at significantly 
higher risk for disease progression. Variant rs307826 results in a threonine to alanine 
substitution at position 494 (Thr494Ala), located in the fifth IgG-like domain of VEGFR3. 
Although the PolyPhen-267 and the Sorting Intolerant From Tolerant (SIFT)68 algorithms 
predict this to be a benign and non-damaging amino acid substitution, several 
pharmacogenetic studies of mRCC patients treated with VEGF-pathway multikinase 
inhibitors showed that this variant is associated with significantly shorter OS and/or 
PFS.27,28,69 A primary hypothesis to explain the effects of rs307826 on differences in OS and 
PFS is that rs307826 results in an amino acid in one of the signaling domains of the receptor, 
which is sufficient to allow VEGFR3 signaling to overcome sorafenib inhibition. Increased 
VEGFR3 signaling could perpetuate increased lymphangiogenesis and RCC spread to the 
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lymphatics, but also increase the pro-angiogenic capability of this receptor. Together, they 
could increase a patient’s risk for disease progression and/or death. 
It is unclear whether rs307826 is truly predictive of treatment response, or if it is a 
prognostic for mRCC. In each of the aforementioned studies, there were not a placebo 
control arms,27,28 or the placebo arm was not genotyped.69 And, in these studies, there were 
not a sufficient amount of GG patients to truly determine whether the variant’s effect on 
reduced OS was driven by sorafenib treatment, and therefore it is important not to over-
interpret these results. However, the results from the exploratory PFS analyses performed in 
this Aim may have helped clarify whether rs307826 could be a predictive variant. In the case 
of rs307826, replication is not as crucial since it has been associated with differences in OS 
and PFS in mRCC patients treated with oral VEGF-pathway inhibitors that inhibit many of 
the same targets as sorafenib (i.e. sunitinib and pazopanib). 
Two additional intragenic variants, found in regulatory regions of their respective 
genes, significantly associated with OS (rs3816375 in ITGAV and rs8047917 in WWOX), and 
could be predictive variants of sorafenib efficacy for mRCC patients. ITGAV encodes for 
integrin alpha-V, which is a member of the integrin superfamily. Integrin alpha-V is an 
adhesion receptor that, when dimerized to a beta subunit, mediates cell-adhesion of the 
cytoskeleton to extra cellular matrix (ECM) proteins, including: vitronectin, fibronectin, 
fibrinogen, collagen, osteopontin and thrombospondin.70 Aside from cellular adhesion, 
integrins have also been implicated in angiogenesis, proliferation and metastasis.71-73 
Although there have not been any studies linking variants in this gene to outcomes in mRCC 
or in patients treated with VEGF-pathway multikinase inhibitors, overexpression of ITGAV 
has been associated with progression, spread and poorer prognosis in patients with colorectal 
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cancer.74,75 In this study, sorafenib-treated mRCC patients with GG genotype experienced 
significantly decreased OS, which could be directly related to overexpression of ITGAV. This 
variant is also located in an intronic region, and could have an effect on transcription factor 
binding and gene expression. Overexpression of ITGAV in these patients could result in 
increased stabilization of the cytoskeleton to ECM proteins, increased angiogenesis and 
metastasis, and ultimately poorer clinical outcomes.  
WWOX encodes for WW domain-containing oxidoreductase, which has shown to be a 
tumor suppressor gene for multiple tumor types.76 WWOX variants have been shown to 
associate with increased disease susceptibility in prostate cancer, clinical staging of lung 
cancer, and decreased survival in patients with multiple myeloma.77-79 In this study, 
sorafenib-treated mRCC patients with one copy of an A allele at rs807917 experienced 
significantly decreased OS and PFS. A plausible hypothesis to explain these associations is 
that since rs8047917 is located in an intronic region of the gene, one copy of the A allele is 
sufficient to cause reduced WWOX. Therefore, sorafenib-treated patients with at least one A 
allele at rs8047917 experience less WWOX expression, and this could lead to their increased 
risk disease for progression and/or death. 
Finally, two intragenic variants significantly associated with OS (SNP rs6719561 1.8 
kb 3’ of UGT1A9 and indel rs200809375 7.5 kb 3’ of NRP-1, and are potential predictive 
variants of sorafenib efficacy for mRCC patients. UGT1A9 encodes for UGT1A9, which is 
integral to phase II metabolism and inactivation, through glucuronidation, of parent sorafenib 
and its N-oxide metabolite.80,81 Previously, pharmacogenetic variants in UGT1A9 have been 
associated with altered sorafenib pharmacokinetics and sorafenib-related toxicities.82,83 Yet, 
this is the first study where a UGT1A9 variant has been associated with differences in 
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survival in patients treated with sorafenib. In this study, mRCC patients with two copies of 
the T allele were shown to have decreased OS and PFS in these studies. One plausible 
hypothesis to explain the association could be that two copies of the T allele result in 
increased sorafenib glucuronidation, leading to decreased drug exposure. And, should 
patients be exposed to lower active drug concentrations over the duration of treatment, this 
could lead to increased risk of progression and death. However, the effects of this variant on 
OS and PFS may not be through UGT1A9. This intergenic variant is indeed in close 
proximity to UGT1A9 (~1.8 kb 3’ of the gene), it is also only approximately 600 bp 5’ of 
HEATR7B1 (also known as MROH2A).  While the function of HEATR7B1 is largely 
unknown, and there have not been any studies conducted on its relationship to sorafenib, it is 
conceivable that rs6719561’s predictive effects on OS and PFS are through this gene. Further 
investigation into this hypothesis is warranted.  
NRP-1 encodes for neuropilin-1 (one of two neuropilins), which is a membrane-
bound receptor that binds several ligands; most notably the VEGF-165 isoform of VEGFA, 
and helps mediate several signaling pathways that control angiogenesis and cell migration.84 
It has also been shown that in aggressive types of RCC, NRP-1 is overexpressed. And, in 
mouse xenograft models reduced NRP-1 levels led to the implanted RCC cells having 
reduced tumor-forming ability.85 One hypothesis for its association with OS in sorafenib-
treated mRCC patients could be that only one copy of the small ATG insertion is sufficient 
enough to cause increased NRP-1 expression. And, overexpressed NRP-1 could increase the 
pro-angiogenic and pro-migratory capabilities of mRCC. However, similar to rs6719561, 
rs200809375’s effects on OS may not be through NRP-1, and additional validation studies 
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should be conducted to determine how this germline variant influences survival in mRCC 
patients treated with sorafenib.  
Data from the studies in this Aim have demonstrated that sorafenib-treated mRCC 
patients with deleterious genotypes in these variants may experience increased angiogenic 
and/or oncogenic signaling, or increased bioinactivation of the drug. This may result in 
decreased sorafenib efficacy, and ultimately shorter time to progression and/or survival. In 
addition, two germline variants were identified that have the potential to be prognostic 
variants of mRCC survival. Clearly, validation of these results is necessary before they are 
incorporated into routine clinical practice. The first necessary step, which will be addressed 
in Aim 2, is to validate these findings in a series of laboratory experiments designed to: 1) 
confirm the functionality of the variant, and 2) provide insight into the mechanistic 
underpinnings of sorafenib response and/or RCC prognosis/pathogenesis. The relationship 
between the predictive variants identified in this study and sorafenib-induced toxicities 
experienced by patients enrolled on TARGET should also be examined. Next, in future 
studies, these results should be replicated in an independent, external cohort of mRCC 
patients treated with sorafenib. Traditionally, replication of positive findings in an external, 
independent cohort of patients has served as one of the gold standard types of validation for 
genotype-phenotype associations.86,87 And, replication studies will help to elucidate whether 
the variant-OS associations identified in this Aim, that seem to be driven by the effects of 
sorafenib, are truly predictive biomarkers. Finally, these potential biomarkers should be 
validated in a prospective clinical trial, which includes an interaction analysis design. This 
will provide the highest level of evidence for the validity of these germline variants as 
predictive and prognostic biomarkers for mRCC patients.88 
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In summary, amid a crowded landscape of targeted multikinase inhibitors recently for 
the treatment of mRCC, there is a clear unmet need to identify and validate predictive and 
prognostic pharmacogenetic germline variants as useful biomarkers to help guide provider 
treatment decisions. The identification of these seven variants is an important first step 
towards that pursuit.  
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TABLES 
Table 2.1. Patient characteristics for the entire TARGET population versus genotyped 
TARGET patients. There were no significant differences between the two populations, nor 
were there within group differences between the sorafenib arm and the placebo arm at 
baseline. Abbreviations: ECOG, Eastern Cooperative Oncology Group; MSKCC, Memorial 
Sloan Kettering Cancer Center 
All TARGET Patients (n = 903) Genotyped TARGET Patients (n = 295) 
Variable 
Sorafenib  
(n=451) 
Placebo  
(n=452) 
Variable 
Sorafenib 
 (n=155) 
Placebo 
 (n=140) 
Male Sex - no. (%) 315 (70) 340 (75) Male Sex - no. (%) 114 (74) 108 (77) 
Median Age - year 
(range) 
58 (19-86) 59 (29-84) 
Median Age - year 
(range) 
59 (19-80) 58 (31-82) 
ECOG Performance 
Status - no. (%) 
  
ECOG Performance 
Status - no. (%) 
  
0 219 (49) 210 (46)    0 83 (54) 81 (58)  
1 223 (49) 236 (52)    1 72 (46) 58 (42) 
2 7 (2) 4 (1)    2 0 0 
Number of Metastatic 
Sites - no. (%) 
  
Number of Metastatic 
Sites - no. (%) 
  
1 62 (14) 63 (14)    1 26 (17) 26 (19) 
2 131 (29) 129 (29)    2 42 (27) 40 (29) 
>2 256 (57) 258 (57)    >2 87 (56) 74 (52) 
Previous cytokine use 
- no. (%) 
374 (83) 368 (81) 
Previous cytokine use 
- no. (%) 
141 (91) 122 (88) 
Median Duration of 
Disease - year (range) 
2 (<1-19) 2 (<1-20) 
Median Duration of 
Disease - year (range) 
1.7 (<1-19.5) 1.5 (<1-16) 
MSKCC Prognostic 
Risk - no. (%) 
  
MSKCC Prognostic 
Risk - no. (%) 
  
Low  233 (52) 228 (50) Low  73 (47) 68 (49) 
Intermediate 218 (48) 223 (49) Intermediate 82 (53) 72 (51) 
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Table 2.2. Covariate selection for the OS multivariate model. For the univariate and 
multivariate Cox PH models, a likelihood ratio test was used. Abbreviations: ECOG, Eastern 
Cooperative Oncology Group; LRT = likelihood ratio test; MSKCC, Memorial Sloan 
Kettering Cancer Center; P, p-value; PH, proportional hazards; PS, performance status. 
* denotes covariates included in the final multivariate model 
Covariate Placebo-Sorafenib P Univariate Cox PH P Multivariate Cox PH P 
Sex 0.56 0.52  
Country 0.91 0.54  
Age 0.07 0.58  
Race 0.10 0.40  
ECOG PS 0.42 0.06  
Time since diagnosis 0.25 0.05 0.06 
Previous cytokine use 0.39 0.96  
MSKCC score 0.89 <0.01 0.05* 
No. of metastatic sites 0.88 <0.01 <0.01* 
Lung or liver 
metastases 
1.00 0.14  
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Table 2.3. Covariate selection for the PFS multivariate model. For the univariate and 
multivariate Cox PH models, a likelihood ratio test was used. Abbreviations: ECOG, Eastern 
Cooperative Oncology Group; MSKCC, Memorial Sloan Kettering Cancer Center; P, p-
value; PH, proportional hazards; PS, performance status. 
# >45% of the cells had expected counts less than 5 (46% for country and 60% for race). In 
these cases, the Fisher’s Exact test was used; * denotes covariates included in the final 
multivariate model.  
Covariate Placebo-Sorafenib P Univariate Cox PH P Multivariate Cox PH P 
Sex 0.48 0.95  
Country 0.75# 0.12  
Age 0.07 0.02 <0.01* 
Race 0.05# 0.06  
ECOG PS 0.42 0.77  
Time since diagnosis 0.24 <0.01 0.06 
Previous cytokine use 0.37 0.67  
MSKCC score 0.80 0.54  
No. of metastatic sites 0.85 0.09  
Lung or liver metastases 0.98 0.03 0.02* 
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Table 2.4. Significant variants associated with OS in TARGET patients. Seven total 
variants (five variants in four genes and two intergenic variants) significantly associated with 
OS by both p-value (p<0.05) and FDR q-value (q<0.1). Five variants associated with OS in 
patients from the sorafenib arm, while two variants associated with OS when both treatment 
arms were combined. Variants are listed in descending order, from smallest to largest, by p-
value. No variants were significant by p-value and after FDR correction in patients from the 
placebo arm. Alt, Alternate; Chr, chromosome; FDR, false discovery rate; HR, hazard ratio; 
HWE, Hardy Weinberg equilibrium; MAF, minor allele frequency; Pos, position; Ref, 
reference; * denotes imputed variants 
Variant ID Chr Gene 
Ref/Alt 
Allele 
Feature MAF HR (95% CI) P-value 
FDR  
Q-value 
Sorafenib Arm  (n=155) 
rs1885657 6 VEGFA T/C Intron 0.17 17.32 (5.69-52.73) 1.39x10-04 0.076 
rs200809375* 10 NA A/ATG 
7.5 kB 3' of 
NRP-1 
0.22 6.77 (2.62-17.5) 2.65x10-04 0.076 
rs6719561* 2 NA C/T 
1.8 kB 3’ of 
UGT1A9 
0.34 3.82 (1.56-9.52) 3.27x10-04 0.076 
rs8047917 16 WWOX T/A Intron 0.08 4.06 (1.88-8.78) 3.27x10-04 0.076 
rs3816375 2 ITGAV A/G Intron 0.38 5.88 (2.11-16.39) 4.87x10-04 0.051 
All Patients (n=295) 
rs307826 5 FLT-4 A/G 
Missense 
(Thr494Ala) 
0.10 13.79 (3.04-62.61) 1.24x10-04 0.088 
rs3024987* 6 VEGFA C/T Intron 0.11 2.98 (1.66-5.37) 8.80x10-04 0.088 
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FIGURES 
Figure 2.1. TARGET trial design 
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Figure 2.2. First and second line therapy recommendations for relapsed or Stage IV 
and surgically unresectable RCC. Per NCCN kidney cancer guidelines version 3.2015 
(http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf), predictors of poor RCC 
prognosis include: lactate dehydrogenase >1.5 the upper limit of normal, hemoglobin level 
less than the lower limit of normal, corrected calcium >10.5 mg/dL (2.5 mmol/L), interval 
less than one year from original diagnosis until initiation of systemic therapy, Karnofsky 
performance score ≤70, and ≥2 metastatic sites. Abbreviations: IFN, interferon; IL, 
interleukin; NCCN, National Comprehensive Cancer Network; PS, performance status 
RANKL, ligand of receptor activator of nuclear factor-κB; RCC, renal cell carcinoma; XRT, 
external radiation therapy. 
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Figure 2.3. Illumina GenomeStudio output from GoldenGate assay. Fluorescence signals 
from the extension and amplification steps were read, and clustering for each individual 
variant was displayed in a scatter plot with the signal intensity on the y-axis and a signal 
intensity ratio on the x-axis. GenTrain scores were derived from the Illumina GenomeStudio 
scatter plots to measure detection reliability based on genotypic clustering distribution. 
Clustering distributions for three variants are included here as an example. 
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Figure 2.4. Kaplan-Meier analysis of OS in the entire TARGET population versus the 
genotyped TARGET patients. The curves show the percent of patients in each treatment 
group who survived while on trial (y-axis) versus time in days (x-axis) for all patients from 
the entire TARGET population (left panel) and the genotyped TARGET patients (right 
panel). Vertical bars on the survival curves indicate censored observations.  
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Figure 2.5. Kaplan-Meier analysis of PFS in the entire TARGET population versus the 
genotyped TARGET patients. The curves show the percent of patients in each treatment 
group who survived without progression while on trial (y-axis) versus time in days (x-axis) 
for all patients from the entire TARGET population (left panel) and the genotyped TARGET 
patients (right panel). Vertical bars on the survival curves indicate censored observations.  
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Figure 2.6. TARGET genotyping study schematics. Genomic DNA from 295 patients 
from the phase III TARGET trial was used in this genotyping study that sought to find 
associations between 11,117 germline variants (1,020 directly genotyped SNPs and 10,097 
imputed SNPs and indels) and clinical phenotypes (OS and PFS). Abbreviations: HWE, 
Hardy Weinberg equilibrium; Indels, insertions/deletions; MAF, minor allele frequency; 
SNP, single nucleotide polymorphism; TARGET, Treatment Approaches in Renal Cancer 
Global Evaluation Trial. 
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Figure 2.7. Results from confirmatory PCR assays. To corroborate genotype calls from 
both the Illumina GoldenGate Assay and Impute2, Taqman® assays were conducted on two 
directly genotyped variants: rs1885657 (panel A) and rs307826 (panel B), and two imputed 
variants: rs3024987 (panel C) and rs8047917 (panel D).  
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Figure 2.8. Kaplan-Meier analysis of OS for rs1885657 (VEGFA). The large panel shows 
that sorafenib-treated patients with the TT genotype live significantly shorter than patients 
with CC or TC genotypes. The other two panels are provided, for reference, to show the 
effects of the variant on OS in the patients from the placebo arm, and when both arms are 
combined. The curves show the percent of patients in each treatment group who survived 
without progression while on trial (y-axis) versus time in days (x-axis). Vertical bars on the 
survival curves indicate censored observations. 
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Figure 2.9. Kaplan-Meier analysis of OS for rs3816375 (ITGAV). The large panel shows 
that sorafenib-treated patients with the GG genotype live significantly shorter than patients 
with AA or AG genotypes. The other two panels are provided, for reference, to show the 
effects of the variant on OS in the patients from the placebo arm, and when both arms are 
combined. The curves show the percent of patients in each treatment group who survived 
without progression while on trial (y-axis) versus time in days (x-axis). Vertical bars on the 
survival curves indicate censored observations. 
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Figure 2.10. Kaplan-Meier analysis of OS for rs8047917 (WWOX). The large panel shows 
that sorafenib-treated patients with the AT genotype live significantly shorter than patients 
with TT genotype. The other two panels are provided, for reference, to show the effects of 
the variant on OS in the patients from the placebo arm, and when both arms are combined. 
The curves show the percent of patients in each treatment group who survived without 
progression while on trial (y-axis) versus time in days (x-axis). Vertical bars on the survival 
curves indicate censored observations. 
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Figure 2.11. Kaplan-Meier analysis of OS for rs6719561 (3’ of UGT1A9). The large panel 
shows that sorafenib-treated patients with the TT genotype live significantly shorter than 
patients with CC or CT genotypes. The other two panels are provided, for reference, to show 
the effects of the variant on OS in the patients from the placebo arm, and when both arms are 
combined. The curves show the percent of patients in each treatment group who survived 
without progression while on trial (y-axis) versus time in days (x-axis). Vertical bars on the 
survival curves indicate censored observations.    
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Figure 2.12. Kaplan-Meier analysis of OS for rs200809375 (3’ of NRP-1). The large panel 
shows that sorafenib-treated patients with the at least one ATG insertion genotype live 
significantly shorter than patients with the AA genotype. The other two panels are provided, 
for reference, to show the effects of the indel on OS in the patients from the placebo arm, and 
when both arms are combined. The curves show the percent of patients in each treatment 
group who survived without progression while on trial (y-axis) versus time in days (x-axis). 
Vertical bars on the survival curves indicate censored observations. 
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Figure 2.13. Kaplan-Meier analysis of OS for rs307826 (FLT-4). The large panel shows 
that in a combined group of patients, those with the GG genotype live significantly shorter 
than patients with AA or AG genotypes. The other two panels are provided, for reference, to 
show the effects of the variant on OS in the patients from the placebo and sorafenib arms. 
The curves show the percent of patients in each treatment group who survived without 
progression while on trial (y-axis) versus time in days (x-axis). Vertical bars on the survival 
curves indicate censored observations. 
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Figure 2.14. Kaplan-Meier analysis of OS for rs3024987 (VEGFA). The large panel 
shows that in a combined group of patients, those with the TC genotype live significantly 
shorter than patients with CC genotype. The other two panels are provided, for reference, to 
show the effects of the variant on OS in the patients from the placebo and sorafenib arms. 
The curves show the percent of patients in each treatment group who survived without 
progression while on trial (y-axis) versus time in days (x-axis). Vertical bars on the survival 
curves indicate censored observations.   
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Figure 2.15. Correlation analyses between OS and PFS. Correlation analyses between OS 
and PFS are provided for A) all TARGET patients, B) among all genotyped TARGET 
patients, C) among genotyped TARGET patients treated with sorafenib, and D) among 
TARGET patients administered placebo. For each of the correlation analyses, patients that 
were censored in the survival analyses were removed. For the correlation test between OS 
and PFS for all TARGET patients, a Spearman rank correlation test was used. For all others, 
a Pearson product moment correlation was used.  
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Figure 2.16. Kaplan-Meier analysis of PFS for rs1885657 (VEGFA). Variant rs1885657, 
which associated with OS, also significantly associated with PFS (p≤0.05) in A) sorafenib-
treated patients, and B) when both treatment arms were combined. The curves show the 
percent of patients in each treatment group who survived without progression while on trial 
(y-axis) versus time in days (x-axis). Vertical bars on the survival curves indicate censored 
observations. Abbreviations: PFS, progression free survival; VEGFA, vascular endothelial 
growth factor A. 
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Figure 2.17. Kaplan-Meier analysis of PFS for three variants previously with OS. Three 
variants, associated with OS, were also associated with PFS: A) rs8047917 in WWOX, B) 
rs3024987 in VEGFA, and C) rs6719561, which is 3’ of UGT1A9, also significantly 
associated with PFS (p≤0.05) in sorafenib-treated patients. The curves show the percent of 
patients in each treatment group who survived without progression while on trial (y-axis) 
versus time in days (x-axis). Vertical bars on the survival curves indicate censored 
observations. Abbreviations: PFS, progression free survival; UGT1A9, Uridine 5'-diphospho-
glucuronosyltransferase 1 family, polypeptide A9; VEGFA, vascular endothelial growth 
factor A; WWOX, WW domain-containing oxidoreductase. 
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Figure 2.18. Kaplan-Meier analysis of PFS for rs307826 (FLT-4). Variant rs307826, 
associated with OS, also significantly associated with PFS (p≤0.05) in A) sorafenib-treated 
patients, and B) when both treatment arms were combined. The curves show the percent of 
patients in each treatment group who survived without progression while on trial (y-axis) 
versus time in days (x-axis). Vertical bars on the survival curves indicate censored 
observations. Abbreviations: FLT-4, fms-related tyrosine kinase 4; PFS, progression free 
survival. 
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CHAPTER 3: VALIDATION OF GERMLINE VARIANTS THAT ASSOCIATE 
WITH OVERALL SURVIVAL IN TARGET TRIAL PATIENTS 
 
3.1 Overview 
Background:  
Statistical associations between genetic variants and outcomes in cancer studies 
should be supported with molecular mechanistic evidence of variant function to aid in 
biomarker validation. The primary objective of this Aim was to validate the functionality of 
germline variants were significantly associated with OS in TARGET patients, through a 
sequential in silico  in vitro approach, and to test the hypothesis that functional validation 
will elucidate the molecular effects of these variants on mRCC biology and sorafenib 
pharmacology. 
 
Methods:  
Germline variants, identified in Aim 1, that significantly associated with OS 
(multivariate model p<0.05 and FDR q<0.1) were analyzed using a selection of in silico 
bioinformatic tools to prioritize which would be validated using laboratory in vitro assays. 
Several resources were used to provide information on variant allele frequencies and LD 
patterns (e.g. 1,000 Genomes Project data, Ensembl and dbSNP). Others helped to predict the 
myriad ways variants influence gene regulation by leveraging ENCODE data (e.g. Ensembl, 
the UCSC genome browser, HaploReg, and Regulome DB). One non-synonymous germline 
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variant in a coding region of FLT-4 (rs307826) was assessed for function using cell viability 
assays. Dual reporter gene luciferase assays were used to examine effects of variants on gene 
expression. Only intragenic variants were selected for functional validation; therefore, no 
experiments were in the two intergenic variants identified in Aim 1 (rs6719561 and 
rs200809375). 
 
Results:  
In silico tools helped predict functionality for five intragenic variants which were 
associated with OS in Aim 1. These tools prioritized intronic SNPs in VEGFA (rs1885657 
and rs3024987) and rs307826 for functional validation. Cell viability assays revealed that 
rs307826 (G allele) results in a more resistant phenotype for HEK-293 cells treated with 
sorafenib. Dual reporter gene luciferase assays validated functionality of the two VEGFA 
variants (as well as two variants in perfect LD with rs1885657) in three different cell lines.  
 
Conclusions:  
In silico tools were useful for prioritizing variants for functional, in vitro validation. 
In vitro experiments validated the functionality of intronic VEGFA variants (rs1885657 and 
rs3024987), and the coding variant in FLT-4 (rs307826). Additional experiments should be 
conducted to further elucidate the mechanisms underlying molecular effects that these 
variants have on OS in mRCC patients.   
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3.2 Introduction 
Findings from pharmacogenetic and pharmacogenomic studies (e.g. candidate gene, 
GWAS, and now next generation sequencing) continue to provide a plethora of information 
about genetic variation that underlies both disease pathology and responses to 
pharmacotherapy. Statistical associations between genetic variants and outcomes (e.g. OS 
and/or PFS) in cancer studies should be properly supported with molecular mechanistic 
evidence of variant function, and the lack of mechanistically-based effects underlying clinical 
phenotypes is a major limitation for biomarker validation.1 And, a clear understanding of the 
molecular effects of candidate variants, selected from significant associations between 
genotype and clinical phenotypes, is often absent. In fact, none of the previous 
pharmacogenetic studies of oral VEGF-pathway inhibitors used for the treatment of mRCC 
have conducted studies to validate their observed clinical associations.2-8  
Replication of positive findings in an external, independent cohort of patients has 
traditionally served as a gold standard for validation of genotype-phenotype relationships.9,10 
However, validation of clinical variant-phenotype associations through replication can be 
problematic because independent, external cohorts of patients that match the discovery 
cohort (e.g. baseline patient characteristics, clinical presentation, and pharmacotherapies used 
in the treatment of their cancers) are not always easily obtainable, and do not provide insights 
into the mechanisms underlying disease pathology and/or drug response. Currently, a suitable 
replication cohort of mRCC patients treated with sorafenib is not available. Therefore, 
functional validation of these clinical associations becomes even more important to the 
overall goal of identifying and validating clinically useful biomarkers to aid clinicians in the 
treatment of mRCC.  
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The primary objective of this Aim was to validate the functionality of germline 
variants, identified in Aim 1, through a sequential in silico  in vitro approach, and to test 
the hypothesis that functional validation will elucidate the molecular effects of these variants 
on mRCC pathogenesis, angiogenesis and/or sorafenib pharmacology. 
 
3.3 Materials and Methods 
3.3.1 In Silico Functional Prediction 
In silico bioinformatic analyses will help to predict the functionality of the significant 
variants identified in Aim 1, and will help prioritize which variants will be pursued for in 
vitro functional validation. Genotype data from Caucasian patients of the 1,000 Genomes 
Project (http://www.1000genomes.org) was downloaded and visualized in HaploView to 
investigate LD and haplotype structure.11 The Broad Institute’s HaploReg version 2 
(http://www.broadinstitute.org/mammals/haploreg/haploreg_v2.php) and version 3 
(http://www.broadinstitute.org/mammals/haploreg/haploreg_v3.php), the dbSNP website 
(http://www.ncbi.nlm.nih.gov/projects/SNP), and the Ensembl website (www.ensembl.org) 
were also be used to assess LD for variants of interest and to help analyze haplotype 
structure.12,13 To help prioritize variants of interest for in vitro validation, only those in high 
LD (r2 >0.8; based on Caucasians from the 1000 Genomes Project) with a significant variant 
identified in Aim 1 were considered relevant to the haplotype structure.  
Additionally, data from the Encyclopedia of DNA Elements (ENCODE) Consortium 
was extensively queried, through the use of online resources (e.g. the HaploReg, the 
University of California Santa Cruz [UCSC] Genome Browser [https://genome.ucsc.edu], 
and the Center for Genomics and Personalized Medicine at Stanford University’s Regulome 
90 
DB version 1.1 website [http://regulomedb.org]).14-16 Output from these in silico 
bioinformatic tools that provided evidence of variant functionality helped prioritize candidate 
variants for in vitro validation based on the potential of the variant to alter regulatory 
pathways and/or gene function. Variants from Aim 1 that were associated with OS, and  
additional variants in high LD with the variants identified from Aim 1, that had predicted 
evidence of histone modifications (promoter or enhancer histone marks), open chromatin 
(DNaseI hypersensitivity peaks), or changes to transcription factor binding motifs were 
prioritized for in vitro validation in the laboratory.  
Finally, the SIFT and PolyPhen-2 algorithms were used to better understand the 
effects of amino acids substitutions caused by non-synonymous variants in gene coding 
regions.17,18  
 
3.3.2 Laboratory Functional Validation 
Cell Culture 
HEK293 (ATCC) cells were maintained-in DMEM with 10% FBS and 1% 
penicillin/streptomycin, and Caki-1 human clear-cell metastatic renal cell carcinoma cells 
were cultured in McCoy’s 5A (Iwakata and Grace Mod.) with L-glutamine media (ATCC, 
Manassas, VA, USA) with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific, 
Waltham, MA, USA) and 1% and penicillin/streptomycin (Mediatech, Manassas, VA, USA). 
Human telomerase-immortalized microvascular endothelial (TIME) cells and human liver 
parenchyma endothelial cells (LPEC) were cultured in endothelial basal media (EBM-2) with 
5% FBS and supplemented with the EGM®-2 MV bullet kit (Lonza Inc., Allendale, NJ, 
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USA), per the manufacturer instructions. All cells were maintained in 5% CO2 at 37 oC and 
grown to desired confluency (80-90%). 
 
Dual Reporter Gene Luciferase Assays 
Dual reporter gene luciferase assays were performed by inserting a pGL4.26 
[luc2/minP/Hygro] plasmid (Promega, Madison, WI, USA), with a minimal promoter and 
Firefly luciferase gene into all cell lines that were assayed. This pGL4.26 plasmid was 
utilized in all reporter gene assays. The pGL4.26 plasmids with cloned sequences of interest 
were synthesized by GeneWiz (Research Triangle Park, NC, USA). Restriction sites were 
identified using CLC Sequence Viewer 6.6.2 (CLC Bio, Cambridge, MA), and mutagenesis 
primers were designed using Agilent Technology’s QuikChange Primer Design program 
(http://www.genomics.agilent.com/primerDesignProgram) Site-directed mutagenesis was 
carried out using a QuikChange II XL Site-Directed Mutagenesis Kit (Agilent, Santa Clara, 
CA), per manufacturer instructions.  Sanger-based DNA sequencing, using 3730xl Genetic 
Analyzers (Applied Biosystems) and performed at the UNC Mammalian Genotyping Core, 
was used to confirm site-directed mutagenesis.  
Two VEGFA variants that were prioritized for functional validation (rs1885657 and 
rs3024987) were tested for their functional effects on the transcriptional activity of VEGFA. 
An additional two variants that are in perfect LD (r2=1.0) with rs1885657 (rs58159269, and 
rs943070) were also selected. First, a 1,320 bp VEGFA fragment (chr6:43739302-43740622) 
was cloned upstream of a minimal promoter in pGL4.26 using KpnI and NheI for the 5’ and 
3’ restriction sites, respectively. DNA clones containing the reference sequence with each 
reference allele (rs1885657 T, rs943070 C, and rs58159269 T) were generated.  DNA clones 
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containing each variant allele (rs1885657 C, rs943070 G, and rs58159269 C) were all 
generated through site-directed mutagenesis. A separate DNA clone containing all three 
variant alleles (rs1885657 C/rs943070 G/rs58159269 C) was also generated through site-
directed mutagenesis.  
For rs3024987, a 463 bp VEGFA fragment (chr6:43741162-43741625) was cloned 
upstream of a minimal promoter in pGL4.26 using NheI and XhoI for the 5’ and 3’ 
restriction sites, respectively. DNA clones containing the reference sequence with the 
reference allele (rs304987 C) were generated. Again, allelic variation (rs3024987 T) was 
introduced through site-directed mutagenesis, and DNA clones containing the variant allele 
were produced. 
Once cells were grown to desired confluency (80-90%), they were seeded in 24-well 
plates at a density of 5x104 cells per well. Caki-1 cells lines were transfected using 
lipofectamine (Invitrogen), using the reporter gene plasmid construct of interest and a Renilla 
HSV-TK plasmid (Promega), in 24-well plates. TIME and LPEC cell lines were transfected 
in 24-well plates by TransIT®-2020 reagent (Mirus Bio LLC, Madison, WI, USA) and used 
a reporter gene plasmid of interest with a Renilla plasmid containing an SV40 promoter 
(Promega). Additionally, LPEC cells were treated with CombiMag (Oz Biosciences, San 
Diego, CA, USA) and were transfected under magnetoporation. All cells were lysed 40 h 
after transfection, and the luciferase assays were then conducted according to the 
manufacturer instructions (Promega). Firefly luciferase and Renilla were loaded into 96-well 
plates and read on a Beckman Coulter DTX 880 Multimode Detector (Beckman Coulter, 
Inc., Brea, CA, USA). 
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Each mutant of the three constructs for SNPs in the VEGFA haplotype (rs1885657, 
rs58159269, and rs943070), a “triple variant” construct that contained all three mutations, a 
reference construct, and an empty pGL4.26 plasmid were each transfected in four 
independent experiments, using triplicate wells. For rs3024987, a construct containing the 
mutant, a reference construct, and an empty pGL4.26 plasmid were each transfected in four 
independent experiments, using triplicate wells. Luciferase activity was defined as a ratio of 
Firefly to Renilla luciferase. Luciferase activity for each of the variant constructs was 
normalized to the luciferase activity of the empty pGL4.26 vector. For rs304987, differences 
in luciferase activity were tested between the variant and reference, using a two-sided t-test. 
For rs1885657, a one-way ANOVA was conducted, and then pairwise comparisons to the 
reference were conducted for each variant, and also for the “triple variant.” A Dunnett’s 
correction was used to correct for multiple tests for rs1885657. All calculations were 
performed and figures created using GraphPad Prism® version 5.03 (GraphPad Software, 
Inc., La Jolla, CA, USA) software. All statistical analyses were confirmed using SAS 
software, version 9.2 (SAS, Cary, NC, USA). 
 
Cell Viability Assays 
 Sorafenib tosylate (LC Laboratories, Woburn, MA) was reconstituted in 100% 
DMSO (Thermo), and stock concentrations (0.5–100 mM) were prepared. Working 
concentrations were then prepared in DMEM before addition to cells. The final 
concentrations of sorafenib used in cell viability assays ranged from 0.5–30 µM. The final 
concentration of DMSO introduced to cells was 0.2% in all experimental wells. The 
VEGFR3 Thr494Ala amino acid substitution, caused by rs307826, was introduced into the 
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pCMV6-XL5 expression vector containing FLT-4 cDNA (Origene Technologies, Rockville, 
MD, USA) through the use of the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent 
Technologies, Santa Clara, CA, USA), as per the manufacturer’s instructions. Sanger-based 
sequencing was again performed at the UNC Mammalian Genotyping Core to confirm site-
directed mutagenesis. 
Once cells were grown to desired confluency (80-90%), they were seeded in 24-well 
plates at a density of 5x104 cells per well. After 24 h, reference and variant vectors were 
transfected into HEK-293 cells using Lipofectamine® 2000 (Invitrogen).  In vivo, VEGFC is 
the ligand that is required for VEGFR3 dimerization and activation. So, after a 24 h 
transfection, cells were stimulated with VEGFC diluted in DMEM to a final 200 ng/mL 
concentration, or with a matched volume of DMEM media for unstimulated cells, for 1 h 
prior to the administration of sorafenib. Twelve concentrations of sorafenib (final 
concentration: 0 µM, 0.5 µM, 1 µM, 2 µM, 5 µM, 6 µM, 8 µM, 9 µM, 10 µM, 15 µM, 18 
µM, 20 µM, and 30 µM) were then added to cells, in triplicate, and incubated for 72 h. The 
concentrations of sorafenib selected for these assays overlap the estimated pharmacologically 
relevant concentration range for sorafenib (approximately 6-15 µM).19,20  Triplicate wells 
were also treated with 100% DMSO (final concentration of 20% in DMEM media), and 1% 
DMSO (final concentration of 0.2% in DMEM media) as controls. After a 72 h sorafenib 
incubation, alamarBlue® cell viability reagent (Life Technologies, Grand Island, NY, USA) 
was added to cells at an amount equal to 10% of the culture volume and incubated at 37 oC 
for 2 h. 
Fluorescence, with excitation wavelength at 530-560nm and emission wavelength at 
590 nm, was measured using a Beckman Coulter DTX 880 Multimode plate reader 
95 
(Beckman Coulter, Inc.), and relative fluorescent units (RFU) were reported. Using the RFU 
output, the following equation was used to calculate the percent viability for each sorafenib 
concentration: ((PVconc – PVD20)/(PVD0.2 – PVD20) * 100), where PVconc is the percent viability 
of cells for a given concentration in experimental wells, PVD20 is the percent viability of cells 
in control wells treated with 20% DMSO, and PVD0.2 is the percent viability of cells in 
control wells treated with 0.2% DMSO. Experiments were performed, on different days in 
duplicate, and an average percent viability was used for all analyses. For all analyses, 
sorafenib concentrations were log10 transformed and a four-parameter non-linear regression 
model was used to assess log10 concentration versus percent viability, and to obtain IC50 
values. Two-sided t-tests were used to assess differences between IC50 values for VEGFC-
stimulated mutant-transfected HEK cells and VEGFC-stimulated reference-transfected HEK 
cells, and between IC50 values for VEGFC-stimulated mutant-transfected HEK cells and 
unstimulated mutant-transfected HEK cells. All calculations were performed and figures 
created using GraphPad Prism® version 5.03, and all statistical analyses were again 
confirmed using SAS software, version 9.2. 
 
3.4 Results 
3.4.1 In silico predictions 
To understand more about the variants identified and their LD structure, as well as to 
prioritize variants for in vitro validation based on their predicted functionality, a series of in 
silico analyses were conducted. Variants from Aim 1 with evidence of promoter or enhancer 
histone modifications (e.g. H3K4me1, H3K4me3 and H3K27ac marks), evidence of DNase 
sensitivity, evidence that they influence transcription factor binding through changes to 
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transcription factor binding motifs and/or evidence of being an expression quantitative trait 
locus (eQTL), were prioritized for in vitro functional validation. 
For the VEGFA variants identified in Aim 1 (rs1885657 and rs3024987) and two 
variants in perfect LD with rs1885657 (rs58159269 and rs943070), there was substantial 
evidence that they exist in a regulatory region. In multiple cell lines, there was evidence of 
both promoter and enhancer histone marks (H3K4me1, H3K4me3 and H3K27ac marks) 
(Table 3.1 and Figure 3.1).  Briefly, methylation or acetylation modifications, or marks, to 
histones can influence how accessible the chromatin is to transcription, thereby influencing 
gene expression. H3K4me1 histone mark is a mono-methylation of lysine 4 of the H3 histone 
protein and is associated with enhancers and DNA regions downstream of transcription start 
sites. An H3K4me3 histone mark indicates tri-methylation of the same lysine residue and is 
associated with promoters that are active or poised to be activated. And, a H3K27ac histone 
mark indicates acetylation of lysine 27 of H3, and like H3K4me1, a H3K27ac mark is also 
often indicative of a transcription enhancer.21 
These four VEGFA variants also revealed evidence of altered transcription factor 
binding and/or altered transcription factor motifs, and areas of DNase hypersensitivity (Table 
3.1 and Figure 3.1). Variants in active regulatory regions (e.g. promoters and enhancers) 
often reveal evidence of DNase hypersensitivity. Areas of DNase hypersensitivity indicate 
loss of condensed chromatin structure, which exposes DNA and makes it accessible for 
transcription.21,22 
No renal endothelial cell lines were analyzed during the ENCODE project.  This was 
a potential limitation to leveraging ENCODE resources because RCC is highly dependent on 
angiogenesis and host vascular endothelium. In addition, analyzing data from an endothelial 
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cell type was essential because sorafenib, in part, targets host vascular endothelium. 
Therefore, examining data from human umbilical vein endothelial cells (HUVEC) was 
important because it provided insight into regulatory elements within the cell type closest to 
renal endothelial cells. In HUVECs, there was evidence of H3K4me1, H3K4me3, and 
H3K27ac marks at rs1885657. For rs58159269, there was evidence of H3K4me3, and 
H3K27ac marks. For rs943070 and rs3024987, there was evidence of H3K27ac (Figure 3.2). 
By Regulome DB, the variant predicted to have the most influence on regulation of 
VEGFA was rs59159269. It had a Regulome DB score of 2b (Table 3.2), which means there 
was evidence of altered transcription factor binding sites, any transcription factor motif, a 
DNase footprint, and a DNase peak. Variants rs1885657, rs943070, and rs3024987 all had a 
Regulome DB score of 4, which means there was evidence of a DNase peak and altered 
transcription factor binding. Collectively, there was sufficient ENCODE prediction data to 
prioritize these variants for functional validation.  
There was only minimal evidence in ENCODE that rs3816375 in ITGAV and 
rs8047917 in WWOX were in regions that would affect gene regulation (Tables 3.3 and 3.4, 
respectively). There is no data to provide a Regulome DB score for rs3816375, and the 
Regulome DB score for rs8047917 was 6. Based on minimal ENCODE evidence in the 
UCSC Browser, HaploReg and Regulome DB, these two variants were not prioritized for 
functional validation. 
Variant rs30726 was not predicted to be deleterious or cause a harmful amino acid 
substitution. While a threonine to alanine amino acid substitution results in a change from a 
medium-sized and polar amino acid to a small-sized and hydrophobic amino acid,23 rs307826 
received a score of 0.53 from SIFT, which  means the algorithm predicted that the amino acid 
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substitution would be tolerated.18 Similarly, rs307826 received a score of 0.005 from 
PolyPhen-2, which means the algorithm predicted that the amino acid substitution would be 
benign.17 
 
3.4.2 Variant Effects on Cell Viability  
To validate the functionality of rs307826 and to gain insight into whether this non-
synonymous variant in a coding region of FLT-4 has an effect on VEGFR3 signaling, vectors 
containing reference and mutant cDNA were transfected into HEK-293 cells and 
subsequently treated with sorafenib. Cell viability assays were conducted to generate IC50 
values for VEGFC-stimulated and unstimulated reference cells, as well as VEGFC-
stimulated and unstimulated mutant cells. 
Cells were treated in triplicate wells with 12 concentrations of sorafenib (0–30 µM), 
and cell viability relative to untreated controls (0.2% DMSO only) was determined through 
the alamarBlue® cell viability assay. First, a statistically significant difference in sorafenib 
cytotoxicity was observed between reference-transfected and mutant-transfected HEK-293 
cells that were not stimulated by VEGFC (p<0.0001). The IC50 for reference-transfected cells 
was 7.58 µM, while the IC50 for mutant-transfected cells was 15.45 µM (Figure 3.3). Second, 
a statistically significant difference in sorafenib cytotoxicity was observed between 
reference-transfected and mutant-transfected HEK-293 cells that were both stimulated by 
VEGFC prior to sorafenib administration (p<0.0001). The IC50 for reference-transfected cells 
was 2.02 µM, while the IC50 for mutant-transfected cells was 7.67 µM (Figure 3.3). Finally, a 
statistically significant difference in sorafenib cytotoxicity was observed between VEGF-
stimulated and unstimulated mutant-transfected HEK-293 cells (p<0.0001) (Figure 3.3). 
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3.4.3 Variant Effects on Transcriptional Activity  
To provide insight into the mechanisms underlying the variant-OS associations 
observed among intronic variants identified in Aim 1, variants were assessed for their 
function as potential effectors of regulatory activity using dual reporter gene luciferase 
assays. Genomic regions containing the reference sequence, or sequence with the variants (or 
those in perfect LD with the identified variant) were cloned into a pGL4.26 plasmid construct 
containing a minimal promoter and downstream of the Firefly luciferase gene. Allelic 
variation (rs1885657 C allele, rs58159269 C allele, rs943070 G allele, or rs3024987 T allele) 
were introduced by site-directed mutagenesis. These assays were performed to determine 
how each variant (or the construct with three variants) affected the transcriptional activity of 
the minimal promoter. 
For the VEGFA variant that associated with shorter OS in patients treated with 
sorafenib (rs1885657), and the two variants in perfect LD (rs943070 and rs58159269), 
significant increases in luciferase activity in LPEC cells were observed individually for all 
three variants, as well as for the “triple variant.” For rs1885657 (T>C), the C allele increased 
luciferase activity by an average of 48% (p<0.05). For rs58159269 (T>C), the C allele 
increased luciferase by an average of 70% (p<0.001). For rs943070 (C>G), the G allele 
increased luciferase by an average of 40% (p<0.05). And, for the triple variant, luciferase 
was increased by an average of 98% (p<0.01), when compared to the reference alleles 
(Figure 3.4).  
In the TIME human endothelial cell line, increased luciferase activity was again 
observed.  For rs1885657 (T>C), the C allele increased luciferase activity by an average of 
57% (p<0.001). For rs58159269 (T>C), the C allele increased luciferase by an average of 
100 
80% (p<0.001). And, for the triple variant, luciferase was increased by an average of 99% 
(p<0.001), when compared to the reference alleles. Luciferase activity was not significantly 
different between rs943070 and the reference allele in TIME cells (Figure 3.4). 
Finally, in the clear-cell mRCC Caki-1 cell line significant increases in luciferase 
activity were observed individually for rs1885657, rs58159269 and rs943070, as well as for a 
haplotype of all three SNPs. For rs1885657 (T>C), the C allele increased luciferase activity 
by an average of 30% (p<0.05). For rs58159269 (T>C), the C allele increased luciferase by 
an average of 56% (p<0.001).  For rs943070 (C>G), the G allele increased luciferase by an 
average of 35% (p<0.01).  And, for the triple variant, luciferase was increased by an average 
of 70% (p<0.001), when compared to reference (Figure 3.4). 
For VEGFA rs3024987 (C>T), which was associated with shortened OS in a 
combined analysis of both study arms, significant increases in luciferase activity were 
observed in all three cell lines.  In LPEC cells, the T allele increased luciferase activity by an 
average of 34% (p=0.0032), when compared to reference. In the TIME cells, the T allele 
increased luciferase activity by an average of 38% (p=0.0002). Finally, in Caki-1 cells, the T 
allele increased luciferase activity by an average of 32% (p=0.0001), when compared to 
reference (Figure 3.5). 
 
3.5 Discussion 
The primary objective of this Aim was to validate the functionality of germline 
variants, identified in Aim 1, through a sequential in silico  in vitro approach, and to test 
the hypothesis that functional validation will elucidate the molecular effects of these variants 
on mRCC pathogenesis, angiogenesis and/or sorafenib pharmacology. For candidate gene-
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candidate variant studies, where a tagging SNP variant approach has been applied or where 
the functionality of the variant is unknown, relying on clinical associations severely limits the 
ability to translate candidate variants into clinically useful prognostic or predictive 
biomarkers.  
The initial step towards predicting if the candidate variants identified in Aim 1 were 
functional was to understand the LD structure of the other variants associated with the 
candidate. Sequencing data from the 1,000 Genomes Project was important for identifying 
other variants in high LD with the candidate variant that could also be functional. After 
gaining an appreciation of the haplotype and LD structure of each candidate variant, in silico 
bioinformatic tools were leveraged to understand more about whether the identified variants 
were in regulatory regions.24,25 Additional in silico resources, such as HaploReg, and 
RegulomeDB, that provided an interpretation of ENCODE data (e.g. histone modifications, 
transcription factor binding, eQTLs, and chromatin structure) helped predict the functionality 
of intronic variants and prioritized them for validation,16,21,22 The in silico predictions for 
variant functionality were consistent between HaploReg and Regulome DB (except for 
rs3816375, for which there was no prediction information in Regulome DB).  Ensembl 
Variant Effect Predictor (http://uswest.ensembl.org/info/docs/tools/vep/ 
index.html?redirect=no) incorporated resources like SIFT18 and PolyPhen-217 to help predict 
the effects of non-synonymous variants. Table 3.6 has been provided to summarize key 
results from Aims 1 and 2, including; the clinical association for each variant, in silico 
predictions concerning function as regulatory elements or as a deleterious amino acid 
substitution, and in vitro experiment results. 
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The in silico bioinformatic tools predicted that the four VEGFA variants identified in 
Aim 1 would be functional, and thus they were prioritized for laboratory validation. In Aim 
1, patients in the sorafenib arm with the CC genotype for rs1885657achieved significantly 
worse OS and PFS. This association could be caused by differences in regulatory elements 
(e.g. enhancer activity that results in altered transcription factor binding) at rs1885657, which 
could result in increased VEGFA expression. In addition, analyses of combined treatment 
arms revealed that patients with at least one copy of the T allele for rs3024987 also achieved 
poorer OS. This intronic variant is also likely to alter transcription factor binding and 
increase VEGFA expression. In both instances, increased VEGFA expression could 
conceivably lead to increased angiogenic capability of mRCC. 
Data from functional assays performed in in Aim 2 support the hypothesis that 
rs1885657 and rs3024987 are functionally active variants. Luciferase assay data validated the 
in silico predictions, revealing increased luciferase activity for rs1885657 rs943070, 
rs58159269, and rs3024987. Luciferase assays were chosen to help validate these variants 
because they test the transcriptional effects of genetic variants in potential regulatory regions, 
and  provide an  initial understanding of the mechanisms underlying the variant-OS 
associations observed in Aim 1.25 
The luciferase assay data also provided evidence that these variants could all be 
functional and acting independently to affect VEGFA expression through multiple different 
transcriptional regulatory elements. Because a tagging variant approach was used for many 
of the variants selected for Golden Gate genotyping in Aim 1, the original hypothesis tested 
in these experiments was that rs1885657 might only be a proxy for another functional 
variant. However, these data have shown that rs1885657 and two other variants in perfect LD 
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(rs58159269 and rs943070) are all likely to be biologically relevant, and that the entire three-
SNP haplotype is indeed functional. These data support a new hypothesis that combinational 
effects of multiple enhancer variants, in high LD with one another, will together increase 
VEGFA expression, and confer differences in OS to mRCC patients.26 While previous 
pharmacogenetic studies of oral VEGF-pathway inhibitors have identified SNPs that 
associate with OS and/or PFS in mRCC patients, none have attempted to functionally 
validate of their findings.5,27,28 Prior to these studies, rs1885657 and rs3024987 were of 
unknown significance. But, increased cellular transcription of VEGFA by the C allele of 
rs1885657, the C allele of rs58259269, the G allele of rs94307 and/or the T allele of 
rs3024987, combined with their  respective associations with OS, align well with the 
hypothesis that increased VEGFA expression increase the angiogenic potential of mRCC. 
In Aim 1, analyses when treatment arms were combined revealed that patients with 
the GG genotyped for rs307826 achieved significantly worse OS and PFS. The SNP variant 
rs307826 causes a threonine to alanine substitution at position 494 (Thr494Ala), located in 
the fifth IgG-like domain of VEGFR3. While the PolyPhen-217 and SIFT18 algorithms, did 
not predict this variant to be deleterious and cause a damaging amino acid substitution, 
several pharmacogenetic studies of mRCC patients treated with oral VEGF-pathway 
inhibitors have associated rs307826 with significantly shorter OS and/or PFS.2,3,8 
FLT-4 encodes for VEGFR3, a transmembrane kinase receptor that has been 
traditionally linked to lymphangiogenesis.29 But, VEGFR3 is also expressed in tumor 
vasculature,30 and inhibition of VEGFR3 can suppress vascular network formation.31 
Preclinical models have also suggested that VEGFR3 could possibly be more relevant than 
VEGFR2 (a primary driver of angiogenic signaling, and a main target for the VEGF-pathway 
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inhibitors used to treat mRCC) for the development of metastases.32 One notable study 
recently characterized the structure and function of VEGFR3, and revealed that the fifth IgG-
like receptor domain is critical to receptor signaling.33 Cell viability assays, which showed 
the cells overexpressing the variant G allele, were more resistant to sorafenib. These data 
support the primary hypothesis that this amino acid substitution results in increased VEGFR3 
signaling, resistance to sorafenib, and thus an increased risk of disease progression and death. 
While more common for non-synonymous variants to result in amino acid 
substitutions that alter protein function, evidence supports the alternate hypothesis that this 
non-synonymous variant can also modify FLT-4 expression.34-36 Although the in silico 
predictive evidence is not as compelling as for the VEGFA variants, HaploReg does reveal 
evidence of altered enhancer marks and changes to transcription factor binding motifs (Table 
4.5). Therefore, investigating rs307826 as an effector of gene expression should also be 
considered.  
Although not prioritized for validation by the in silico resources that use ENCODE 
data, rs3816375 in ITGAV and rs8047917 in WWOX could still potentially be functional. As 
previously mentioned, ENCODE experiments were not performed in a kidney endothelial 
cell line, nor in an mRCC line. These two variants were significantly associated with OS 
after a rigorous statistical design, which sought to avoid Type I error and detection of 
spurious variant-phenotype associations, was employed in Aim 1. Therefore, it would be 
premature to dismiss these two variants completely. For the two intergenic variants that 
associated with OS (rs6719561 and rs200809375), validation is still required. Luciferase 
assays could potentially provide insight into their activity as enhancers; however, because 
they are not located within genes it would be difficult to ascertain on which gene they act. In 
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addition, the physiologic relevance on a clinical phenotype of variants in intergenic regions 
could be directly related to currently unknown non-coding RNAs, (e.g.  microRNAs, or  
macro long non-coding RNAs).37 Certainly, additional future validation experiments 
involving these two variants should be conducted. 
Functional evidence by one validation method should not be relied upon because it is 
rarely sufficient to provide a mechanistic foundation to support clinical associations.25,38 
Additional laboratory validation experiments should be conducted on the variants identified 
in Aim 1 to ascertain if they influence gene expression, and to characterize the mechanistic 
underpinnings that result in altered gene expression. For example, variants with evidence of 
luciferase activity should be prioritized for additional in vitro functional validation by 
electromobility shift assays (EMSA). And, phosphorylation assays assessed through 
traditional Western blotting, enzyme-linked immunosorbent assays (ELISA), or by 
leveraging a mass spectrometry-based proteomic approach could provide necessary 
confirmation that rs307826 influences VEGFR3 signaling. 
Ultimately, variant constructs used in reporter gene assays are analyzed out of their 
natural context, and state. And, for cell viability and/or phosphorylation assays, cDNA 
vectors likely overexpress the gene more than what occurs in vivo.25 Therefore, the creation 
of isogenic endothelial cell lines, using clustered regularly interspaced short palindromic 
repeats (CRISPR)/cas9 or transcription activator-like effector nuclease (TALEN) 
technologies, could for the first time isolate how these variants influence gene expression, 
receptor signaling, even angiogenesis. 
In summary, the findings from Aim 2 provide evidence that the variants identified in 
Aim 1, which significantly associated with OS in TARGET patients treated with sorafenib, 
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are functional. These data lay provide validation of these germline variants, and also lay the 
groundwork for future studies that will further elucidate the molecular mechanisms 
underlying these variants. These data provide the next essential step towards conducting 
prospective trials that will then confirm them as predictive and prognostic biomarkers. 
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TABLES 
Table 3.1. HaploReg output for rs1885657 and rs3024987. VEGFA variants in high LD 
(r2≥0.8) with rs1885657 are shown. Additionally, rs3024987, which is in moderate LD with 
rs1885657 (r2≥0.6), is included. The Regulome DB score for rs1885657 is 4, for rs58159269 
is 2b, for rs943070 is 4, and for rs3024987 is 4. In TARGET, the CC genotype for rs1885657 
was associated with significantly shorter OS in patients from the sorafenib arm (p=1.39x10-
04, q=0.076). The CT genotype was associated with significantly shorter OS in a combined 
analysis of both patient arms (p=8.80x10-04, q=0.088). Abbreviations: LD, linkage 
disequilibrium; SNP, single nucleotide polymorphism. 
Position 
LD 
(r²) 
Variant Ref Alt 
EUR 
freq 
Promoter 
histone 
marks 
Enhancer 
histone 
marks 
DNAse 
Proteins 
bound 
Motifs 
changed 
GENCODE 
genes 
dbSNP 
functional 
annotation 
chr6:43739446 1 rs58159269 T C 0.20 24 organs 6 organs 
30 
organs 
13 bound 
proteins 
14 altered 
motifs 
VEGFA intronic 
chr6:43740094 1 rs1885657 T C 0.20 22 organs 12 organs 
18 
organs 
4 bound 
proteins 
5 altered 
motifs 
VEGFA intronic 
chr6:43740451 0.99 rs943070 C G 0.20 21 organs 13 organs 
28 
organs 
7 bound 
proteins 
ATF3, 
BDP1 
VEGFA intronic 
chr6:43740840 0.61 rs3024987 C T 0.13 19 organs 15 organs 
GI, 
MUS 
 
5 altered 
motifs 
VEGFA intronic 
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Table 3.2. Regulome DB scoring system. This table is adapted from one found on the 
Regulome DB website (http://regulomedb.org/). Abbreviations: eQTL, expression 
quantitative trait locus/loci; TF, transcription factor. 
Score Supporting Data 
1a   eQTL + TF binding + matched TF motif + matched DNase Footprint + DNase peak 
1b   eQTL + TF binding + any motif + DNase Footprint + DNase peak 
1c   eQTL + TF binding + matched TF motif + DNase peak 
1d   eQTL + TF binding + any motif + DNase peak 
1e   eQTL + TF binding + matched TF motif 
1f   eQTL + TF binding / DNase peak 
2a   TF binding + matched TF motif + matched DNase Footprint + DNase peak 
2b   TF binding + any motif + DNase Footprint + DNase peak 
2c   TF binding + matched TF motif + DNase peak 
3a   TF binding + any motif + DNase peak 
3b   TF binding + matched TF motif 
4   TF binding + DNase peak 
5   TF binding or DNase peak 
6   Other 
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Table 3.3. HaploReg output for rs3816375. ITGAV variants in high LD with rs3816375 
(r2≥0.8) are included. There was no data in Regulome DB to provide a score for rs3816375. 
In TARGET, the GG genotype for rs3816375 was associated with significantly shorter OS in 
patients from the sorafenib arm (p=4.87x10-04, q=0.051). Abbreviations: LD, linkage 
disequilibrium; SNP, single nucleotide polymorphism. 
Position 
LD 
(r²) 
Variant Ref Alt 
EUR 
freq 
Promoter 
histone 
marks 
Enhancer 
histone 
marks 
DNAse 
Proteins 
bound 
Motifs 
changed 
GENCODE 
genes 
dbSNP 
functional 
annotation 
chr2:187503226 1 rs4667108 T C 0.40 
 
BLD, 
SKIN   
Cdx, 
TATA 
ITGAV intronic 
chr2:187505486 1 rs3816375 A G 0.40 
 
BLD, 
BONE 
LNG 
 
4 altered 
motifs 
ITGAV intronic 
chr2:187513708 0.87 rs202185248 
23-
mer 
T 0.58 
    
Mef2 ITGAV intronic 
chr2:187517655 0.91 rs4667109 T C 0.39 
    
CEBPG, 
Foxp1, 
PLZF 
ITGAV intronic 
chr2:187532010 0.92 rs41265951 G T 0.39 
    
TATA ITGAV intronic 
chr2:187533741 0.93 rs2290083 T C 0.39 
    
5 altered 
motifs 
ITGAV intronic 
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Table 3.4. HaploReg output for rs8047917. WWOX variants in high LD with rs8047917 
(r2≥0.8) are included. Regulome DB score for rs8047917 is 5, for rs77533819 is 6, and for 
rs7190335 is 6. There is evidence of siPhycons for rs7190335. In TARGET, the TA genotype 
for rs8047917 was associated with significantly shorter OS in patients from the sorafenib arm 
(p=3.27x10-04, q=0.076). Abbreviations: LD, linkage disequilibrium; SNP, single nucleotide 
polymorphism. 
Position 
LD 
(r²) 
Variant Ref Alt 
EUR 
freq 
Promoter 
histone 
marks 
Enhancer 
histone 
marks 
DNAse 
Proteins 
bound 
Motifs 
changed 
GENCODE 
genes 
dbSNP 
functional 
annotation 
chr16:78184378 0.83 rs8052567 C G 0.07 
    
Ets WWOX intronic 
chr16:78187380 0.98 rs16947192 T C 0.07 
    
ATF3 WWOX intronic 
chr16:78188868 1 rs77533819 T C 0.07 
 
4 organs 
  
5 altered 
motifs 
WWOX intronic 
chr16:78189414 1 rs8047917 T A 0.07 
 
6 organs LNG 
 
E4F1,HM
G-IY, 
XBP-1 
WWOX intronic 
chr16:78190218 0.96 rs7190335 T C 0.07 
 
BRST, 
BRN, 
SKIN 
SKIN, 
LNG  
5 altered 
motifs 
WWOX intronic 
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Table 3.5. HaploReg output for rs307826. There are no variants in high LD with rs307826 
(r2≥0.8); however, this SNP is in low LD (r2=0.38) with rs307821, which is another non-
synonymous variant previously associated with survival in patients treated with pazopanib 
and sunitinib. There is evidence of SiPhycons with rs307826 (not shown in table). The 
Regulome DB score for rs307826 is 5. In TARGET, the GG genotype was associated with 
significantly shorter OS in a combined analysis of both patient arms (p=1.24x10-04, q=0.088). 
Abbreviations: LD, linkage disequilibrium; SNP, single nucleotide polymorphism. 
Position 
LD 
(r²) 
variant Ref Alt 
EUR 
freq 
Promoter 
histone 
marks 
Enhancer 
histone 
marks 
DNAse 
Proteins 
bound 
Motifs 
changed 
GENCODE 
genes 
dbSNP 
functional 
annotation 
chr5:180051003 1 rs307826 A G 0.11  10 organs   
Egr-1 ,Irf, 
NRSF 
FLT-4 missense 
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Table 3.6. Summary of key results. For the seven variants identified in Aim 1, this table 
summarizes the key results from Aims 1-2: the clinical association, in silico predictions, and 
in vitro validation results. Abbreviations: HEK, human embryonic kidney; IC50, half maximal 
inhibitory concentration. 
Variant Gene 
Clinical 
Association 
HaploReg Evidence 
Regulome 
DB Score 
SIFT/ 
PolyPhen-2 
In Vitro 
Validation 
Results 
rs307826 FLT-4 
GG associated 
with decreased 
OS in 
combined 
analysis: 
• p=1.24x10-04 
• q=0.088 
Moderate: 
• Enhancer histone 
marks in 10 organs 
• 3 altered motifs 
5 
SIFT: 
• 0.53 
• Tolerated 
 
PolyPhen-2: 
• 0.005 
• Benign 
Resistant IC50  
in HEK cells 
transfected 
with rs307826 
and treated 
with sorafenib 
rs1885657 VEGFA 
CC associated 
with decreased 
OS in sorafenib 
arm: 
• p=1.39x10-04 
• q=0.076 
High: 
• Promoter histone 
marks in 22 organs 
• Enhancer histone 
marks in 12 organs 
• DNase 
hypersensitivity in 18 
organs 
• 4 proteins bound 
• 5 altered motifs 
4 N/A 
Increased 
luciferase 
activity 
(whole 
element and 
variant allele) 
in: 
• Caki-1 
• LPEC 
• TIME 
rs3024987 VEGFA 
CT associated 
with decreased 
OS in 
combined 
analysis: 
• p=8.80X10-04 
• q=0.088 
High: 
• Promoter histone 
marks in 19 organs, 
• Enhancer histone 
marks in 15 organs 
• DNase 
hypersensitivity in 2 
organs 
• 5 altered motifs 
4 N/A 
Increased 
luciferase 
activity 
(variant 
allele) in: 
• Caki-1 
• LPEC 
• TIME 
rs3816375 ITGAV 
GG associated 
with decreased 
OS in sorafenib 
arm: 
• p=4.87x10-04 
• q=0.051 
Moderate: 
• Enhancer histone 
marks in 2 organs 
• DNase 
hypersensitivity in 1 
organ 
• 4 altered motifs 
N/A N/A N/A 
rs8047917 WWOX 
TA associated 
with decreased 
OS in sorafenib 
arm: 
• p=3.27x10-04 
• q=0.076 
Moderate: 
• Enhancer histone 
marks in 6 organs 
• DNase 
hypersensitivity in 1 
organ 
• 3 altered motifs 
5 N/A N/A 
113 
rs200809375 
3' of 
NRP-1 
ATG associated 
with decreased 
OS in sorafenib 
arm: 
• p=2.65x10-04 
• q=0.076 
Minimal: 
• 2 altered motifs 
6 N/A N/A 
rs6719561 
3' of 
UGT1A9 
Associated with 
OS in sorafenib 
arm: 
• p=3.27x10-04 
• q=0.076 
Minimal: 
• 2 altered motifs 
5 N/A N/A 
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FIGURES 
Figure 3.1. UCSC Browser’s ENCODE output for VEGFA variants. ENCODE output 
from the University of Santa Cruz (UCSC) Genome Browser for variants rs1885657, 
rs3024987, rs58159269 and rs943070 is represented in this figure under a region on 
chromosome 6 (43,739,300-43,741,000). A) Regions where there is evidence of histone 
modifications are shown here (H3K4me1, H3K3me3, and H3K27ac marks). Individual 
colors represent evidence in individual cell lines. B) Evidence of DNase hypersensitivity is 
shown here. Black represents a region with more hypersensitivity. C) ChIP-Seq evidence of 
altered binding motifs for different transcription factors. Black represents evidence of altered 
transcription factor binding, while the lighter the shade of grey represents fewer cell lines 
that demonstrated altered binding for an given transcription factor.  Abbreviations: ChIP-Seq, 
chromatin immunoprecipitation-sequencing. 
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Figure 3.2. Histone marks in HUVEC cells for VEGFA variants. ENCODE output from 
the UCSC Genome Browser for variants rs1885657, rs3024987, rs58159269 and rs943070 is 
represented in this figure under a region on chromosome 6 (43,739,300-43,741,000). 
Regulatory regions where marks are present that are evident of histone modifications 
(H3K4me1, H3K3me3, and H3K27ac marks) are shown for HUVEC cells. Abbreviations: 
HUVEC, human umbilical vein endothelial cells; UCSC, University of Santa Cruz.   
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Figure 3.3. Effects of rs307826 on cell viability in reference-transfected, and mutant-
transfected HEK-293 cells. Transfected cells were treated 12 concentrations of sorafenib 
(0–30 µM) and then with alamarBlue® to assess cell viability and generate IC50 values. 
Stimulated cells were treated with VEGFC (200 ng/mL) prior to sorafenib administration. 
Relative fluorescence units (RFUs) were generated, and RFUs were used to determine the 
percent of viable cells present for a given concentration. Concentrations were compared to 
untreated controls with 0.2% DMSO. The IC50 for unstimulated reference-transfected cells 
was 7.58, while the IC50 for VEGFC-stimulated reference-transfected cells was 2.02.  The 
IC50 for unstimulated mutant-transfected cells was 15.4, while the IC50 for VEGFC-
stimulated mutant-transfected cells was 7.67. For the purpose of this figure, reference 
constructs with the A allele were referred to as reference, and mutant constructs with the 
rs307826 G allele were referred to as Mut.  
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Figure 3.4. Dual reporter gene assay results for luciferase activity of SNPs in VEGFA. 
Relative luciferase activity of SNPs is represented in Caki-1, TIME and LPEC cell lines 
(from left to right).  SNP luciferase activity is normalized to empty pGL4.26 plasmid 
luciferase activity. The mean ± SEM of the transfection experiments in quadruplicate is 
shown. In this figure, WT refers to the reference allele. Abbreviations: LPEC, liver 
parenchyma endothelial cells; SEM, standard error of the mean ; SNP, single nucleotide 
polymorphism; TIME, telomerase-immortalized microvascular endothelial; VEGFA,  
vascular endothelial growth factor A; WT, wild type. *p≤0.05, **p≤0.01, ***p≤0.001. 
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Figure 3.5. Dual reporter gene assay results for luciferase activity of rs3024987. Relative 
luciferase activity of SNPs is represented in Caki-1, TIME and LPEC cell lines (from left to 
right).  SNP luciferase activity is normalized to empty pGL4.26 plasmid luciferase activity. 
The mean ± SEM of the transfection experiments in quadruplicate is shown. Abbreviations: 
LPEC, liver parenchyma endothelial cells; SEM, standard error of the mean ; SNP, single 
nucleotide polymorphism; TIME, telomerase-immortalized microvascular endothelial; 
VEGFA, vascular endothelial growth factor A; WT, wild type.  
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CHAPTER 4: IDENTIFYING GENETIC MARKERS FOR CYTOTOXIC RESPONSE 
TO SORAFENIB IN MOUSE EMBRYONIC FIBROBLAST CELLS 
 
4.1 Overview 
Background:  
Sorafenib is an oral multikinase inhibitor that decreases tumor angiogenesis and 
proliferation. The antitumor efficacy and toxicity profiles of sorafenib vary among patients. 
Novel pathways and targets of sorafenib activity remain to be identified, and no predictive 
biomarkers of sorafenib activity exist to help guide clinicians. This aim sought to identify 
novel genes associated with sorafenib activity by using an in vitro methodology based upon 
mouse genomics and high-throughput screening of multiple cell health parameter 
phenotypes. 
 
Methods:  
Primary mouse embryonic fibroblasts (MEFs) from 32 inbred strains were profiled 
for sorafenib cytotoxicity utilizing high content imaging and simultaneous evaluation of cell 
health parameters. The 32 strains were genomically characterized previously. MEFs were 
treated with ten concentrations of sorafenib (0–300 µM), incubated for 24 and 72 h, then 
fixed and stained. Cell viability, MEF cell membrane permeability, mitochondrial membrane 
potential, and cytochrome C release were assessed (Table 4.1). Image analysis software 
assessed the effects of sorafenib on each phenotype. Dose response curves were generated 
from data using a Brain-Cousens model, and EC50 or IC50 values for each strain were 
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identified. Genome-wide association (GWA) mapping, using the efficient mixed-model 
associations (EMMA) and SNPster algorithms, was performed to identify quantitative trait 
loci (QTLs) associated with sorafenib activity. Approximately 277,000 single nucleotide 
polymorphisms were tested, and genomic loci discovered by EMMA, with p-values 
<1.0x10-7, were identified as potential candidate genes.  These genes were then examined 
using stringent, multi-faceted criteria before being selected for future laboratory validation.  
 
Results:  
Interstrain IC50 variability among the 32 MEF strains was observed after 72 h 
sorafenib incubations (17.2-44.5 µM). One peak (chromosome 9 from 51-52 Mb;  
p=1.0x10-8), which reached genome-wide significance and significantly associated with 
cytochrome C release, was identified. From this peak, candidate genes that may underlie 
variability in sorafenib-induced cytochrome C release from mitochondria have been 
identified. A total of nine genes, expressed in MEF cells at mRNA level, are present in this 
QTL. Interstrain IC50 variability, which associated with VOC, was also observed after 72 h 
sorafenib incubations (17-32 µM). One peak potentially associated with cell viability 
(chromosome 4 from 119,500,000-120,750,000; p=2.2x10-5). From this peak, candidate 
genes that may underlie variability in sorafenib cytotoxicity and cell viability have been 
identified. A total of 13 candidate genes, expressed in MEF cells at mRNA level, are present 
in this QTL. 
 
 
 
124 
Conclusions:  
This innovative high content cellular genetics approach has detected robust interstrain 
cellular differences in sorafenib activity. One QTL region, which reached genome-wide 
significance and potentially associates with sorafenib-induced cytochrome C release from 
mitochondria, was identified. An additional QTL was identified that potentially associates 
with sorafenib cytotoxicity and cell viability. Candidate genes for functional validation have 
been prioritized through a multi-faceted set of criteria. Future steps for this work include 
functional validation of candidate genes, using knockdown and overexpression approaches, 
in MEF and human cell lines. Ultimately, variants in candidate genes that are successfully 
validated will be genotyped in TARGET patients and tested for associations with OS, PFS, 
and sorafenib-induced toxicities. 
 
4.2 Introduction 
Since the approval of sorafenib in 2005, major advancements have been made in the 
treatment of metastatic clear-cell RCC.  These advancements, defined as improved OS and 
PFS for a majority of patients, are largely due to molecular knowledge underlying disease 
pathology. Subsequent to sorafenib, three additional angiogenesis inhibitors (axitinib, 
pazopanib, and sunitinib), and two inhibitors of mTOR (everolimus and temsirolimus) were 
approved by the U.S. FDA. While axitinib, pazopanib, sorafenib, and sunitinib belong to the 
same class of oral multikinase inhibitors that target the VEGF pathway, they all differ in the 
exact kinases they inhibit, the potency of kinase inhibition, clinical pharmacology, dosing 
and dose intensity, and ultimately clinical efficacy. 
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 Sorafenib is an exceptionally promiscuous oral multikinase inhibitor used in the 
treatment of RCC, hepatocellular carcinoma and thyroid cancer.1,2 Originally, sorafenib was 
developed as a RAF inhibitor based on in vitro screen showing its potent inhibition of RAS 
serine/threonine isoforms.3,4 Similarly, it was also shown to be a potent inhibitor of the 
several other targets in the RAS/MEK/ERK signal transduction cascade, the c-KIT receptor, 
initiation factor eIF4E and the anti-apoptotic protein MCL-1.2,5-7 Most notably though, 
sorafenib has been shown to be an effective VEGF-pathway and angiogenesis inhibitor by 
targeting several kinases, including: VEGFR-1-3, PDGFR-β, FLT-3, and FGF-1.2,6,7  
However, recent data has begun to emerge revealing novel and previously unknown 
targets of sorafenib. More recently, sorafenib has been shown to be a ligand for multiple 
serotonin receptors,8 an inhibitor of additional anti-apoptotic proteins not directly tied to 
angiogenesis (e.g. cyclin B1, cyclin D1 and survivin),9 and has been found to also affect the 
immune system (e.g. on the function of dendritic cells, and by modulating effector CD4+ cell 
and regulatory T cell function).10,11 There are very likely many novel and still undiscovered 
targets of sorafenib, and many of these targets are likely susceptible to germline genetic 
variation. 
Previous studies have shown that fine genome mapping, through genome wide 
association studies (GWAS), can be successfully performed in a panel of diverse inbred 
strains of mice to identify genetic loci that contain candidate genes that modulate both single 
gene and polygenic traits.12-15 But to date, there have been few examples of animal GWAS 
pharmacogenetics, and even those that have been published have not analyzed the 
contribution of genetics to multikinase inhibitor (e.g. sorafenib) activity.16-19 Moreover, 
previous pharmacogenetic studies of VEGF-pathway inhibitors of the same class as sorafenib 
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(e.g. pazopanib and sunitinib) have focused on associations between variants in drug 
metabolizing/transporter genes or genes involved with angiogenesis, and clinical phenotypes 
(e.g. OS, PFS and drug-induced toxicities).20-24 And, the only study in humans to test 
genotype-clinical phenotype associations in mRCC patients was not conducted in patients 
treated with sorafenib.25 
 In this Aim, MEFs from 32 inbred isogenic strains were treated with sorafenib in a 
concentration-response format. Phenotypic measurements of cell health were obtained 
through the use of high-content imaging, and GWAS was performed to identify potential 
candidate quantitative trait loci QTLs and candidate genes that underlie sorafenib activity 
(Figure 4.1). The use of genetically well-characterized inbred mouse strains provides a viable 
model system to analyze the genetic basis for drug activity and cytotoxicity.  These MEF 
strains can be used in a high-throughput cellular genetics approach for four main reasons: 
retention of the exact genetic composition of the mouse strain from which they are isolated, 
selection of these 32 strains increases the likelihood of detecting genetic differences that 
could underlie differences in sorafenib response and/or identify novel nodes in sorafenib 
signaling pathways, technological advances (e.g. high-content imaging) have allowed for 
better characterization of cellular phenotypes, and technological advances (e.g. siRNA loss of 
function and cDNA over-expression in vitro validation techniques) have allowed for 
functional validation of QTLs. This Aim will test the hypothesis that differential cell health 
and response data (e.g. EC50 or IC50 values) from 32 MEF cells lines treated with sorafenib, 
can be used in GWAS to identify candidate genes associated with sorafenib response, which 
will ultimately lead to the discovery of novel genes for future pharmacogenetic testing in 
patients treated with sorafenib. 
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4.3 Materials and Methods 
4.3.1 Animals 
Primary mouse embryonic fibroblast (MEF) cells derived from 32 inbred strains were 
obtained from The Jackson Laboratory (Bar Harbor, ME) were used in this screen: 
129S1/SvImJ, A/J, AKR/J, BALB/cByJ, BTBR T+ tf/J, BUB/BnJ, C3H/HeJ, C57BL/6J, 
C57BR/cdJ, CBA/J, CE/J, CZECHII/EiJ, DBA/2J, FVB/NJ, I/LnJ, KK/HlJ, LP/J, MA/MyJ, 
MOLF/EiJ, MRL/MpJ, NOD/ShiLtJ, NON/ShiLtJ, P/J, PERA/EiJ, PL/J, PWK/PhJ, RIIIS/J, 
SEA/GnJ, SJL/J, SM/J, SWR/J, and WSB/EiJ. Cells were harvested from male mice aged 10-
12 weeks. The isogenic strains chosen for this screen were a subset of strains from the Mouse 
Phenome Project.12 
 
4.3.2 Cell Culture 
 Each of the 32 MEF cell lines was expanded from passage 0 to passage 2 using 
DMEM (Cellgro, Manassas, VA) supplemented with 10% FBS (Cellgro), 1% non-essential 
amino acid solution (Sigma Aldrich, Milwaukee, WI), and 1% penicillin/streptomycin 
(Sigma Aldrich). MEF cells were maintained at 37oC and 5% CO2. When MEF cells reached 
90% confluence they were harvested. MEF cells were seeded into 384-well, PDL-coated 
Aurora 200 micron COP polymer plates (Aurora Biosciences/Brooks Life Science Systems, 
Fremont, CA) using Multidrop 384 dispensers (Thermo Scientific, Waltham, MA) to a final 
concentration of 5x104 cells/mL per well. Seeding densities were confirmed by an Invitrogen 
Countess automated cell counter (Invitrogen, Carlsbad, CA). For each 384-well microtiter 
plate (n=4 replicates), 12 wells were assigned to each of the 32 strains (Figure 4.2A). Cells 
were plated with two different densities: 1500 cells/well for the 24 h time point and 1000 
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cells/well for the 72 h time point. A final volume of 5 µL of cells in supplemented DMEM 
was administered to each well. Plates were incubated overnight at 37oC and 5% CO2. 
 
4.3.3 High Content Screening 
 The cytotoxic effects of sorafenib on MEF cells were screened using a nine-point 
logarithmic dose response. Sorafenib response was assessed 24 and 72 h post administration.  
Stock solutions were prepared in DMSO to create a master microtiter plate for the screens: 
75 mM, 25 mM, 8.33 mM, 2.78 mM, 0.93 mM, 0.31 mM, 0.10 mM, 0.03 mM, and 0.01 mM. 
Three-fold serial dilutions were prepared using DMSO (Sigma Aldrich) and a Biomek 2000 
(Beckman Coulter, Brea, CA), and the final sorafenib concentrations used in the screens 
were: 300 µM, 100 µM, 33 µM, 11 µM, 3.7 µM, 1.2 µM, 0.41 µM, 0.14 µM, and 0.045 µM. 
Two separate positive control microplates, containing valinomycin in DMSO, were prepared. 
For the 24 h time point, valinomycin with a concentration of 8.33 mM (final diluted 
concentration of 33 µM) was prepared. For the 72 h time point, valinomycin with a 
concentration of 5 µM (final diluted concentration of 20 nM) was prepared. The MEF cells 
were dosed with 200 nL of each sorafenib concentration, in quadruplicate, from the stock 
solution in the master microtiter plate using a slot pin tool (V&P Scientific, San Diego, CA) 
on a Biomek FX liquid handling automation system (Beckman Coulter). For plate reference 
control compounds, one well for each cell line was treated with valinomycin in DMSO, one 
well was treated with vehicle only (DMSO 0.4% final concentration) and one well for each 
cell line was treated with media only (Figure 4.2A). 
After 24 h or 72 h incubation with the compounds, cells were labeled and processed 
using the Thermo Cellomics Multiparameter Cytotoxicity 3 Kit protocol (Thermo Scientific, 
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Rockford, IL) and HCA Image Amp protocol (Perkin Elmer, Waltham, MA). First, MEF 
cells were stained with Mitotracker Orange dye (Invitrogen, Carlsbad, CA) to assess 
mitochondrial membrane potential, and YOYO-1 cell permeability dye (included in the 
Multiparameter Cytotoxicity 3 Kit) and incubated at 37oC. Next, MEF cells were fixed with 
16% paraformaldehyde, washed, labeled with anti-Cytochrome C antibody (Thermo), and 
finally counterstained with Hoechst 33342 nuclear stain (included with the Multiparameter 
Cytotoxicity 3 Kit). All dyes, buffer, and antibodies were administered using Multidrop 384 
well dispensers. All wash steps were completed using a BioTek ELx405 Select microtiter 
plate washer (BioTek, Winooski, VT). 
 
4.3.4 Image Acquisition and Analysis 
Plates were sealed once staining was completed, and subsequently imaged on the 
Cellomics ArrayScan VTi™ high content imager (Thermo), using 10X/0.45NA objective 
lens (Figure 4.2B). Cells expressing fluorescent bioprobes for Hoechst 33342 (386 nm), 
YOYO-1 (485 nm), Mitotracker Orange (549 nm), and Cytochrome C–Alexafluor 647 (650 
nm) were excited with LED light engine (L µM encor, Beaverton, OR), and emitted light 
through a Quadband filter set (Semrock, VT) to collect fluorescence signal using a 12-bit 
Orca-ER II CCD Camera (Hamamatsu, Japan). Exposure times were <0.05 seconds, and four 
fields per well were captured. Next, a compartmental analysis algorithm identified: valid 
object counts based on Hoechst nuclear staining (cell loss), mean average intensity of 
YOYO-1 positive cells in the nucleus (membrane permeability), mean average intensity of 
Mitotracker Orange in the cytoplasm (mitochondrial function), and mean average intensity of 
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Cytochrome C–Alexafluor 647 (apoptosis) in the cytoplasm (Table 4.1, Figure 4.2C). All 
generated data was exported using the vHCS View client (Thermo).  
Captured images were manually inspected for data integrity. Wells were rejected for 
replicate analyses from the final analysis if an image was not properly focused, contained a 
fluorescent artifact, or if debris occupied >20 % the field area. Outliers that failed the QC 
criteria were filtered and removed from the final data analyses.  
 
4.3.5 Response Analyses 
Values generated by the image analysis algorithm for each MEF strain were 
normalized to the DMSO control well on each plate. For the cell viability phenotype, 
hereafter referred to as Valid Object Count (VOC), values were normalized against the 
DMSO average among the quadruplicate plates for each individual MEF line). Dose response 
curves were created in F-Curve software, for each MEF cell line by fitting the normalized 
quadruplicates to a Brain-Cousens model implemented by the drc package (version 1.8-1) for 
R (Figure 4.2D).26 Brain-Cousens was chosen to account for biphasic response and biological 
shifts sometimes observed from toxic compound dose responses (e.g. hormesis).27 The Brain-
Cousens equation is: f(x,(b,c,d,e)) = c+((d+fx−c)/(1+exp(b(log(x)−log(e))))). 
All curves were visually inspected for outliers. In cases where outliers were removed, 
a new fit was performed in F-curve. Dose-response curves, generated using F-curve and the 
Brain Cousens model, were used to calculate the individual effective concentration (EC) or 
inhibitory concentration (IC) values of each MEF line. For the phenotypic endpoints where 
response decreased (VOC and cytochrome C release), IC50 through to EC80 values in six 
stepwise increments of 5% were interpolated from the fitted function (Figure 4.3). 
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4.3.6 Quantitative Trait Loci Mapping 
 GWA mapping was performed using the respective half-maximal effective 
concentration (EC50) and half-maximal inhibitory concentration (IC50) values for each cell 
health phenotype using the EMMA and SNPster algorithms.28,29 Only phenotypes with EC50 
or IC50 values for ≥27 strains were used in GWAS. The SNPster algorithm uses a bootstrap 
model to calculate the significance of association analysis from an inferred haplotype 
structure determined by overlapping three-SNP windows for each strain. A one-way 
ANOVA F-statistic from associations between the haplotypes and either EC50 or IC50 values 
for each phenotype. Then, p-values were generated after the phenotype values were 
bootstrapped (1x106 times), and thus the maximum –log(P) value was 6.28 Conversely, 
EMMA used single SNPs for GWA mapping, where the ANOVA F-statistic and p-values 
were generated from associations between the individual marker and phenotypic value.29 
EMMA SNPs were filtered to remove non-informative markers and redundant SNPs, where 
adjacent polymorphisms have the same allelic distribution pattern across the inbred mouse 
strains. P-values generated from these associations were corrected for multiple comparison 
testing using a Bonferroni correction, and therefore the threshold for genome-wide 
significance using EMMA was a p-value of 1.8x10-7, or a –log(P) value of ≥6.74. 
 Although EC50 and IC50 values were chosen a priori to represent the phenotype for 
each cell health parameter, a QC step was performed next to assess the robustness of 
genotype-phenotype associations. The identification of QTLs for each of the four phenotypes 
verified selecting the SNPs with the highest association scores (top 2% of association scores 
by –logP value) across EC50-80 and IC50-80 ranges, and the top 2% association scores were 
averaged at each SNP position (Figure 4.4A and 4.4B). Genomic regions with mean –logP 
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≥4.0 (including a window of 100 kb on each side) were selected for further analysis using 
EC50 or IC50 association data (Figure 4.4C). Genes that completely or partially overlap the 
regions associated with drug response were selected for pathway and functional enrichment 
analysis. Candidate genes were selected from the University of California Santa Cruz 
(UCSC) mouse RefSeq database (assembly mm9, http://genome.ucsc.edu/) (Figure 4.5). 
 The SNP genotypes used for association mapping were obtained from the Mouse 
Diversity Array set, available from the Comparative Genomics Database website (CGD; 
http://cgd.jax.org/cgdsnpdb/).30 SNPs were trimmed from the final set based on redundancy 
(identical haplotype pattern at a particular locus), missingness (few calls for a specific SNP 
among the 32 strains), and if they demonstrated a lack of genetic variability among the 32 
strains. After pruning, approximately 277,000,000 SNPs were used for the analyses. 
Manhattan plots were visualized using R version 3.1.0 and the UCSC Mouse Genome 
Browser on the Mouse July 2007 (NCBI37/mm9) Assembly (https://genome.ucsc.edu).31  
 
4.3.7 Candidate Gene Selection 
Candidate gene selection was conducted using a multi-step, multi-faceted approach 
(Figure 4.6). Genomic regions with mean –logP ≥4.0 for a given phenotype were moved 
forward for further analysis. Next, to increase efficiency of all downstream analyses, the first 
step in candidate gene selection was to examine genes with likely cellular responses in 
MEFs, so only genes with known expression levels in MEFs were selected. Subsequently, 
expression levels of genes were examined in kidney cells from six strains of inbred mice 
(A/J, AKR/J, C3H/HeJ, C57BL/6J, CBA/J, and DBA/2J).  Kidney cell expression was 
prioritized over other tissue types because of its relevance to the patients and tumor type 
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described extensively in Aims 1-2. Expression levels were measured in MEFs and using the 
Affymetrix Mouse Genome 430 2.0 Array (Santa Clara, CA). Genes were considered 
expressed if their expression level was greater than 50 for at least one of the strains following 
data processing with the gcRMA algorithm. 
Next, QTL regions that overlapped using both SNPster and EMMA algorithms were 
prioritized, and genes in these regions were still considered candidates. However, it is 
important to note that these QTL regions need not have a –logP ≥6.74 to still be considered. 
Candidate genes were further prioritized based on: literature evidence biology that underlies 
sorafenib response or cancer pathogenesis, differential haplotype structure between MEF 
strains with low EC50 or IC50 values versus those with high values, evidence of functional 
annotation using the UCSC Genome Browser and/or the Ensembl website 
(www.ensembl.org), evidence of cis-acting gene regulation among candidate genes in a QTL 
region, if there was presence of potentially deleterious non-synonymous coding SNPs within 
a QTL, or if there were direct connections between a candidate gene and sorafenib or known 
targets of sorafenib (e.g. receptors, transcription factors, kinases, etc.).32-35 
 The Mouse Genome Informatics Database (MGI; http://www.informatics.jax.org) and 
the CGD resources were used to examine non-synonymous coding SNPs in candidate genes 
within 30 MEF strains used for GWAS. Build 137 on the dbSNP website 
(http://www.ncbi.nlm.nih.gov/projects/SNP) was used to confirm the SNP position (m38) 
and amino acid substitution for a given non-synonymous SNP. PROVEAN (Protein 
Variation Effect Analyzer) version 1.1.322, PANTHER (Protein Analysis Through 
Evolutionary Relationships) version 9.0 and SIFT (Sorting Intolerant From Tolerant) version 
1.03 were utilized to assess that candidate non-synonymous SNPs would cause deleterious 
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effects to protein structure or function.36-39 For PROVEAN, a score of -2.5 indicates that the 
SNP results in alterations to the functional effect on the protein. For the PANTHER, a 
subSPEC (substitution position-specific evolutionary conservation) score of -3 indicates that 
there is a 50% probability that a score is deleterious (Pdeleterious= 0.5), MSA indicates the 
number of multiple sequence alignments, NIC (number of independent counts) is an estimate 
of observations used to calculate the amino acid probabilities. Pwt and Psubstituted refer to the 
respective probabilities of the wild-type (WT) and substituted amino acids. For the SIFT 
algorithm, a score <0.05 indicates that the SNP would likely cause deleterious effects on the 
protein.  Protein data for a given SNP was considered significant if PROVEAN predicted the 
protein to likely be deleterious, if PANTHER returned a score ≤-3, and/or if SIFT returned a 
score <0.05. Mouse Phylogeny Viewer (https://msub.csbio.unc.edu/) was used to examine 
haplotype structure among the MEF strains for a given QTL or candidate gene.40 Finally, 
Ingenuity® Pathway Analysis was used to determine if direct connections between a 
candidate gene and sorafenib or known targets of sorafenib (e.g. receptors, transcription 
factors, kinases, etc.) could be predicted (http://www.ingenuity.com).35 
 
4.4 Results 
4.4.1 High Content Imaging Screen 
A high content imaging screening approach based on mouse genetics was selected to 
simultaneously evaluate multiple cell health parameters involved with early and late 
apoptosis. The study design allowed MEF cells from 32 inbred mouse lines of the Mouse 
Phenome Project to be plated on a single 384-well plate and then treated with sorafenib in a 
10-point concentration-response curve manner (and with positive and negative controls) for 
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each strain. A total of four 384-well plates were successfully stained, imaged and analyzed 
during the experiments conducted for this Aim. Approximately 1.5% of the wells from all 
four plates were discarded due to image quality issues after visual inspection of each of the 
wells in question. The WSB/EiJ required re-analysis across the four plates due to issues 
related to the analysis algorithms versus the strain’s small-sized nucleus. Ultimately, issues to 
do with nucleus size also confounded analyses in F-Curve, and the WSB/EiJ strain was 
removed. In addition, due to problems with plating during the screen, the SWR/J strain was 
removed. The final SNPster and EMMA GWA mapping studies included 30 MEF lines for 
four cell health parameter phenotypes and both 24 h and 72 h sorafenib incubation time 
points. 
 
4.4.2 Quantitative Trait Loci Mapping 
 Using GWA mapping through the SNPster and EMMA, only two of the four 
phenotypes (Cytochrome C release and VOC) at the 72 hour time point revealed QTL 
regions with –logP value ≥4.0, and QTL regions that overlapped on both algorithms were 
identified. No QTL regions with –logP value ≥4.0 were identified for any of the four 
phenotypes after 24 h incubation with sorafenib. Similarly, no QTL regions with –logP value 
≥4.0 were identified for the cell permeability or mitochondrial membrane potential 
phenotypes after 72 h incubation with sorafenib. 
IC50 variability across the strains was observed for Cytochrome C release (Figure 4.7) 
and VOC (Figure 4.8) after a 72 h incubation with sorafenib, which indicated significant 
genetic variability among the strains for these two phenotypes. One genome-wide significant 
QTL (p=1.0x10-8, –logP=8), which overlapped using both SNPster and EMMA algorithms, 
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was identified for the Cytochrome C release phenotype: chromosome 9, position 50,500,000-
52,500,000 (Figure 4.9). A total of seven genes (Figure 4.10) were identified under this QTL 
(Arhgap20, Btg4, Fdx1, Layn, Pou2af1, Rdx, and Zc3h12c). The gene directly under the 
genome-wide significant peak, Arhgap20, was not expressed in MEF or mouse kidney cells. 
Among the genes under this genome-wide significant peak, only Fdx1, Layn, Rdx, and 
Zc3h12c were expressed in both MEF cells (Table 4.2) and in mouse kidney cells. Fdx1 
expression in kidney cells was 12,679.96, Layn expression was 64.23, Rdx expression was 
1,829.55, and Zc3h12c was 196.79. These four genes associated with Cytochrome C release 
were prioritized for candidate gene selection. 
A second notable QTL (p=2.2x10-5, –logP=4.66), which overlapped using both 
SNPster and EMMA algorithms, was identified for the VOC phenotype: chromosome 4, 
position 119,000,000-121,500,000 (Figure 4.11). A total of 13 genes (Figure 4.12) were 
identified under this QTL (Ctps, Col9a2, Exo5, Edn2, Foxo6, Hivep3, Kcnq4, Nfyc, Rims3, 
Scmh1, Slfnl1, Smap2, and Zpf69). Among the genes under this genome-wide significant 
peak, only Ctps, Exo5, Nfyc, Scmh1, Smap2, and Zpf69 were expressed in both MEF cells 
(Table 4.3) and in mouse kidney cells. Notably, Scmh1 was the gene closest to being directly 
under the peak. No probe sets were available to assess expression in Foxo6. Ctps expression 
in kidney cells was 615.64, Exo5 expression was 534.41, Nfyc expression was 498.13, 
Scmh1expression was 87.54, Smap2 expression was 222.71 in one probe set, and Zpf69 
expression was 125.74. These four genes associated with Cytochrome C release were 
prioritized for candidate gene selection 
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4.4.3 Candidate Gene Selection 
 Four genes (Fdx1, Layn, Rdx, and Zc3h12c) within the genome-wide significant QTL 
associated with Cytochrome C release (chromosome 9, position 50,500,000-52,500,000) 
were expressed in MEFs and mouse kidney tissue. For this phenotype, seven strains (SM/J, 
RIIIS/J, C57BL/6J, C57BR/cdJ, PL/J, MA/MyJ, and AKR/J) were more sensitive to the 
cytotoxic effects of sorafenib after a 72 h incubation. Differences in haplotype structure 
among these four genes were noted for the seven sensitive strains, when compared to the 23 
strains more insensitive to sorafenib in terms of cytochrome C release (Figure 4.13). The 
only exception involved Layn, where the second most sensitive strain (RIIIS/J) had the same 
haplotype structure as the insensitive strains. For this reason, Layn was not considered a 
viable candidate gene.  Among genes within this QTL, all were included in pathways directly 
related to sorafenib response and/or known signaling targets of sorafenib; however, one was 
found to have no direct connections to sorafenib or known targets of sorafenib (Zc3h12c) and 
was excluded. Only Rdx was shown to have a direct connection to a known target of 
sorafenib, FLT-1 (Figure 4.14). Only three potentially deleterious non-synonymous SNPs, in 
two genes, were identified among these potential candidates (Table 4.4). Only two non-
synonymous SNPs in Layn (rs33773426 and rs32764902) were predicted to be potentially 
deleterious. Finally, none of the six candidate genes within the QTL region associated with 
VOC revealed evidence of cis-acting gene regulation (data not shown). Considering data 
from all criteria, Rdx will be prioritized as a candidate gene for future validation studies.  
Six genes (Ctps, Exo5, Nfyc, Scmh1, Smap2, and Zpf69) within the QTL that 
associated with VOC/cell viability (chromosome 4, position 119,000,000-121,500,000) were 
expressed in MEFs and mouse kidney tissue. For this phenotype, 13 strains (C57BL/6J, 
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CZECHII/EiJ, RIIIS/J, FVB/NJ, SEA/GnJ, NON/LtJ, AKR/J, C57BR/cdJ, PWK/PhJ, 
BUB/BnJ, MA/MyJ, KK/HIJ, and A/J) were considered more sensitive to the cytotoxic 
effects of sorafenib after a 72 h incubation. Differences in haplotype structure among these 
four genes were noted for the 13 sensitive strains, when compared to the 17 strains more 
insensitive to sorafenib in terms of cell viability (Figure 4.15). Among genes within this 
QTL, all were included in pathways directly related to sorafenib response and/or known 
signaling targets of sorafenib; however, two were found to have no direct connections to 
sorafenib or known targets of sorafenib (Slfnl1 and Zfp69) and were excluded. Only Nfyc was 
shown to have a direct connection to a known target of sorafenib (PDGFR-β). Nfyc was also 
shown to have a direct connection to the oncogenic protein MYC (Figure 4.16). Only nine 
potentially deleterious non-synonymous SNPs, in five genes, were identified among these 
potential candidates (Table 4.5). Only one non-synonymous SNP in Schmh1 (rs28256862) 
and two SNPs in Zpf69 (rs27485619 and rs32769909) were predicted to be potentially 
deleterious. Finally, none of the six candidate genes within the QTL region associated with 
VOC revealed evidence of cis-acting gene regulation (data not shown). Considering data 
from all criteria, Nfyc and Scmh1 will be prioritized as a candidate gene for future validation 
studies. 
 
4.5 Discussion 
The primary objective of this Aim was to test the hypothesis that that differential cell 
health and response data (e.g. EC50 or IC50) from 32 MEF cells lines treated with sorafenib, 
can be used in GWAS to identify candidate genes associated with sorafenib response, which 
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will ultimately lead to the discovery of novel genes for future pharmacogenetic testing in 
patients treated with sorafenib.  
There are many advantages of conducting a high content in vitro screen of drugs 
based on mouse cellular genetics. For instance, this type of high-throughput technology 
allows for multiplexed measurements of several endpoints, and the evaluation of subtle 
cytological changes in response to drug can be observed.18 In addition, inbred mouse lines 
allow for greater reproducibility, when compared to primary human cell lines, due to genetic 
stability of the strains, which allows for robust GWA mapping studies based on the known 
and static nature of inbred and immortalized mouse lines. These strains are genetically and 
phenotypically diverse, and have a substantial number of recombinations, which improves 
GWA mapping resolution.18,28 Therefore, a relatively small number of inbred mouse strains 
can be used, like had been done in this Aim, to discover new genotype-phenotype 
associations that are applicable to human populations. This also enables this type of high-
throughput screen to capture a broad range of drug response variance, and identify genes that 
underlie drug response at a cellular level.18,41 
Aim 1 identified germline variants that significantly associate with OS and PFS 
through a candidate gene/candidate SNP approach. Since this approach leverages existing 
knowledge about mRCC pathogenesis/prognosis, angiogenesis and/or sorafenib 
pharmacology, there is virtually no chance that novel and previously unidentified signaling 
pathways and/or candidate genes will be discovered. This cellular genetics approach, using 
high-content cellular imaging and genetic mapping, has helped discover novel genes and 
pathways involved with sorafenib cytotoxicity and provide a better understanding of the 
variability observed with this phenotype. 
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A total of seven genes expressed in MEF cells at mRNA level were present in the 
QTL that associated with the Cytochrome C release phenotype after a 72 h incubation with 
sorafenib. After a multi-step and multi-faceted schema (Figure 4.6), one candidate gene was 
selected for future in vitro validation studies. Rdx encodes for radixin, which is a component 
of the ezrin-radixin-moesin (ERM)-binding phosphoprotein-50 (EBP50) complex, and is 
conserved between humans and mice. In humans, radixin, as part of the EBP50 complex 
(also known as NHERF1), belongs to the family of PDZ scaffolding proteins, has been 
shown to act as a tumor suppressor in multiple tumor types.42-46 Additionally, EBP50 has 
been shown to promote apoptosis in hepatocellular carcinoma (HCC) by modulating β-
catenin/E-cadherin, and to potentially enhance the metastatic potential of renal cell 
carcinoma.47,48 This is important because sorafenib has been approved by the U.S. FDA for 
the treatment of both mRCC and unresectable HCC.2 More recently, in an osteosarcoma 
model, sorafenib was shown to inhibit phosphorylation of the ERM complex.49 
A total of 13 genes expressed in MEF cells at mRNA level were present in the QTL 
that associated with VOC/cell viability after a 72 h incubation with sorafenib. After the same 
criteria were applied as before (Figure 4.6), two candidate genes were selected for future in 
vitro validation studies. Nfyc encodes for the C subunit of the nuclear factor-gamma (NF-γ) 
transcription factor. This transcription factor complex is conserved between humans and 
mice, and binds to CCAAT motifs in the promoter regions. In humans, NF-γC is integral to 
the trimerization of NF-γA, NF-γB and NF- γC, and is a target for regulatory proteins MYC 
and p53.50  NF-γC has also been shown to regulate DNA-dependent transcription of one of 
sorafenib’s primary targets, PDGFR-β, which is for pericyte formation.51 Scmh1 encodes for 
sex comb on midleg homolog 1 (Drosophila) protein, which forms multiprotein complexes 
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with other polycomb group proteins to help retain the transcriptionally repressed state of 
other genes. Traditionally associated with male spermatogenesis, Scmh1is also conserved 
between humans and mice.52 Nothing is currently known about whether Scmh1 directly 
affects cancer risk, pathogenesis, or prognosis; however, Scmh1 has recently been shown to 
directly and indirectly regulate geminin stability.53 Geminin is a key protein involved in 
DNA replication, has been linked to cancer, and therefore Scmh1 variants could be important 
in cancer and in sorafenib response.54-57 
Future studies to validate these candidate genes will certainly be conducted. First, the 
prioritized candidate genes (e.g. Rdx and Fdx1 for Cytochrome C release, as well as Nfyc and 
Scmh1 for VOC) will be validated in MEF cells using in vitro knockdown and 
overexpression approaches to confirm the capability of this high content imaging screening 
approach as a viable method for gene selection. In vitro methods, using and siRNA approach 
for knockdown and a pCMV-SPORT6 vector-based approach for overexpression, have been 
previously described.18 Validation of candidate genes identified in this study will follow a 
similar experimental design. Second, for genes validated by in vitro knockdown and/or 
overexpression in MEF cells and are conserved in humans, a second round of knockdown 
and overexpression experiments will be conducted. Orthologous human siRNA and 
overexpression vectors will be introduced to a human endothelial cell line (e.g. TIME cells) 
and a human mRCC cell line (e.g. Caki-1 cells) to confirm the putative effects of these genes 
on sorafenib response. Although translating results from an in vitro mouse screen to human 
in vivo studies may seem like a daunting task, it has been successfully accomplished 
previously.16,17,58 Therefore, for genes that are validated in both MEFs and human cell lines, 
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candidate SNPs will be identified, and genotyped in TARGET patients from the sorafenib 
arm to test associations with clinical phenotypes (OS, PFS, and sorafenib-induced toxicities). 
In summary, this innovative high content cellular genetics approach has detected 
robust interstrain cellular differences in sorafenib activity.  One QTL region, which reached 
genome-wide significance, which potentially associates with sorafenib-induced cytochrome 
C release from mitochondria, was identified. An additional QTL was identified that 
potentially associates with sorafenib cytotoxicity and cell viability. Candidate genes for 
functional validation have been prioritized through a multi-faceted set of criteria. Future 
steps for this work include functional validation of candidate genes, using knockdown and 
overexpression approaches, in MEF and human cell lines.  
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TABLES 
Table 4.1. Description of the high content imaging output data features. This description 
includes HCS feature, the corresponding probes used in assay, biological indication 
measured, and IC50 curve fitting trends projected following normalization of data to DMSO 
control. All generated data was exported using the vHCS View client from Thermo. 
Abbreviations: DMSO, dimethyl sulfoxide; HCS, high content screening. 
No. HCS Feature 
IC50 
Trend 
Probe Reagent 
Biological 
Indicator 
1 Valid Object Count Down Hoechst 33342 Stain Cell count / cell loss 
2 
Mean Size Intensity of YoYo-1 
positive cells in nucleus 
Up YOYO-1 Dye 
Comprised nuclear 
membrane 
3 
Mean Average intensity of 
Mitotracker in the cytoplasm 
Down 
Mitotracker Orange 
Dye 
Mitochondria 
function impaired 
4 
Mean Intensity of the 
Cytochrome C–Alexafluor 647 
Down 
Anti-Cytochrome C 
Antibody 
Apoptosis 
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Table 4.2. MEF cell expression of candidate genes within the QTL associated with 
Cytochrome C release. A total of seven genes were identified under that QTL region, and 
their respective expression levels, for all available expression probe sets, are presented in this 
table. Expression level values for six MEF lines and MEF expression levels reported in the 
BioGPS website (www.biogps.org) are included. Abbreviations: MEF, mouse embryonic 
fibroblast; QTL, quantitative trait locus/loci. 
Gene Full Name Probeset ID BioGPS DBA/2J C57BL/6J A/J AKR/J C3H/HeJ CBA/J 
Arhgap20 Rho GTPase activating protein 20 
1427522_at 9.27 7.308 7.161 7.29 7.732 7.296 7.331 
1429918_at 4.64 5.779 5.802 5.771 5.985 5.766 5.804 
Btg4 B cell translocation gene 4 1426520_at 5.37 4.447 4.467 4.44 4.544 4.446 4.519 
Fdx1 Ferredoxin 1 1449108_at 427.69 450.403 602.196 407.316 519.105 455.606 458.031 
Layn Layilin 
1442608_at 37.78 26.79 50.201 44.105 49.095 45.52 44.256 
1444165_at 190.09 78.682 90.642 95.183 114.413 92.013 72.725 
Pou2af1 
POU domain, class 2, 
associating factor 1 
1416957_at 4.64 6.061 6.094 6.088 6.193 6.089 6.329 
Rdx Radixin 
1416179_a_at 5282.61 3173.472 3026.9 3018.068 3043.828 2336.223 2598.385
1416180_a_at 841.34 558.965 465.09 480.598 400.75 389.205 424.604 
1448236_at 1394.17 1069.25 1001.683 956.406 931.784 870.561 933.532 
Zc3h12c 
Zinc finger CCCH type containing 
12C 
1437111_at 29.09 12.706 10.79 10.788 10.886 10.775 9.29 
1441787_at 13.25 7.611 7.66 9.071 7.789 7.651 7.689 
1444402_at 87.68 69.316 67.363 60.562 79.447 51.012 59.074 
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Table 4.3. MEF cell expression of candidate genes within the QTL associated with Valid 
Object Count. A total of 13 genes were identified under that QTL region, and their 
respective expression levels, for all available expression probe sets, are presented in this 
table. Expression level values for six MEF lines and MEF expression levels reported in the 
BioGPS website (www.biogps.org) are included. Abbreviations: MEF, mouse embryonic 
fibroblast; QTL, quantitative trait locus/loci. 
Gene Full Name Probeset ID BioGPS DBA/2J C57BL/6J A/J AKR/J C3H/HeJ CBA/J 
Ctps cytidine 5'-triphosphate synthase 1416563_at 2799.2 3289.424 2690.554 2226.492 3148.194 2547.071 2913.795
Col9a2 collagen, type IX, alpha 2 1450673_at 4.64 5.723 5.72 5.686 5.821 5.713 5.821 
Exo5 exonuclease 5 1428903_at 187.44 147.003 175.026 172.678 156.161 160.716 146.567 
Edn2 endothelin 2 1449161_at 4.64 5.599 5.61 5.712 5.685 5.613 5.601 
Foxo6 forkhead box O6 none N/A N/A N/A N/A N/A N/A N/A 
Hivep3 
human immunodeficiency virus 
type I enhancer binding protein 3 
1439660_at 8.68 4.062 4.064 4.05 4.111 4.05 4.072 
1450132_at 4.64 6.208 6.168 6.204 6.307 6.195 6.221 
1421150_at 4.64 4.219 4.23 4.213 4.266 4.212 4.253 
1429134_at 5.02 5.899 5.369 5.383 5.498 5.604 5.431 
1458802_at 8.21 56.808 15.764 15.702 20.173 15.884 16.002 
Kcnq4 
potassium channel, voltage gated 
KQT-like subfamily Q, member 4 
1435721_at 5.39 3.96 4.206 4.188 4.24 4.19 4.377 
Nfyc 
nuclear transcription factor Y, 
gamma 
1448963_at 523.45 300.231 247.408 283.674 237.023 242.022 267.626 
Rims3 
regulating synaptic membrane 
exocytosis 3 
1459042_at 4.64 5.843 5.841 5.833 5.98 5.852 5.897 
1435971_at 4.68 4.799 4.78 4.75 4.838 4.778 4.808 
Scmh1 sex comb on midleg homolog 1 
1426241_a_at 281.63 57.533 100.8 53.924 114.368 91.96 90.253 
1439554_at 8.57 5.244 5.279 5.25 5.35 5.249 5.275 
1441573_at 7.28 6.3 6.338 6.29 6.407 6.304 6.333 
Slfnl1 schlafen like 1 1455838_at 7.13 4.385 4.396 4.368 4.501 4.376 4.51 
Smap2 small ArfGAP 2 1450675_at 164.3 174.581 104.31 112.917 110.652 110.834 110.447 
Zfp69 zinc finger protein 69 
1458274_at 4.64 9.08 8.936 9.11 9.499 9.368 9.19 
1425209_at 14.79 11.118 16.559 12.406 11.115 9.893 10.529 
1435916_at 79.19 61.218 67.965 61.141 54.539 47.654 46.759 
1425210_s_at 55.95 17.165 18.55 17.514 16.922 17.508 14.864 
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Table 4.4. Non-synonymous coding SNPs and deleterious protein effects for genes 
associated with Cytochrome C release. The Mouse Genome Informatics Database (MGI; 
http://www.informatics.jax.org) and the Center for Genome Dynamics website (CGD;; 
http://cgd.jax.org/cgdsnpdb) were used to examine non-synonymous coding SNPs in 
candidate genes. Build 137 on the dbSNP website (http://www.ncbi.nlm.nih.gov/ 
projects/SNP) was used to confirm SNP position (m38) and amino acid substitution for each 
non-synonymous SNP. PROVEAN, PANTHER Classification System and SIFT (via 
Ensembl; http://www.ensembl.org) were used to assess that candidate non-synonymous 
SNPs would cause deleterious effects to protein structure or function. For PROVEAN, a 
score of -2.5 predicts alterations to the functional effect on the protein. For the PANTHER, a 
subSPEC (substitution position-specific evolutionary conservation) score of -3 predicts a 
50% probability that a score is deleterious (Pdeleterious=0.5), MSA is the number of multiple 
sequence alignments, NIC (number of independent counts) is an estimate of observations 
used to calculate the amino acid probabilities. Pwt and Psubstituted (Psubs) refer to the respective 
probabilities of the WT and substituted amino acids. For SIFT, a score <0.05 predicts the 
SNP to likely cause deleterious effects on the protein. Protein data was considered significant 
if PROVEAN predicted the protein to likely be deleterious, if PANTHER score ≤ -3, and/or 
if SIFT score <0.05. Protein data was highlighted in red if the protein was likely deleterious 
using PROVEAN and/or SIFT, and/or had a PANTHER score ≤-3. Protein data was 
highlighted in yellow if the PANTHER score was ≤-2 but >-3. Protein data was highlighted 
in yellow if the PANTHER score was ≤-2 but >-3. No non-synonymous variants, among the 
30 selected MEF strains, were identified in Fdx1 and Pou2af1 using MGI and CGD 
resources.
Gene 
SNP ID 
(dbSNP Build 
137) 
Position (m38) Substitution Protein Change 
PROVEAN 
Score 
Prediction SIFT Prediction 
Sub 
SPEC 
Pdel 
MSA 
Position 
Pwt P subs NIC 
Arhgap20 rs46602632 9:51831708 G>A Arg282Lys 0.867 Neutral 1 Tolerated -0.62 0.08 216 0.18 0.36 1.005 
 rs47224784 9:51848572 A>G Ile574Met -0.727 Neutral 0.07 Tolerated 2.38 0.35 501 0.36 0.03 1.128 
 rs51861578 9:51849843 G>T Arg998Leu -0.059 Neutral 0.71 Tolerated -0.36 0.07 916 0.12 0.09 1.128 
Btg4 rs13461391 9:51116640 A>G Ile37Val -0.346 Neutral 0.34 Tolerated -0.65 0.09 47 0.34 0.35 1.952 
 rs13461390 9:51117988 A>G Ile158Val 0.29 Neutral 1 Tolerated -0.89 0.11 174 0.17 0.23 1.952 
 rs32767530 9:51119206 G>A Cys202Tyr 2.231 Neutral 1 Tolerated -0.81 0.10 218 0.10 0.15 1.601 
Layn rs33773426 9:51057643 A>C Thr267Pro -1.316 Neutral 0.63 Tolerated -2.60 0.40 272 0.03 0.62 0.858 
 rs32764902 9:51063251 C>A Ser196Tyr -2.179 Neutral 0.01 Deleterious -1.92 0.25 201 0.11 0.01 1.049 
Rdx rs49859267 9:52081129 T>A Ser401Thr -0.202 Neutral 0.39 Tolerated N/A- no hit 
Zc3h12c rs51475643 9:52144261 G>A Val83Ile -0.16 Neutral 0.26 Tolerated N/A- no hit 
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Table 4.5. Non-synonymous coding SNPs and deleterious protein effects for genes 
associated with Valid Object Count. The Mouse Genome Informatics Database (MGI; 
http://www.informatics.jax.org) and the Center for Genome Dynamics website (CGD;; 
http://cgd.jax.org/cgdsnpdb) were used to examine non-synonymous coding SNPs in 
candidate genes. Build 137 on the dbSNP website (http://www.ncbi.nlm.nih.gov/ 
projects/SNP) was used to confirm SNP position (m38) and amino acid substitution for each 
non-synonymous SNP. PROVEAN, PANTHER Classification System and SIFT (via 
Ensembl; http://www.ensembl.org) were used to assess that candidate non-synonymous 
SNPs would cause deleterious effects to protein structure or function. For PROVEAN, a 
score of -2.5 predicts alterations to the functional effect on the protein. For the PANTHER, a 
subSPEC (substitution position-specific evolutionary conservation) score of -3 predicts a 
50% probability that a score is deleterious (Pdeleterious=0.5), MSA is the number of multiple 
sequence alignments, NIC (number of independent counts) is an estimate of observations 
used to calculate the amino acid probabilities. Pwt and Psubstituted (Psubs) refer to the respective 
probabilities of the WT and substituted amino acids. For SIFT, a score <0.05 predicts the 
SNP to likely cause deleterious effects on the protein. Protein data was considered significant 
if PROVEAN predicted the protein to likely be deleterious, if PANTHER score ≤ -3, and/or 
if SIFT score <0.05. Protein data was highlighted in red if the protein was likely deleterious 
using PROVEAN and/or SIFT, and/or had a PANTHER score ≤-3. Protein data was 
highlighted in yellow if the PANTHER score was ≤-2 but >-3. Protein data was highlighted 
in yellow if the PANTHER score was ≤-2 but >-3. No non-synonymous variants, among the 
30 selected MEF strains, were identified in Fdx1 and Pou2af1 using MGI and CGD 
resources 
Gene 
SNP ID (dbSNP 
Build 137) 
Position (m38) Substitution Protein Change 
PROVEAN 
Score 
Prediction SIFT Prediction 
Sub 
SPEC 
Pdel 
MSA 
Position 
Pwt Psubs NIC 
Col9a2 rs27518053 4:121039754 C>T Leu14Phe -0.946 Neutral 0.05 Tolerated -2.30 0.33 13 0.55 0.04 0.919 
 rs27517992 4:121049711 C>T Thr298Ile -0.979 Neutral 0.05 Tolerated -0.59 0.08 431 0.12 0.18 1.327 
 rs48849764 4:121053103 G>A Ala482Thr 0.71 Neutral 0.49 Tolerated -1.27 0.15 603 0.21 0.05 0.919 
 rs45643752 4:121053104 C>T Ala482Val -1.15 Neutral 0.29 Tolerated -0.36 0.07 603 0.21 0.13 0.919 
 rs27500263 4:121054292 G>A Arg610His -2.382 Neutral 0.02 Deleterious -0.76 0.10 871 0.17 0.10 1.327 
Edn2 rs27502234 4:120161517 C>G Ser3Cys -0.874 Neutral 0.1 Tolerated -2.32 0.34 43 0.11 0.01 1.397 
 rs27502233 4:120161519 G>A Ala4Thr -0.341 Neutral 0.1 Tolerated -1.28 0.15 44 0.28 0.10 1.397 
Foxo6 rs46653639 4:120269032 C/T Ala189Thr 0.529 Neutral 1 Tolerated -3.75 0.68 84 0.05 0.02 19.67 
Hivep3 rs27517176 4:120095806 G>T Asp4420Tyr -1.452 Neutral No SIFT Score N/A- no hit 
 rs27517175 4:120096389 C>T Ala634Val 0.571 Neutral No SIFT Score N/A- no hit 
 rs27517174 4:120096692 G>A Gly735Glu 0.719 Neutral No SIFT Score N/A- no hit 
 rs27517173 4:120097642 A>G Ser1052Gly -1.547 Neutral No SIFT Score N/A- no hit 
 rs27517171 4:120098851 G>A Gly1455Ser 0.742 Neutral No SIFT Score N/A- no hit 
 rs27517170 4:120099034 A>C Met15116Leu -0.111 Neutral No SIFT Score N/A- no hit 
 rs31783440 4:120132367 G>A Gly2005Glu -1.095 Neutral No SIFT Score N/A- no hit 
Scmh1 rs28256862 4:120508090 A>G Lys317Arg -1.668 Neutral 0.03 Deleterious -2.53 0.39 315 0.43 0.06 2.28 
 rs28256861 4:120508182 G>A Val348Ile -0.061 Neutral 1 Tolerated -1.18 0.14 345 0.09 0.13 2.28 
Slfnl1 rs28256783 4:120533203 T>C Val17Ala -0.595 Neutral 0.3 Tolerated N/A- no hit 
 rs28256782 4:120533307 A/G Ser52Gly 1.988 Neutral 1 Tolerated N/A- no hit 
 rs28256775 4:120535130 T>G His207Gln 1.465 Neutral 1 Tolerated N/A- no hit 
Zfp69 rs27485635 4:120930397 A>G Thr574Ala -0.329 Neutral 0.82 Tolerated N/A- no hit 
 rs27485631 4:120931234 C>G His295Asp -2.404 Neutral 0.65 Tolerated -1.54182 0.18875 163 0.18199 0.03284 1.001 
 rs27485619 4:120934354 G>A Gly197Ser -0.401 Neutral 0.87 Tolerated -2.77593 0.44422 64 0.71378 0.03472 1.091 
 rs32769909 4:120935120 A>G Gln153Arg 2.012 Neutral 1 Tolerated -2.00436 0.2698 22 0.47005 0.04965 0.996 
 rs27485601 4:120947398 A>C Glu92Ala -0.193 Neutral 1 Tolerated N/A- no hit 
 rs32810951 4:120947503 C>T Thr57Ile -0.081 Neutral 1 Tolerated N/A- no hit 
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FIGURES 
Figure 4.1. A high-throughput cellular genetics approach to identify QTLs and 
candidate genes that associate with sorafenib response. 
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Figure 4.2. Experimental workflow for high-throughput screening of MEF cell lines in a 
concentration-response format after administration of sorafenib.  A) Layout of 32 MEF 
strains on a single 384-well microtiter plate. 1500 cells/well for 24 h time point plates, and 
1000 cells/well for 72 h time point plates in a total of 50 µL of media were dispensed into 
each well. A total of 200 nL of ten sorafenib concentrations (0-300 µM) was added to each of 
ten wells. B) Cell staining reagents were added, incubated and then imaged via high-content 
imaging. From left to right: image 1 was nuclei staining representing cell viability, image 2 
was membrane permeability, image 3 was mitochondrial membrane potential, and image 4 
was cytochrome C antibody staining. C) Images were analyzed using Cellomics vHCS 
Toolbox Compartmental Analysis software. D) Dose response curves for each of the 32 MEF 
strains are generated by F-curve software for each of the four cell health phenotypes. IC50 
values from the dose response curves are then used for GWAS. This figure was adapted, with 
permission, from Suzuki, et al. Front Genet. 2014;5:272. Abbreviations: GWAS, genome 
wide association studies; HCS, high content screening; IC50, half maximal inhibitory 
concentration; MEF, mouse embryonic fibroblast; 
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Figure 4.3. Dose response curves and IC50 values generated using a Brain-Cousens 
model. Endpoints with a downward trend produced IC80 to IC50 values, decreasing in 5%-
effect steps. Cytochrome C release from MA/MyJ MEF cells after 72 hour sorafenib 
incubation is displayed here. Abbreviations: IC50, half maximal inhibitory concentration; 
IC80, concentration to achieve 80% inhibition; MEF, mouse embryonic fibroblasts. 
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Figure 4.4. Example of QTL interval selection. A) Up to seven SNPster GWA results, 
derived from IC50 through IC80, were used to account for slight differences in dose-response 
curve slopes. B) The 2% SNPs with highest –logP scores were averaged between the SNPster 
results to detect the SNPs that have consistently higher association scores. C) The region 
surrounding SNPs with an average –logP greater than 4.0 was determined as the QTL. If 
SNPs were located within 1 Mb of each other, the entire interval between them was included. 
Additionally, 100 kb on each side of the outermost SNPs were also included. The resulting 
interval, in this diagram, is indicated by the blue bar. Abbreviations: GWA, genome wide 
association; IC50, half maximal inhibitory concentration; IC80, concentration to achieve 80% 
inhibition; QTL, quantitative trait locus/loci; SNP, single nucleotide polymorphism. 
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Figure 4.5. Example of candidate gene selection from GWAS.  A) GWA Manhattan plot 
(here Cytochrome C release after 72 h sorafenib incubation is presented). The region with the 
highest –logP value is selected for further analysis. B) Detailed region under the identified 
QTL with candidate genes. C) Haplotype structure of the inbred MEF strains in the QTL 
region. Abbreviations: Genome wide association; GWAS, genome wide association studies, 
MEF, mouse embryonic fibroblasts; QTL, quantitative trait locus/loci. 
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Figure 4.6. A multi-step and multi-faceted schematic for candidate gene selection. 
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Figure 4.7. Distribution of IC50 values associated with Cytochrome C release across 32 
MEF strains. The distribution of Cytochrome C release IC50 values shows variability (17-
45µM) across 32 MEF strains. These data were then used as the basis for GWAS. Thirty of 
the 32 strains represented here were used for GWAS, with only SWR/J, and WSB/EiJ 
excluded from final analyses. Abbreviations: GWAS, genome wide association studies; IC50, 
half maximal inhibitory concentration; MEF, mouse embryonic fibroblasts. 
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Figure 4.8. Distribution of IC50 values associated with Valid Object Count release 
across 32 MEF strains. The distribution of Valid Object Count IC50 values shows variability 
(17-32µM) across 32 MEF strains. These data were then used as the basis for GWAS. Thirty 
of the 32 strains represented here were used for GWAS, with only SWR/J, and WSB/EiJ 
excluded from final analyses. Abbreviations: GWAS, genome wide association studies; IC50, 
half maximal inhibitory concentration; MEF, mouse embryonic fibroblasts. 
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Figure 4.9. Manhattan plots for Cytochrome C release. GWA Manhattan plots were 
generated for MEF cells exposed to sorafenib for 72 hours and associated with Cytochrome 
C release. Panel A shows results generated from the EMMA algorithm and panel B shows 
results generated from SNPster. One notable QTL with a –logP value ≥4.0 was identified 
(chromosome 9, position 50,500,000-52,500,000). This QTL reached genome-wide 
significance by the EMMA algorithm with a –logP value ≥6.74. Abbreviations: EMMA, 
efficient mixed model association; GWA, genome wide association; MEF, mouse embryonic 
fibroblasts, QTL, quantitative trait locus/loci. 
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Figure 4.10. Genes under the QTL associated with Cytochrome C release. A total of 
seven genes were identified under a QTL on chromosome 9 (50,500,000-52,500,000). 
Abbreviations: QTL, quantitative trait locus/loci. 
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Figure 4.11. Manhattan plots for Valid Object Count. GWA Manhattan plots were 
generated for MEF cells exposed to sorafenib for 72 hours and associated with VOC. Panel A 
shows results generated from the EMMA algorithm and panel B shows results generated 
from SNPster. One notable QTL with a –logP ≥4.0 was identified (chromosome 4, position 
119,000,000-121,500,000).  This QTL was notable, albeit not genome-wide significant, by 
the EMMA algorithm with a –logP value ≥4.66. Abbreviations: EMMA, efficient mixed 
model association; GWA, genome wide association; MEF, mouse embryonic fibroblasts, 
QTL, quantitative trait locus/loci; VOC, valid object count. 
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Figure 4.12. Genes under the QTL associated with Valid Object Count. A total of 13 
genes were identified under a QTL on chromosome 4 (position 119,000,000-121,500,000). 
Abbreviations: QTL, quantitative trait locus/loci. 
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Figure 4.13. Haplotype structure for genes associated with the Cytochrome C release 
QTL. The haplotype structure of select inbred mouse strains within chromosome 9 (position 
50,500,000-52,500,000), which represents the areas directly under and surrounding the 
genome-wide significant peak observed for this phenotype after 72 h incubation of sorafenib. 
Strains are shown in descending order from most sensitive to least sensitive. The blue arrow 
represents the location directly under the peak (position 51595846), the red arrow represents 
the location of Arhgap20 (position 51573457-51661164), and the green arrow represents the 
location of Rdx (position 51855255-51896843). The haplotype structure was visualized with 
the Mouse Phylogeny Viewer (https://msub.csbio.unc.edu/). Abbreviations: QTL, 
quantitative trait locus/loci. 
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Figure 4.14. Ingenuity pathway analysis for genes with the QTL associated with 
Cytochrome C release. Seven genes within the QTL associated with Cytochrome C release 
were input into an Ingenuity Pathway Analysis with sorafenib and known targets of sorafenib 
(BRAF, FLT-1, FLT-3, FLT-5, FGFR1, KIT, KDR, PDGFR-β, RET, and RAF-1). Only direct 
connections were included. Zc3h12c is not represented in this analysis because no direct 
connections to sorafenib and/or sorafenib targets were identified. A direct connection 
between a candidate gene and sorafenib or a sorafenib target is denoted in red. 
Abbreviations: QTL, quantitative trait locus/loci. 
 
  
165 
Figure 4.15. Haplotype structure for genes associated with the Valid Object Count 
QTL. The haplotype structure of the inbred mouse strains within chromosome 4 (position 
119,000,000-121,500,000), which represents the areas directly under and surrounding the 
highest peak observed for this phenotype after 72 h incubation of sorafenib. Strains are 
shown in descending order from most sensitive to least sensitive. The blue arrow represents 
the location directly under the peak (position 119987827), the red arrow represents the 
location of Scmh1 (position 120077886-120202804), and the green arrow represents the 
location of Nfyc (position 120430040-120498346). The haplotype structure was visualized 
with the Mouse Phylogeny Viewer (https://msub.csbio.unc.edu/). Abbreviations: QTL, 
quantitative trait locus/loci. 
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Figure 4.16. Ingenuity pathway analysis for genes with the QTL associated with Valid 
Object Count. Thirteen genes within the QTL associated with VOC were input into an 
Ingenuity Pathway Analysis with sorafenib and known targets of sorafenib (BRAF, FLT-1, 
FLT-3, FLT-5, FGFR1, KIT, KDR, PDGFR-β, RET, and RAF-1). Only direct connections 
were included. Zfp69 and Slfnl1 are not represented in this analysis because no direct 
connections to sorafenib and/or sorafenib targets were identified. A direct connection 
between a candidate gene and sorafenib or a sorafenib target is denoted in red. 
Abbreviations: QTL, quantitative trait locus/loci. 
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CHAPTER 5: DISCUSSION, PERSPECTIVE AND FUTURE DIRECTIONS 
 
5.1 Summary and Scope 
Over the past decade the treatment landscape for mRCC has changed dramatically 
due to the U.S. FDA approval of multiple agents that target tumorigenic and angiogenic 
pathways. The approval of seven agents, which target the VEGF-pathway (axitinib, 
pazopanib, sorafenib and sunitinib), and mTOR (everolimus and temsirolimus) have helped 
increase median survival time amongst mRCC patients.1-8 Nevertheless, despite these major 
advancements, many mRCC patients experience disease progression while on treatment, and 
eventually die from their cancer. There is currently a shortage of clinically relevant 
prognostic and predictive pharmacogenetic markers that have been translated for routine 
incorporation into clinical practice.9-11  
A “one-size-fits-all” paradigm might apply well to the Frank Zappa album of the 
same name, or might be appropriate for clothing like sweatpants and socks; however, it is a 
poor way to approach the treatment of advanced and metastatic cancer patients. It has been 
well established that, for cancer patients, responses to treatment vary greatly,12-14 and it is 
understood that genetic variations in therapeutic targets of medications can lead to altered 
treatment efficacy.15 Pharmacogenetics examines interindividual genetic variability that 
influences the course of drug action so that medication regimens may be optimized to 
maximize response, while minimizing drug-induced toxicity.  Personalized medicine through 
genetics and genomics is the overarching goal for the field of pharmacogenetics and vital to 
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the evolution of effective treatment paradigms (Appendix 1).16 Currently, there is an unmet 
need, yet an opportunity, to identify and validate predictive and prognostic pharmacogenetic 
biomarkers that can help clinicians individualize treatment strategies for mRCC patients.  
Sorafenib is a multikinase inhibitor with potent activity against angiogenic, 
oncogenic, and stromal kinases, as well as the RAF/MEK/ERK signaling pathway, which 
leads to inhibition of tumor proliferation and angiogenesis. Data from the pivotal phase III 
randomized, placebo-controlled, TARGET trial confirmed a significant OS and PFS benefit. 
Several clinical trials focused on sorafenib have revealed a high degree of interindividual 
variability in sorafenib pharmacokinetics.17-21 Considerable interindividual variability in 
response to sorafenib is also observed clinically.2,22,23  
This dissertation research stemmed from the hypothesis that germline genetic variants 
in mRCC patients will help explain the interindividual differences in sorafenib response and 
patient survival. Thus, the primary objective of this dissertation was to identify and validate 
germline genetic variants that are predictive of sorafenib response, as well as variants that are 
prognostic markers of survival in mRCC patients. The key findings of this work include:  
1) the identification of five germline variants associated with OS in patients from the 
sorafenib and two variants associated with OS in a combined analysis of both treatment arms, 
2) the validation of four intronic variants (rs3816375 in ITGAV, rs1885657 and rs3024987 in 
VEGFA, and rs8047917 in WWOX) in dual reporter gene luciferase assays, as well as the 
validation of one exonic variant (rs307826 in FLT-4) in a cell viability assay, and 3) the 
identification of a genome-wide significant QTL on mouse chromosome 9 associated with 
cytochrome C release, and a second QTL on mouse chromosome 4 associated with cell 
viability, in 32 MEF strains treated with sorafenib for 72 h. The major translational 
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implication of this dissertation research is that it provides a foundation for future laboratory 
and replication studies to confirm the analytical validity of these findings, followed by 
prospective clinical trials that will evaluate both the clinical validity and clinical utility of 
these variants as predictive biomarkers of sorafenib efficacy and/or prognostic biomarkers of 
survival for patients with mRCC.   
 
5.2 Key Findings 
Sorafenib affects tumor vascular endothelium,24 the tumor microenvironment,25 and 
as a VEGF-pathway inhibitor it also has effects on the host vascular endothelium and 
pericytes.26,27  Because RCC is dependent on angiogenesis and the VEGF pathway, it is a 
pathway that is a viable target for pharmacotherapy.28,29 And, because angiogenesis is 
primarily a host-mediated process,30 there is excellent rationale for investigating germline 
variants as predictors of sorafenib efficacy and/or as markers with prognostic significance.  
The primary objective of Aim 1 was to identify germline genetic markers that 
associate with OS. The secondary objective of the study was to prospectively analyze how 
the variants that associated with OS are also related to differences in PFS. Five germline 
variants within genes were found to significantly associate with OS (multivariate p≤0.05 and 
q≤0.1): two variants (rs1885657 and rs3024987) were in intronic regions of VEGFA, 
rs3816375 was in an intronic region in ITGAV, rs8047917 was in an intronic region of 
WWOX, and rs307826 was in a coding region of FLT-4. In addition, two intergenic variants 
(rs200809375 and rs6719561) were found to be in close proximity to NRP-1 and UGT1A9, 
respectively. Five of the seven variants associated with OS in the sorafenib-treated TARGET 
patients (rs1885657, rs3816375, rs6719561, rs8047917, and rs200809375), while two of the 
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variants only associated with OS in a combined analysis of both TARGET treatment arms 
(rs30786 and rs3024987). FDR was employed in lieu of correcting the family-wise error rate 
(e.g. Bonferroni correction). Variants were deemed significant if their multivariate model p-
value was ≤0.05 and also if their FDR q-value was ≤0.1. A p-value threshold of ≤0.05 was 
certainly appropriate for these analyses because discovery pharmacogenetic cohorts 
commonly utilize this same p-value threshold, and reserve corrections for multiple 
comparisons for subsequent replication pharmacogenetic studies that test associations in 
independent cohorts of patients. However, a replication cohort was not identified to validate 
these findings, and therefore an FDR correction was employed in this discovery cohort to 
reduce the chances of obtaining spurious findings due to type I error. FDR was selected over 
a Bonferroni correction because Bonferroni can be overly conservative because all tested 
associations are considered independent observations, which is clearly not the case in genetic 
association studies where variants are often in linkage with one another (and therefore not 
truly independent observations). While there is currently no consensus on the appropriate 
FDR threshold in the literature, FDR q-value ≤0.1 is an appropriate threshold because it was 
chosen a priori with the assumption that the variants significantly associated with OS would 
be subsequently validated through a combination of in silico prediction tools and in vitro 
experiments.  
PFS was correlated with OS, so these seven variants were also tested for associations 
with PFS.  Among the five original variants that associated with OS in the sorafenib arm, 
rs1885657, rs6719561 and rs8047917 also significantly associated with PFS (p≤0.05). 
Among the two variants that associated with OS in analyses when the treatment arms were 
combined, only rs307826 significantly associated with PFS (p≤0.05). Interestingly, rs307826 
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was also associated with PFS among the patients from the sorafenib arm. Because these 
analyses were a secondary endpoint, and exploratory in nature, they were not corrected for 
multiple comparisons.  
The primary objective of Aim 2 was to functionally validate germline variants that 
associated with OS (identified through Aim 1) to elucidate the molecular drivers underlying 
differences in sorafenib efficacy, as well as mRCC pathogenesis, angiogenesis and/or 
sorafenib pharmacology. First, in silico analyses, which leveraged information from 
ENCODE, predicted which variants were likely functional, and helped prioritize laboratory 
validation of variants based on their potential to alter regulatory pathways and/or gene 
function. The Broad Institute’s HaploReg website (http://www.broadinstitute.org/mammals/ 
haploreg/haploreg_v3.php), the UCSC Genome Browser (https://genome.ucsc.edu), and 
Stanford’s Center for Genomics and Personalized Medicine Regulome DB website 
(http://regulomedb.org) revealed that the intronic SNP variants, identified in Aim 1, in 
VEGFA (rs1885657 and rs3024987) were likely to be located in functionally active regions. 
Data from in vitro dual reporter gene luciferase assays confirmed the in silico predictions, 
and showed increased luciferase activity in the rs1885657 variant C allele (and in a “triple 
variant” construct that contained variant alleles for two SNPs in perfect LD with rs1885657: 
the rs943070 variant G allele, and the rs58159269 variant T allele), and the rs3024987 
variant T allele. These data are consistent with the observed clinical association that patients 
with two copies of the variant C allele at rs1885657 experience significantly shorter OS and 
PFS, and support the hypothesis that the haplotype, which includes rs1885657 C allele, the 
rs943070 G allele, and the rs58159269 C allele, causes increased VEGFA expression, which 
results in increased angiogenesis, and ultimately shorter patient survival. Cell viability assays 
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revealed that the non-synonymous SNP in FLT-4 (rs307826), which causes threonine to 
alanine amino acid substitution in the fifth IgG-like domain of VEGFR3, results in a more 
resistant phenotype when HEK-293 cells were treated with sorafenib. These data are 
consistent with the observed clinical association that patients with two copies of the variant G 
allele at this locus experience significantly shorter OS and PFS, and support the hypothesis 
that the amino acid substitution results in increased VEGFR3 signaling and resistance to 
sorafenib.  The findings from Aim 2 provide evidence that the variants identified in Aim 1 
are functional, and it lays the groundwork for future studies that will aim to better understand 
the molecular mechanism underlying these variants, and trials to validate them as predictive 
and prognostic biomarkers.  
The primary objective of Aim 3 was to test the hypothesis that that differential cell 
health and response data (e.g. EC50 or IC50) from 32 MEF cells lines treated with sorafenib, 
can be used in GWAS to identify candidate genes associated with sorafenib response, which 
will ultimately lead to the discovery of novel genes for future pharmacogenetic testing in 
patients treated with sorafenib. A total of seven genes were present in the QTL that 
associated with the cytochrome C release phenotype after a 72 h incubation with sorafenib. 
One candidate gene (Rdx) was selected for future in vitro validation studies. Rdx encodes for 
radixin, which is a component of the ezrin-radixin-moesin-binding phosphoprotein-50 
(EBP50) complex, has been shown to act as a tumor suppressor in multiple tumor types.31-35 
A total of 13 genes were present in the QTL that associated with cell viability after a 72 h 
incubation with sorafenib. Two candidate genes (Nfyc and Scmh1) were selected for future in 
vitro validation studies. Nfyc is a transcription factor that is a key regulator of MYC and 
p53,36  and has been shown to regulate DNA-dependent transcription of PDGFR-β.37 Scmh1 
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encodes for a protein that helps repress transcription, and has been shown to regulate 
geminin. Interestingly, geminin has been shown to regulate DNA replication and has been 
linked to cancer.38-41  
 
5.3 Future Directions 
Although the results described by this dissertation research have laid the foundation 
for these variants as biomarkers, there are still many future studies that should be conducted. 
First, this dissertation has presented only the results of variants that satisfied extremely 
stringent statistical criteria, which included an FDR multiple comparisons correction. 
However, variants that did not pass the FDR correction (q≤0.1), but were significant by p-
value (p≤0.05) should be evaluated, and potentially prioritized (along with the variants 
described in Aims 1-2) for replication pharmacogenetic studies in an independent cohort of 
sorafenib-treated patients.  
Replication of positive findings in an external, independent cohort of patients has 
served as the gold standard for validation of genotype-phenotype relationships.42,43 
Pharmacogenetic studies have identified a vast set of genetic variants as predictors of 
chemotherapy efficacy and toxicity. The majority of these proposed variants have failed to 
produce similar results across different studies, which has limited the clinical utility of 
pharmacogenetics.9,10 Therefore, prospective replication of pharmacogenetic findings in 
independent and external cohorts of patients is essential to hasten the implementation of 
pharmacogenetics into routine clinical practice (Appendix 2).44 Currently, a suitable 
replication cohort of mRCC patients treated with sorafenib is not available; however, 
collaborations with investigators on the Axitinib Versus Sorafenib in Advanced Renal Cell 
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Carcinoma (AXIS) trial should be pursued.8 Briefly, AXIS was a randomized phase III trial 
compared axitinib to sorafenib as second-line therapy in patients with mRCC. This cohort 
would not only have the potential to replicate findings from this work in their sorafenib-
treated patients, patients from the axitinib arm could potentially help identify variants that 
have a class effect among VEGF-pathway inhibitors used in the treatment of mRCC. 
Additionally, collaboration with the investigators on the ASSURE (E2805) trial 
(ClinicalTrials.gov NLM Identifier NCT00326898) should be pursued. This placebo-
controlled phase III trial examined the effectiveness, using PFS as the primary endpoint, of 
either sorafenib or sunitinib in the treatment of mRCC patients in the adjuvant treatment 
setting. While this cohort might not be optimal since ASSURE patients have not relapsed 
post-nephrectomy and do not have metastatic disease, this cohort could still be advantageous 
for two reasons: 1) it is a placebo-controlled trial, and thus comparisons to the TARGET 
patients from the placebo arm could be made, and 2) the sunitinib-treated patients could 
potentially help identify variants that have a class effect among VEGF-pathway inhibitors 
used in the treatment of mRCC.  
Next, all directly genotyped and imputed variants used in the OS analyses should be 
used to test associations with PFS, and also with common sorafenib-induced toxicities (e.g. 
hypertension, diarrhea, rash, and hand foot skin reaction). Replication of those results in an 
independent cohort of sorafenib-treated patients is also important. Additionally, there is 
accumulating evidence that sorafenib pharmacokinetics are at least partially mediated by 
drug transporters.45,46 Candidate variants in SLC22A1, SLCO1B1 and SLCO1B3, which 
encode for OCT1, OATP1B1 and OATP1B3, respectively, could be selected for the next 
round of genotyping using DNA from TARGET patients. Ultimately, a prospective clinical 
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trial, analyzing the effects of these variants on OS and PFS in sorafenib-treated patients, 
should be conducted to confirm clinical validity of the associations and their clinical utility as 
mRCC biomarkers. 
Additional functional validation of variants that associated with OS, identified in Aim 
1, is required. Results from the cell viability assays provided proof of concept that rs307826 
alters receptor signaling and confers increased resistance to sorafenib. However, the 
hypothesis that rs307826 results in altered receptor signaling requires confirmation. This can 
be accomplished through phosphorylation assays and traditional Western blotting. Alternate 
approaches, which would quantitatively compare the how the rs307826 G allele affects 
VEGFR3 phosphorylation when compared to the reference A allele, would be to leverage 
either ELISA assays or a proteomic mass spectrometry approach. While the non-synonymous 
variant likely causes a change in protein function, an alternative hypothesis is that the 
rs307826 G allele could alter FLT-4 expression. Therefore, dual reporter gene luciferase 
assays could be conducted to assess variant effects on gene expression.  
Additional laboratory validation experiments should be conducted on the variants 
identified in Aim 1 to ascertain if they influence gene expression, and to characterize the 
mechanistic underpinnings that result in altered gene expression. Variants that are predicted 
by ENCODE to influence transcription factor binding, based ChIP-Seq data and evidence of 
changes to transcription factor binding motifs, will be prioritized for additional in vitro 
functional validation by EMSA. Additional cell viability assays could be conducted to 
associate differences in gene expression with sorafenib response. Finally, using 
CRISPR)/cas9 or TALEN technologies, the creation of isogenic endothelial cell lines could 
for the first time isolate how variants (e.g. SNPs)  directly affect cellular phenoypes (e.g. 
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angiogenesis and/or VEGF-pathway inhibitor responses). TIME cell lines will be utilized 
because they retain many of the features of primary endothelial cells,47 without issues related 
to senescence and loss of endothelial phenotypes after multiple cell passages.48 
For the two intergenic variants that associated with OS (rs6719561 and rs200809375), 
validation is still required. Dual reporter gene luciferase assays would have indeed provided 
insight into their activity as enhancers; however, because they are not located within genes it 
would be difficult to ascertain on which gene the enhancer is active. One possible validation 
method that could be employed is the chromosome conformation capture (3C) technology.  
Intergenic regulatory elements can influence gene regulation through cis-interactions (i.e. on 
a gene in close proximity to the variant) or through trans-interactions (i.e. on a gene a great 
distance away from the variant) by engaging in direct physical interactions with target genes 
or with other elements.49 Therefore, the 3C technology could provide valuable validation that 
these variants help to regulate UGT1A9 and NRP-1, respectively.  Variant rs6719561 is in 
close proximity to two genes (approximately 1.5 kb 3’ of UGT1A9, and 600 bp 5’ of 
HEATR7B1), and thus provides some ambiguity about which gene is associated with 
differences in OS. After 3C is performed, the promoter of UGT1A9 and HEATR7B1could be 
cloned into a vector with a construct containing rs6719561, and dual reporter gene luciferase 
assays could be conducted to detect differences in activity.  
Future studies to validate the candidate genes identified in Aim 3 will certainly be 
conducted in MEF cells using in vitro knockdown and overexpression approaches. The 
prioritized candidate genes (Rdx and Fdx1 for Cytochrome C release, and Nfyc and Scmh1 
for VOC) will be validated using and the same siRNA knockdown and pCMV-SPORT6 
vector-based overexpression approaches that have been previously described.50 Any of the 
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genes validated through these siRNA and/or overexpression experiments in MEF cells will 
be repeated in orthologous human siRNA and overexpression vectors, and tested in human 
cell lines (e.g. the human endothelial TIME cells, and the human mRCC Caki-1 cells) to 
confirm the effects of these genes on sorafenib response. Finally, for genes that validate in 
human and MEF cell lines, a second candidate gene-candidate SNP genotyping study will be 
conducted using TARGET patient DNA.   
 
5.4 Conclusions 
In conclusion, the primary objective of this dissertation was to identify and validate 
germline genetic variants that are predictive of sorafenib response, as well as variants that are 
prognostic markers of survival in mRCC patients. The identification and validation of 
predictive pharmacogenetic variants may help determine which patients should be treated 
with sorafenib. In a crowded landscape of targeted agents for the treatment of mRCC, 
identification, validation, and then ultimately clinical incorporation of these predictive 
variants into routine clinical practice could help guide clinician treatment decisions. 
Additionally, the identification of novel prognostic markers may provide insight into RCC 
pathogenesis/prognosis, or identify patients who would benefit from more intensive therapies 
and/or monitoring. The studies from Aims 1-2 of this dissertation have identified and 
validated seven pharmacogenetic variants that associate with OS among mRCC patients 
originally enrolled on the phase III TARGET trial. Among the seven identified germline 
variants, five (rs3816375 in ITGAV, rs1885657 in VEGFA, rs8047917 in WWOX, as well as 
rs6719561 in a region 3’ of UGT1A9, and rs200809375 in a region 3’ of NRP-1) have the 
potential to be variants that are predictive of sorafenib efficacy. It is unclear if the remaining 
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two variants that associated with OS (rs307826 in FLT-4 and rs3024987 in VEGFA) are 
purely prognostic, or if they also possess predictive effects. Replication of these associations 
in an independent and external cohort of mRCC patients treated with sorafenib is of utmost 
importance before incorporating them into routine clinical practice. Additional laboratory 
validation of these variants, to elucidate the molecular underpinnings of their predictive 
and/or prognostic effects, should also be conducted. In Aim 3, innovative high content 
cellular genetics approach has detected robust interstrain cellular differences in sorafenib 
activity.  One QTL region, which reached genome-wide significance, which potentially 
associates with sorafenib-induced cytochrome C release from mitochondria, was identified. 
An additional QTL was identified that potentially associates with sorafenib cytotoxicity and 
cell viability. Candidate genes for functional validation have been prioritized through a 
multi-faceted set of criteria. Future steps for this work include functional validation of 
candidate genes, using knockdown and overexpression approaches, in MEF and human cell 
lines. Collectively, this dissertation research has identified variants in genes known to be 
central to angiogenesis and/or sorafenib pharmacology, as well as QTLs that influence 
sorafenib’s pro-apoptotic capabilities. This work lays a critical foundation for future studies 
that will help validate novel biomarkers that will aid clinicians in the treatment of patients 
with mRCC.   
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APPENDIX 11: CAN KNOWLEDGE OF GERMLINE MARKERS OF TOXICITY 
OPTIMIZE DOSING AND EFFICACY OF CANCER THERAPY? 
 
A1.1 Overview 
The systemic treatment of cancer with traditional cytotoxic chemotherapeutic agents 
and more targeted agents is often complicated by the onset of adverse drug reactions (ADRs). 
Pharmacogenetic prediction of ADRs might have consequences for dosing and efficacy. This 
review discusses relevant examples where the germline variant-toxicity relationship has been 
validated as an initial step in developing clinically useful pharmacogenetic markers, and 
provides examples where germline variants have influenced dosing strategies and/or survival 
or other outcomes of efficacy. This review will also provide insight into the reasons why 
more pharmacogenetic markers have not been routinely integrated into clinical practice. 
 
A1.2 Introduction 
It is well established that when cancer patients are administered chemotherapy, their 
clinical response will vary greatly.1-3 While many patients experience a complete or partial 
response, for a sizable proportion of these patients the chemotherapy will be largely 
ineffective despite the onset of toxicities, which might be severe, and even life threatening. 
Often these adverse drug reactions (ADRs) will lead to hospitalizations.4 Numerous factors 
                                                           
1 This chapter was published in Biomarkers in Medicine in 2012 (Crona D and Innocenti F. Biomark 
Med. 2012;6(3):349-62). 
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influence whether a patient will experience an ADR, including baseline clinical and 
demographic characteristics and genetics. Among available efficacious regimens, the 
selection of the safest regimen for a given patient, is not guided by molecular biomarkers, 
but, rather, by considerations related to the patient’s age, comorbidities, and performance 
status. 
Traditional cytotoxic chemotherapy and more novel molecularly-targeted agents 
(some of them also called “biologics”) are the two core pharmacotherapeutic paradigms at 
the center of modern cancer care. Phase I trials identify the dose-limiting toxicities (DLTs) of 
a new chemotherapeutic agent, and 5 doses are advanced until the onset of DLTs to define its 
maximum tolerated dose (MTD) to be used in phase II trials. For most approved 
chemotherapeutic agents, there is only one dose, rather than a dose range. This dose-
escalation design to MTD intrinsically narrows the distance between toxic and effective 
doses.  It is natural to expect that one single dose might not be tolerated by some patients and 
during the entire duration of the scheduled cycles of treatment. As a result, the onset of 
serious grade 3 or 4 toxicities (as defined by the National Cancer Institute Common 
Terminology Criteria for Adverse Events, CTCAE, version 4.036) can largely affect drug 
dosing and dose intensity.  
In all therapeutic areas, ADRs account for an estimated 7% of all hospital admissions, 
occur in 10-20% of all patients, and result in significantly increased hospital stays.7 The costs 
to the health system associated with ADR-related morbidity exceed $3.6 billion annually in 
the United States. ADRs are consistently among the top 10 reasons for death among 
patients.8 Several studies have reported on the incidence of cancer chemotherapy-related 
ADRs. A meta-analysis of 1,219 colorectal cancer patients, who received 5-fluorouracil as 
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part of their regimen, revealed that up to 31% experienced grade 3-4 neutropenia.9 A more 
recent meta-analysis disclosed that approximately 30% of 2,090 non-small cell lung cancer 
patients who received docetaxel experienced grade 3-4 neutropenia.10 It is estimated that 
greater than 60,000 oncology patients are hospitalized due to severe neutropenia and its 
complications each year in the United States, and that neutropenia is associated with an 
inpatient mortality rate of 6.8% annually.7 Dose-toxicity curves often differ between 
traditional cytotoxic chemotherapies and targeted molecular agents, and efficacy may occur 
in targeted agents at doses that do not cause significant toxicities.5 Although the development 
of dosing strategies for targeted agents and biologics are still largely dependent on the 
identification of the MTD, there is significant debate concerning the practicality of 
abandoning traditional dosing strategies in favor of the identification of a minimal effective 
dose or the optimal biologic dose (OBD).11 OBD can be defined as the dose associated with a 
pre-specified most desirable effect on a biomarker among all doses studied. 5 There are those 
who argue that the dosing of targeted agents should continue to follow the traditional MTD 
dose-finding model because they believe there is still a lack of knowledge concerning OBD 
strategies.12 But, others favor investigation of a minimal effective dose,13 or optimum 
biologic dose.14,15 
Since dose-toxicity curves and OBD dosing strategies for targeted agents could be 
starkly different from traditional cytotoxic chemotherapy, the ADRs associated with these 
agents are rarely life-threatening, but still no less serious. These drugs tend to be associated 
with more non-hematological ADRs and less neutropenia than the traditional cytotoxics. 
ADRs, which adversely affect quality of life and activities of daily living, can result in non-
compliance to oral targeted agents. For instance, a post-approval survey of epidermal growth 
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factor receptor (EGFR) inhibitors revealed that 76% of respondents were non-compliant to 
therapy due to rash, and that up to 32% of clinicians discontinued therapy due to rash.7 
Moreover, at least 11% of patients who receive cetuximab experience grade 3-4 rash, 16 
which could lead to dose modifications by the clinician or non-adherence by the patient and 
ultimately complicate efficacy and survival outcomes. Up to 15% of patients treated with 
bevacizumab experience grade 3-4 hypertension, 7 and are at a significantly higher risk of 
grade 3-4 proteinuria and hypertension at both low and high doses.17 
These common ADRs are still very concerning because medication non-adherence 
compromises dose-intensity and ultimately survival.18,19 Maintenance of dose intensity in 
patients for the entire course of their treatment is extremely important because it has been 
shown both prospectively and retrospectively, in a variety of tumor types, to be correlated 
with more positive outcomes.20,21 Dose intensity is a function of both dose and frequency, 
and modifications to either chemotherapy dosing or frequency, as a result of ADRs, are 
detrimental to outcomes.22 Dosing is often adjusted based on renal or hepatic function, 
hematologic counts, results of basic metabolic panels, or drug levels measured in plasma. In 
addition, chemotherapy package inserts also provide recommendations on how to adjust 
dosing (usually dose reductions or dose interruptions) based upon the onset of toxicity. 
Although very pragmatic, this approach of personalizing chemotherapy dose remains 
inefficient, expensive, and adversely affects the quality of life of patients. However, certain 
ADRs have been researched as surrogate pharmacodynamic markers, and seem to possess a 
predictive role for chemotherapy response and efficacy. The relationship between drug-
induced rash, dose escalation, and survival has been investigated in EGFR inhibitors such as 
erlotinib and cetuximab. Likewise, the relationships linking drug-induced hypertension, the 
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dose of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab, and survival 
have been explored. These studies support both the paradigm that these specific ADRs are 
likely pharmacodynamic proxies for efficacy, and the approach of dosing patients to OBD 
rather than MTD. 
Pharmacogenetics examines interindividual genetic variability that influences the 
course of drug action so that medication regimens may be optimized to maximize response, 
while minimizing drug-induced toxicity.  Personalized medicine through genetics and 
genomics is the overarching goal for the field of pharmacogenetics and vital to the evolution 
of effective treatment paradigms. The ability to predict and mitigate ADRs in oncology is of 
paramount importance because a majority of chemotherapeutic agents are dosed to their 
MTD, and possess a narrow therapeutic index between efficacy and toxicity. There is 
currently a dearth of clinically relevant prognostic and predictive pharmacogenetic markers 
derived from germline variants that have been translated for routine incorporation into 
clinical practice.23-25 There is an opportunity to better understand the relationship between 
germline variants, toxicity, and chemotherapy dose so that more of these pharmacogenetic 
markers may be utilized clinically to individualize therapies for cancer patients. 
The purpose of this review is to analyze the available literature to elucidate pertinent 
germline variant-ADR relationships, and to describe how these associations may impact the 
delivery of an optimal chemotherapy dose to patients and, consequently, affect survival 
outcomes. We have chosen to systematically concentrate on a focused number of validated 
germline pharmacogenetic variants that associate with ADRs and the manner in which those 
variants might influence downstream effects, such as chemotherapy dosing and survival 
outcomes. This review should not be construed as a complete evaluation of all 
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pharmacogenetic variants detailed in oncology-related literature, as this has been addressed 
extensively in many recent reviews.26-28 However, the resulting effects of these associations 
on dosing and survival have never been analyzed in detail. For each specific gene discussed, 
we will not review a comprehensive list of all alleles in each of the genes. Rather, we have 
highlighted several specific pharmacogenetic variants that account for the majority of 
variability in each gene to highlight our approach. 
 
A1.3 Establishing the Relationship Between Germline Variants and Toxicity 
Validation of pharmacogenetic markers related to ADRs is of utmost importance to 
clinicians so they may personalize the most efficacious and safe regimen for each patient, 
without sacrificing dose intensity. With the advent of hypothesis-driven candidate gene 
studies and more unbiased genome-wide approaches, oncology researchers have begun to 
characterize the genetics that underlie serious ADRs. The labels for over twenty 
chemotherapeutic agents have been rewritten or revised to include information regarding 
pharmacogenetic markers. Specifically, seven of these agents (6-mercaptopurine, 6-
thioguanine, 5-fluorouracil, capecitabine, irinotecan, nilotinib, and imatinib) include 
language describing a gene-toxicity relationship, which emphasizes the growing importance 
of validating clinically useful pharmacogenetic markers to prevent the onset or mitigate the 
severity of ADRs.29 
Numerous pharmacogenetic studies have been conducted in an attempt to identify 
novel germline variants that conclusively associate with ADRs. A majority of the validated 
pharmacogenetic markers, and those primarily discussed in this review, are germline variants 
that contribute to differences in drug metabolizing enzymes of drug inactivation. A classic 
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example is the thiopurine antimetabolite, 6-mercaptopurine, an integral component in the 
treatment of pediatric acute lymphoblastic leukemia (ALL).30 6-mercaptopurine is activated 
into thioguanine nucleotides (TGNs), which are then incorporated into the DNA and interfere 
with the activity of nucleic acid-processing enzymes.26 Thiopurine-S-methyltransferase 
(TPMT) inactivates 6-mercaptopurine through methylation. Genetic variations in the TPMT 
gene (*2, *3A, and *3C) lead to TPMT deficiency and reduced inactivation of 6-
mercaptopurine,31 and usually these patients have increased TGN erythrocyte levels.32,33 
The germline variant-toxicity relationship between uridine-5’-diphospho-
glucuronosyltransferase (UGT) and irinotecan has also been studied extensively. UGT1A1 is 
responsible for the inactivation of the active metabolite of irinotecan through 
glucuronidation. Irinotecan is commonly used in advanced colorectal cancer in combination 
with 5-fluorouracil. An inverse relationship exists between the number of TA repeats in the 
UGT1A1 promoter, and the transcriptional efficiency of the gene,34 its protein35 and mRNA 
expression,36 and the  level of glucuronidation of the active metabolite of irinotecan.37,38 
UGT1A1-deficient patients are homozygous carriers of the *28 variant (7 TA repeats, versus 
6 repeats in 1*1). In addition, the germline variant-toxicity relationship has been validated 
between dihydropyrimidine dehydrogenase (DPD) and fluoropyrimidines. 5-fluorouracil, and 
its oral equivalent capecitabine, are routinely used in the treatment of gastroesophageal, 
hepatocellular and colorectal cancers. DPD is responsible for up to 85% of the catabolism of 
fluoropyrimidine antimetabolites,23 and the DPYD*2A variant has been associated with 
decreased DPD catabolic activity.  
The germline variants described above are associated with increased risk of 
myelotoxicity (most notably neutropenia), as well as other potentially lethal clinical sequelae. 
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Myelosuppression is often the DLT of many chemotherapeutic agents due to their 
mechanisms of action, which target highly replicating cells like those of the bone marrow. 
Neutropenia can be routinely measured and quantified, which increases the ability to 
characterize pharmacodynamic effects of these medications with relative precision.  
Complications associated with neutropenia (i.e. infection and sepsis) are associated with 
poorer outcomes and increased costs to the health system. It has been estimated that the cost 
of inpatient treatment of neutropenia for one patient exceeds $13,000 per hospitalization.39 
Overall, severe neutropenia has a detrimental effect on dose intensity, not only in terms of 
the drug causing neutropenia but also to all other combined chemotherapies administered as 
part of that regimen.20,40TPMT deficient patients are at greater risk for 6-mercaptopurine–
induced ADRs, mainly severe myelosuppression.32,33 The positive predictive value of the 
TPMT genotype test has been estimated to be 67-100%.41 UGT1A1-deficient patients are at a 
9.3 fold higher risk for the development of irinotecan-induced grade 4 neutropenia, than 
patients with non-deficient UGT1A1 activity.42 The positive predictive value of a 
UGTA1A1*28/*28 genotype to detect grade 3-4 toxicity has been estimated to be 50%.43 
Approximately 20-50% of patients who experienced a grade 3-4 ADR are carriers of 
DPYD*2A,44-47 and exhibited decreased DPD activity.47 They have a 3.4-fold higher risk for 
grade 4 neutropenia when compared to patients with normal DPD activity.48 The positive 
predictive value of DPYD*2A for grade 3-4 toxicity has been estimated at 46%.49 Germline 
variants have also been associated with chemotherapy-induced ADRs other than 
myelotoxicities, such as neutropenia. Genetic associations have been investigated linking 
hypertension with bevacizumab, and skin toxicities with EGFR inhibitors (i.e. cetuximab, 
panitumumab, erlotinib and gefitinib). Skin rash has been reported in approximately 80% of 
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patients taking these drugs.50 Inhibition of EGFR signaling in basal keratinocytes leads to 
abnormalities in cell growth, differentiation and maturation, as well as an inflammatory 
response, which ultimately leads to the onset of rash.51 One proposed germline 
polymorphism associated with skin rash is a CA dinucleotide repeat in intron 1 of EGFR.52 
The number of CA repeats is inversely proportional to expression of EGFR, and shorter CA 
repeats have been linked to greater incidence of skin toxicity.53-55 Bevacizumab is a 
monoclonal antibody that binds to VEGF and inhibits angiogenesis. Evidence suggests a link 
between hypertension and impaired angiogenesis,56 and treatment with bevacizumab has 
been associated with increased incidence of grade 3-4 hypertension.17,57,58 A meta-analysis of 
12,656 patients demonstrated that bevacizumab significantly increases the risk of all grade 
hypertension by 23.6% (95% CI: 20.5-27.1%) and grade 3-4 hypertension by 7.9% (CI: 6.1-
10.2%), relative to control patients on concurrent traditional chemotherapies.57 In another 
study of patients who took bevacizumab, two VEGF germline genotypes (-634CC and  
-1498TT) were associated with lower rates of grade 3-4 hypertension.59 This was the first 
trial to investigate biomarkers associated with bevacizumab-induced hypertension. Emerging 
data have confirmed a similar relationship and showed that patients with either the -634CCor 
-1498TT genotypes, who were treated with the VEGF-inhibitor sunitinib, had less incidence 
of hypertension (P = 0.03, in both cases).60 Nevertheless, at this stage, the variants in EGFR 
and VEGF require additional validation before they can be used as predictive markers of 
toxicity.  
The process of pharmacogenetic marker validation still faces several major hurdles 
before these markers are integrated into routine clinical practice. Conflicting data generated 
from pharmacogenetic trials have been reported for many of the most well characterized 
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potential markers. For example, the UGT1A1*28/*28 genotype was not associated with 
severe diarrhea (another common side effect of irinotecan) in one study, but it was in 
others.42,61,62 In addition, inconsistencies concerning the functional variant associated with a 
particular ADR complicate the validation of pharmacogenetic markers. For example, data 
points to -216G/T and -191C/A EGFR variants, rather than CA dinucleotide repeats in intron 
1, as the causative single nucleotide polymorphisms (SNPs) responsible for EGFR inhibitor-
induced skin toxicity.52 The relationship between 5-fluorouracil toxicity and DPYD*2A also 
illustrates another problem in the process of pharmacogenetic marker validation: rare 
germline variants, which have limited predictive power. Data suggests that alternate germline 
variants in DPYD,63 non-coding region genomic variants found through haplotype 
assessment,64 DPYD promoter hypermethylation,65-67 or the influences of TYMS, MTHFR and 
other genes23,27 may play a significant role in explaining the remainder of the germline 
variant-toxicity relationship  involving  neutropenia and 5-fluorouracil. 
 
A1.4 The Effect of the Germline Variant-Toxicity Relationship on Chemotherapy 
Dosing 
While over twenty chemotherapeutic agents have references to pharmacogenetic 
markers in their FDA label,29 a clear disconnect exists between these pharmacogenetic 
markers and dosing recommendations.68 Only 6-mercaptopurine, 6-thioguanine, nilotinib and 
irinotecan include pharmacogenetic-based dose reduction recommendations in their drug 
labels.68 But, given the limited scale of clinical investigations on genotype-based dose 
individualization, they did not recommend mandated pharmacogenetic testing, nor did they 
provide guidance concerning the optimal timing for testing. This same limited scale of 
clinical investigations led the FDA to exclude explicit dose reduction guidelines from the 
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irinotecan or 6-mercaptopurine labels.68 While the package insert for irinotecan includes 
language endorsing dose reductions by one level for patients with the UGT1A1*28/*28 
genotype, these recommendations are not sufficiently specific.69 Genotype-based dose 
modification information should be far more precise because vague dose reduction language 
could conceivably compromise the efficacy of irinotecan if clinicians reduce doses too low.  
Despite the fact that the 6-mercaptopurine label does not contain specific dose 
reductions based on genotype, accumulating data regarding its dosing in TPMT-deficient 
heterozygous70 and homozygous71 patients led to guidelines supporting 50% and at least 90% 
reductions, respectively, of the initial dose of 6-mercaptopurine in pediatric patients treated 
for ALL.  This genotype-based dosing strategy has successfully limited ADRs.72 These 
conclusions were based on studies showing that TPMT-deficient heterozygotes can tolerate 
65% of the standard 75 mg/m2 6-mercaptopurine dose used in pediatric ALL (50 mg/m2 
daily),71,73,74 while homozygotes can receive 1/10th to 1/15th of the standard dose (i.e. 10 
mg/m2 every third day).70 In subsequent studies, patients were prospectively screened for 
TPMT status, and doses of 6-mercaptopurine were reduced in patients with TPMT-deficient 
alleles, according to a pre-specified dosing algorithm.75,76 As a result, these patients were 
successfully treated with 6-mercaptopurine, with rates of grade 3-4 ADRs comparable to 
patients with wild-type TPMT.72 In addition, the identification of TPMT-deficient patients not 
only permits clinicians to rationally reduce doses of 6-mercaptopurine to avoid severe ADRs, 
it also allows them to preserve the dose intensity of the regimen by administering concurrent 
chemotherapies at unadjusted doses and without interruptions.77,78 
The irinotecan doses used in current regimens were previously identified through 
phase I development without stratifying patients for UGT1A1*28. It has been postulated that 
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the dose of irinotecan might be suboptimal in patients with *1/*28 and *1/*1 genotypes, and 
these patients may benefit from higher, safe doses. This hypothesis has been tested in 
colorectal cancer patients treated with irinotecan combined with 5-fluorouracil (FOLFIRI 
regimen).79 Dose-escalation of irinotecan was assessed in *1/*1 and *1/*28 patients, and 
results from these studies showed they were safely and effectively treated with irinotecan 
doses of 370 and 310 mg/m2, respectively. These doses were considerably higher than the 
180 mg/m2 dose currently used in the clinic. Similar dose levels were safely given in another 
study of FOLFIRI (390 and 340 mg/m2, respectively).80 This study also demonstrated that the 
MTD for *28/*28 patients was 130 mg/m2, which is 30% lower than the standard dose. A 
similar conclusion has been also obtained in Japanese patients with *28 and/or *6, the 
common deficient allele in Asians.  *28/*28, *28/*6, and *6/*6 patients also achieved an 
MTD of 150 mg/m2.81 Meta-analyses demonstrated that *28/*28 patients have a significantly 
higher risk for grade 3-4 neutropenia, when compared to *1/*28 and *1/*1, at low doses (RR 
= 2.43; P = 0.003),82 at medium doses (OR = 3.22; P = 0.008) and high doses of irinotecan 
(OR = 27.8; P = 0.005).83 
There are additional examples where a germline-variant toxicity relationship might 
alter dosing. In a capecitabine study of 568 patients with advanced colorectal cancer, all of 
the patients with DPYD*2A experienced at least one grade 3-4 ADR (mostly diarrhea).84 The 
cumulative percentage dose reduction in these patients was significantly higher (50%) than 
wild-type patients (10%). For EGFR and VEGF-pathway inhibitors, there are not data on the 
effect of variants for skin rash and hypertension (respectively) on dosing and dose intensity. 
This represents a significant gap in current knowledge that should be addressed.  
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A1.5 The Downstream Effect of Germline Variants of Toxicity on Dosing and Efficacy 
The assumption that patients should be treated at the highest, safe doses of 
chemotherapy is still the foundation of a successful treatment regimen. Although we believe 
a pharmacogenetic marker of toxicity has high clinical utility, translation of such markers to 
clinical practice will be increased dramatically if ADRs can be linked to efficacy and 
survival. Currently, only the example of TPMT and 6-mercaptopurine exists where the 
knowledge of a germline variant-toxicity-dosing relationship is a tool to optimize efficacy.  
When 6-mercaptopurine doses were determined prospectively, based on TPMT genetic 
status, relapse rates were not significantly different between wild-type patients and those 
with TPMT-deficient genotypes (13.2% + 2.3% versus 6.7% + 6.7%; P = 0.46). In addition, 
patients with TPMT-deficient genotypes were not at significantly higher rates of grade 3-4 
neutropenia when compared to wild-type patients (OR = 1.4; 95% CI = 0.3–6.9; P = 
0.71).72,74 Most importantly, this genotype-based dosing strategy has successfully limited 
potentially life-threatening ADRs, while not sacrificing efficacy in this patient 
population.72,77 The interaction between 6-mercaptopurine and the bone marrow is unique 
because it is not only activated intracellularly in the bone marrow, but is also the site for its 
anti-leukemic efficacy and its myelotoxic DLT. This idiosyncrasy of 6-mercaptopurine 
allows the downstream effects of TPMT genetics on survival to be more directly assessable. 
But aside from the TPMT example, the relationship between germline variant-toxicity, 
chemotherapy dosing and survival outcomes have been extremely difficult to establish. For 
other relationships, the consequences on survival are tested as a secondary endpoint or have 
not been tested at all in clinical trials. 
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Very few genotype-driven dose-optimization studies have prospectively assessed 
objective response rate, progression-free survival, overall survival, or other measures of 
efficacy, as their primary endpoints.  For example, little evidence exists to conclusively link 
UGT1A1 germline variants to ADRs, dose and survival. In a retrospective analysis, dose 
reductions of irinotecan due to UGT1A1*28-related toxicity did not affect progression-free 
survival (10 versus 11 months) or overall survival (19 versus 18 months).85 A second study 
retrospectively evaluated the association between UGT1A1 genotype, prevalence of grade 3-
4 toxicity, and survival outcomes in colorectal cancer patients treated with irinotecan. This 
study demonstrated a significantly higher rate of ADRs, coupled with worse survival, for the 
*28/*28 patients. Grade 3-4 neutropenia was significantly more common in *28/*28 patients 
(24% compared with 8.2% and 5.5% in the *1/*28 and *1/*1 genotypes, respectively; P = 
0.019), while the median overall survival for the three genotypes was also significantly 
different (2.4, 2.0 and 1.6 years for the *1/*1, *1/*28 and *28/*28 genotypes, respectively; P 
= 0.019).86 It is currently unclear whether the results of this study point to a true downstream 
effect of the *28/*28 genotype-neutropenia relationship on survival, or if the decrease in 
median overall survival for patients with the *28/*28 genotype is simply due to neutropenia-
induced dose modifications that decrease overall exposure to irinotecan. Two recent studies 
of irinotecan, dose-escalated by genotype, showed that patients receiving higher doses 
experienced higher response rates than those treated at lower doses. In the first study, 65% of 
the patients treated with doses greater than or equal to the MTD of irinotecan achieved a 
complete or partial response compared with only 25% of patients treated with doses below 
the MTD of irinotecan (P = 0.14). Irinotecan dosed above MTD was an independent 
predictor of response in all patients (OR = 4.38; 95% CI 1.13-17.03; P = 0.03). Median time 
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to progression (TTP) was not significantly different between the patients treated above and 
below the irinotecan MTD (HR = 0.85; 95% CI 0.40-1.80).79 In the second study, 67% of 
patients treated with irinotecan doses >260 mg/m2 achieved a complete or total response, 
compared to only 24% of patients treated with doses <260 mg/m2 (P = 0.001). But unlike the 
previous study, TTP was higher in patients treated with doses >260 mg/m2, when compared 
to patients treated <260 mg/m2 (16 versus 7 months; P = 0.003).80 These data are premature, 
and intervention prospective studies should test the superiority of genotype-driven dosing of 
irinotecan versus standard dosing, in relation to survival in metastatic colorectal cancer. 
The evidence is still too sparse to provide a complete understanding of the 
relationship between germline variants associated with ADRs and survival in patients treated 
with EGFR and VEGF-pathway inhibitors, largely due to a lack of validated SNPs predictive 
of toxicity. Several phase II-III studies have linked the occurrence and severity of EGFR 
inhibitor-induced rash to improvements in survival.87-91 One notable phase III trial of NSCLC 
patients revealed a substantial survival benefit when patients experienced grade 2 and 3 rash 
compared to when no rash was observed (7 and 11 months, respectively, versus 3 months).87 
Moreover, several studies have reported an association between higher response and survival 
with less CA repeats, independently from its effect of skin rash or other toxicities,52,92 but 
other studies failed to validate this relationship.93 A prospective phase II dose-driven 
erlotinib study in NSCLC patients attempted to discover whether dose escalation beyond 
MTD would confer a survival advantage. The results from this dose-to-rash erlotinib dosing 
study revealed that all patients who achieved at least a partial response also experienced rash. 
Progression free survival was significantly extended in patients who experienced grade 2 
rash, when compared to patients without rash (3.5 versus 1.9 months; HR = 0.52; P = 
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0.051).94 But, this study did not investigate the role of germline variants on incidence and 
severity of rash, dose escalation or survival. Furthermore the effects of dose reductions of 
EGFR inhibitors, as a result of grade 3-4 rash, on efficacy and survival have not been 
assessed. Clearly in the case of EGFR inhibitors, the germline variant-rash-dose escalation 
(or reduction) relationship and its effects on efficacy and survival require further and deeper 
examination. 
Studies of patient populations have linked the incidence of bevacizumab-induced 
grade 3-4 hypertension to improved survival outcomes.95,96 More recently, associations 
between VEGF variants and survival have been explored.97,98 A trial of advanced breast 
cancer patients treated with bevacizumab tested VEGF germline variants (-634G/C, -
1498T/C, -2578C/A and -1154G/A) for associations with hypertension and survival. This 
study demonstrated that patients with the -634CC and 1498TT genotypes, who experienced 
grade 3-4 hypertension, achieved superior median overall survival compared to patients with 
no hypertension (38.7 versus 25.3 months; P = 0.002), while the -634G/C and -1498C/T 
variants were not associated with improved survival.59 But, the results of these associations 
have not been readily replicated, and data from other studies have associated improved 
survival outcomes to the  -634GG 98 and 1498CC genotypes.99 However, data from this trial 
did reveal the potentially important impact of the -2578AA and -1154AA genotypes on 
improved survival outcomes.59 The -2578A and the -1498T alleles are in high linkage 
disequilibrium in the 1000 Genomes reference population of Caucasians (LD, r2= 0.966).100 
This suggests that an LD block of genetic variation, containing these variants, may impact 
both phenotypes, and could potentially be useful as predictive markers of both hypertension 
and survival.   
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High VEGF expression and MVD have been associated with decreased survival,101 
and the results from the previous study showed that the -2578A allele trended toward lower 
VEGF expression 59. A plausible mechanistic explanation is that the -2578AA genotype 
causes lower VEGF expression and lower levels of VEGF may slow angiogenesis and the 
vascularization of the tumor, therefore contributing to increased survival. A similar process 
may also account for the bevacizumab-induced hypertension. It can be postulated that 
inhibition of the VEGF pathway, as a result of bevacizumab administration and in 
combination with the -1498TT and -634CC genotypes, may result in impaired 
vascularization. Lower VEGF levels leads to rarefaction, which is a process that results in 
reduced MVD, increased peripheral vascular resistance, and ultimately the onset of 
hypertension.56 The impact of these germline variants, in terms of their effects on 
hypertension and survival, has just begun to be analyzed in studies of other VEGF-pathway 
inhibitors, such as sunitinib.60 Such studies could be extremely useful to prioritize validation 
of these variants in patients prescribed other targeted therapies from this class, which all 
share similar rates of high-grade hypertension. These findings exemplify the challenges 
facing researchers and clinicians, and illustrate the difficulty in applying such information to 
guide dosing. Although we start to understand the intricacy of the effects of VEGF genetics 
on both hypertension and survival, more efforts should address whether genotype-driven 
hypertension of bevacizumab or sunitinib can negatively impact dosing and compromise 
survival.   
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A1.6 Conclusions 
Incorporation of validated pharmacogenetic markers into routine practice is of 
paramount importance to clinicians as they strive to reduce severe and life-threatening 
ADRs. Prevention and mitigation of ADRs improves patient quality of life and compliance to 
chemotherapy, which ultimately may lead to better survival outcomes. Understanding the 
putative relationship between germline variants, ADRs, chemotherapy dosing, and survival is 
essential to the identification and translation of pharmacogenetic markers. We believe that 
any validation approach of pharmacogenetic markers, with potential clinical utility, must 
reflect incorporation of these four key components.  
The examples of TPMT and 6-mercaptopurine, UGT1A1*28 and irinotecan, DPYD 
and the fluoropyrimidines, EGFR and EGFR inhibitors, and VEGF and bevacizumab provide 
illustrations of the varying levels of success that researchers and clinicians have had in 
translating pharmacogenetic molecular markers to the clinic.  Currently, the example of 
prospective TPMT screening and subsequent dose adjustments in pediatric ALL patients has 
been the model for pharmacogenetic success in oncology. Increased numbers of prospective 
clinical trials, similar to those used to justify prospective TPMT testing, are direly needed to 
validate many more pharmacogenetic markers.  Moreover, specific dosing recommendations 
need to be included into drug labels to help guide clinician decision-making processes.  
Dosing recommendations based on TPMT and UGT1A1 genotypes should be clarified and 
prospective trials should be conducted to solidify the relationship linking DPYD, EGFR, and 
VEGF variants to ADRs.  
While a few smaller trials have explored the effect of genotype on ADRs, dosing and 
survival, only a handful of studies have conducted well-powered prospective trials to explore 
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this relationship. This could be due to a number of reasons, ranging from low frequency of a 
particular germline variant (i.e. DPYD*2), to a lack of a convincing body of evidence 
conclusively linking a germline variant to ADRs and dose modifications (i.e. EGFR and 
VEGF-pathway inhibitor germline variants). The DPYD example illustrates how the current 
approach of trying to identify highly penetrant, single gene variants to explain complex 
phenotypes, such as ADRs, to be used as pharmacogenetic markers, may be partially flawed. 
Research to identify novel markers may rely on more sophisticated methods to characterize 
polygenic effects. In addition, research to identify translatable pharmacogenetic makers with 
downstream effects on survival may be complicated by the inability to take into account the 
effects of somatic mutations, tumor heterogeneity, epigenetic factors or other undiscovered 
prognostic confounders. But, identification of pharmacogenetic markers, validated through 
approaches that consider the germline variant-toxicity-survival relationship, will help 
clinicians craft strategies that rationally dose drugs within an enlarged therapeutic window to 
optimize efficacy while mitigating ADRs. 
 
A1.7 Future Perspectives 
Adoption of validated pharmacogenetic markers into routine clinical practice has 
been slow, in part due to the scarcity of genotype-driven trials that implement the approach 
we have outlined. As the field of pharmacogenetics continues to evolve, retrospective meta-
analyses of promising gene variants might validate or refute their use in the clinic. 
Prospective interventional studies involving patients stratified by genotype will be a means of 
systematically collecting phenotype data, while also collecting data on potential confounding 
factors that would inhibit translation of germline variants into clinically useful 
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pharmacogenetic markers. Finally, secondary, pharmacogenetically driven post-hoc analyses 
of phase III studies (which are sufficiently powered for genomic analysis) will further 
analyze the relationship between genetics, dosing strategies, ADRs and survival outcomes. 
Candidate gene and genome-wide association studies are two methods that will continue to 
drive identification of pharmacogenetic markers.102 As the number of approved oral 
chemotherapeutic medications increases, strategies based on germline variant-toxicity-dose 
paradigms need to be developed to help identify patients at increased risk for the onset of 
common ADRs that adversely affect patient quality of life and compliance to therapy. 
Existing statistical models might aid in the process of elucidating the links that 
connect germline variants to toxicity, dosing, and survival. These relationships will be better 
understood by evaluating a cumulative incidence of an event in the context of a regression 
model of competing risks. Interdependence of variables limits the ability of existing 
statistical models to extricate one event of interest, for analysis, from all other competing 
risks. Frequently in cancer studies, several competing events (phenotypes) are present that 
cause treatment failures. The event of interest might occur later in treatment than the 
occurrence of severe ADRs, disease progression, or death, which could result in early 
withdrawal from the study. Use of a standard case-control approach for analyzing the data 
might be flawed because competing risks and cumulative incidences are ignored, and has the 
potential to shroud the identification of pharmacogenetic markers. In recent years, cancer 
researchers have successfully implemented novel methodologies103,104 into cumulative 
incidence competing risks model in their analyses.96,105-107 Future studies, which analyze 
pharmacogenetic markers, should employ these types of analyses because the intricacies of 
the model allow for a more accurate depiction of probabilities of events of interest occurring 
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in the presence of competing risks. By employing this statistical model, researchers will be 
able to compare cumulative incidence curves, between two or more groups stratified by 
genotype, for a phenotype of interest. 
Another reason for the slow inclusion of pharmacogenetic biomarkers into clinic is 
the conspicuous absence of explicit pharmacogenetic-based dosing guidelines published by 
regulatory bodies. The Clinical Pharmacogenetics Implementation Consortium (CPIC) of the 
National Institutes of Health’s Pharmacogenomics Research Network (http://www.pgrn.org) 
and the Pharmacogenomics Knowledge Base (PharmGKB, http://www.pharmgkb.org) 
provide peer-reviewed, updated, evidence-based, freely accessible pharmacogenetic 
guidelines for chemotherapeutic agents.77 These guidelines will facilitate the translation of 
knowledge derived from laboratory-based pharmacogenetic and pharmacogenomic research 
into the clinic, and provide explicit instructions regarding dosing and testing of these agents. 
Dosing information will be customized for patients based on treatment response. Guidelines 
have already been developed for TPMT and 6-thioguanine and 6-mercaptopurine dosing,78 
but the CPIC and other consortia will continue to develop guidelines for gene-chemotherapy 
pairings into the future. In addition to CPIC, other consortia, such as the Pharmacogenetics 
Working Group from the Netherlands, will also continue to publish pharmacogenetic-based 
dosing guidelines for chemotherapy and targeted agents. To date, the Pharmacogenetics 
Working Group has published dosing guidelines for tamoxifen, irinotecan, 6-mercaptopurine, 
and 5-fluorouracil/capecitabine, based on pharmacogenetic markers, but will continue to 
publish guidelines that will complement the work of the CPIC and PharmGKB.108 Published 
pharmacogenetic-based dosing guidelines will undoubtedly aid clinicians in the optimization 
209 
of treatment efficacy, mitigation of toxicity, and improvement of both medication adherence 
as well as quality of life for patients taking chemotherapy. 
Finally, interethnic differences in the distribution of variant alleles could also 
potentially obstruct the adoption of pharmacogenomic standards and impede adoption of 
pharmacogenetic biomarkers into the clinic. Projects, such as the Pharmacogenomics for 
Every Nation Initiative (PGENI, http://www.pgeni.org), will serve to address interethnic 
differences in allele frequency distributions. Currently, PGENI has established regional 
centers in six countries, and are determining allele frequencies of known polymorphisms in 
different populations. Ultimately, initiatives like PGENI will help identify interethnic 
differences that aid in medication formulary decisions, population stratification in genotype-
driven clinical trials, and even target identification early on in the global drug development 
process. 
 
A1.8 Executive Summary 
Adverse Drug Reactions (ADRs) 
• ADRs account for 7% of all hospital admissions, occur in 10-20% of all patients and 
increase hospital stays 
• ADR-related morbidity exceeds $3.6 billion annually in the United States 
• Common toxicities occur frequently in oncology patients and affect medication 
adherence 
• Greater than 60,000 oncology patients are hospitalized annually in the United states 
due to severe neutropenia and neutropenia has an annual mortality rate of 6.8% 
• Prevention and mitigation of ADRs improves quality of life and medication 
adherence, and may lead to better survival outcomes  
210 
Chemotherapy Dose  
• Maintaining dose for the entire course of treatment has been shown prospectively and 
retrospectively, in various tumor types, to be correlated with better outcomes 
• Traditional cytotoxic chemotherapies are dosed to MTD, but novel molecularly-
targeted agents could be dosed to OBD 
TPMT and 6-mercaptopurine 
• TPMT*2, *3A, and *3C account for over 95% of inherited TPMT deficiency. 
• Reduced TPMT function places patients at significantly greater risk for 6-
mercaptopurine–induced ADRs, including neutropenia  
• Patients heterozygous and homozygous for reduced TPMT function alleles receive 
50% and ≥90% reductions of the initial dose of 6-mercaptopurine, respectively 
• Dose reductions in patients with reduced TPMT function results in less grade 3-4 
neutropenia, while preserving positive survival outcomes 
UGT1A1 and Irinotecan 
• TA repeats in the UGT1A1 promoter have been associated with UGT1A1 
transcriptional efficiency and glucuronidation levels of the active metabolite of 
irinotecan  
• The risk of grade 3-4 neutropenia is ~9.3-fold higher in patients with the 
UGTA1A1*28/*28 genotype, when compared to all other patients, UGTA1A1*28/*28 
patients are at significantly higher risk for grade 3-4 neutropenia at low and medium 
doses of irinotecan, when compared to UGTA1A1*1/*28 and UGTA1A1*1/*1 patients 
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• UGT1A1*1 patients were able to tolerate doses that exceed the standard irinotecan 
MTD, and dose reductions to UGT1A1*28 patients due to neutropenia did not 
compromise survival outcomes 
• Explicit dosing recommendations for patients with UGT1A1*1 versus UGT1A1*28 
have not been published 
DPYD and 5-fluorouracil/Capecitabine 
• Germline variants in DPYD have been associated with increased ADRs 
• The DPYD*2 allele is not prevalent in the general population, but is associated with a 
3.4-fold higher risk for grade 4 neutropenia, when compared to patients with normal 
DPD activity 
• The relationship between DPYD*2 genotype, grade 3-4 neutropenia and survival 
remains unclear and requires further investigation 
EGFR and Erlotinib/Cetuximab 
• Skin rash is an ADR that is experienced by  ~80% of patients taking EGFR inhibitors 
• A CA repeat in the intron 1 region of EGFR has been associated with increased 
incidence of rash in patients taking EGFR inhibitors 
• Increased incidence of rash has been associated with increased progression free 
survival 
• The role of germline variants in EGFR inhibitor-induced rash, dosing and survival 
remains unclear 
VEGF and Bevacizumab 
• The onset of hypertension has been correlated with increased survival in patients 
treated with bevacizumab 
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• Bevacizumab-induced hypertension and better survival outcomes may be related to 
germline variations in the VEGF pathway 
• VEGF germline variants have been associated with decreased incidence of 
hypertension (-634CC and -1498TT) and increased survival (-2578AA and -1154AA) 
• The -2578C/A and -1498C/T variants are in high LD, and could be contributing to 
both bevacizumab-induced hypertension and survival outcomes 
• The relationship between VEGF-pathway germline variants and bevacizumab dosing 
is still unclear 
Conclusions 
• Any approach to clinical validation of pharmacogenetic markers must reflect an 
understanding of the relationships between germline variants, ADRs, chemotherapy 
dosing, and survival  
• Consortia, such as PharmGKB, CPIC and the Pharmacogenetics Working Group will 
provide pharmacogenetically-based dosing recommendations for chemotherapeutics 
and aid in the translation of pharmacogenetic markers into clinical practice  
• Initiatives such as PGENI will help identify interethnic differences that aid in 
medication formulary decisions, population stratification in genotype-driven clinical 
trials, and even target identification early on in the global drug development process   
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APPENDIX 22: CLINICAL VALIDITY OF NEW GENETIC BIOMARKERS OF 
IRINOTECAN NEUTROPENIA: AN INDPENDENT REPLICATION STUDY 
 
A2.1 Overview 
The overall goal of this study was to provide evidence for the clinical validity of nine 
genetic variants in five genes previously associated with irinotecan neutropenia and 
pharmacokinetics. Variants associated with ANC nadir and/or irinotecan pharmacokinetics in 
a discovery cohort of cancer patients were genotyped in an independent replication cohort of 
108 cancer patients.  Patients received single-agent irinotecan every three weeks. For ANC 
nadir, we replicated UGT1A1*28, UGT1A1*93 and SLCO1B1*1b in univariate analyses. For 
irinotecan AUC0-24, we replicated ABCC2 -24C>T; however ABCC2 -24C>T only predicted 
a small fraction of the variance. For SN-38 AUC0-24 and the glucuronidation ratio, we 
replicated UGT1A1*28 and UGT1A1*93. In addition to UGT1A1*28, this study 
independently validated UGT1A1*93 and SLCO1B1*1b as new predictors of irinotecan 
neutropenia. Further demonstration of their clinical utility will optimize irinotecan therapy in 
cancer patients.  
 
A2.2 Introduction 
Irinotecan is an anticancer agent commonly used for the treatment of metastatic 
colorectal cancer and other solid tumors. Irinotecan is a potent inhibitor of topoisomerase I, 
                                                           
2 This chapter was published The Pharmacogenomics Journal (Crona DJ, et al. Pharmacogenomics J. 
2015 Apr 14 [Epub ahead of print]. 
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and is initially hydrolyzed to its active metabolite, SN-38, which is then subsequently 
inactivated through UGT1A1-mediated glucuronidation. A significant proportion of patients 
treated with irinotecan develop toxicities, including severe neutropenia. Neutropenia is a 
common, serious, dose-dependent and dose-limiting toxicity of irinotecan.1 
A common, germline genetic variation in UGT1A1 predisposes patients to an 
increased risk of irinotecan-induced toxicities.2, 3 The number of TA repeats in the UGT1A1 
promoter is inversely proportional to the transcriptional efficiency of the gene,4 mRNA 
expression,5 and protein levels.6  Patients with the UGT1A1*28 variant have seven TA 
repeats (compared to six repeats in patients with UGT1A1*1), have decreased SN-38 
glucuronidation,7 and experience increased systemic exposure to SN-38, which results in a 
higher risk of severe neutropenia.1 As a result, an FDA-approved UGT1A1*28 genotyping 
test has been made commercially available,8 and the irinotecan label has been revised to 
include UGT1A1*28 as a predisposing factor for severe neutropenia.9  
Irinotecan-induced neutropenia is a complex, polygenic phenotype. There is 
significant interindividual variation in systemic exposure to both irinotecan and SN-38 that 
cannot be explained solely by UGT1A1*28. Several additional genetic variants contribute to 
both variability in irinotecan pharmacokinetics and the risk of severe neutropenia.10-16 The 
FDA-approved UGT1A1*28 genetic test has only moderate predictive power for severe 
toxicity due to its low positive predictive value,8 and therefore the genetic test has not been 
incorporated into routine clinical practice. The discovery of additional variants associated 
with neutropenia is needed to improve the utilization of irinotecan genetic testing. 
Pharmacogenetic studies have identified a vast set of genetic variants as predictors of 
chemotherapy efficacy and toxicity. The majority of these proposed variants have failed to 
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produce similar results across different studies, which has limited the clinical utility of 
pharmacogenetics.17, 18 Therefore, prospective replication of pharmacogenetic findings in 
independent and external cohorts of patients is essential to hasten the implementation of 
pharmacogenetics into routine clinical practice.  
In a previous study of cancer patients treated with single-agent irinotecan, novel gene 
variants that were associated with irinotecan disposition and toxicity were identified.16  In 
addition to UGT1A1*28, other variants, mostly in drug transporter genes, were associated 
with neutropenia and irinotecan pharmacokinetics. Therefore, we conducted a replication 
study to test the clinical validity of these variants in an external cohort of cancer patients 
treated with single-agent irinotecan.  
 
A2.3 Materials and Methods 
A2.3.1 Study design 
The overall goal of the study was to replicate genetic associations for irinotecan 
neutropenia and pharmacokinetics previously identified in a discovery cohort.16 The primary 
objective was to validate the associations between four genetic variants and absolute 
neutrophil count (ANC) nadir by testing them in an external replication cohort. The 
secondary objective was to validate the effects of eight genetic variants previously associated 
with pharmacokinetic parameters in the discovery cohort by analyzing them in the replication 
cohort. Thus, a total of nine common variants in five genes (ANC nadir and the 
pharmacokinetic phenotypes shared two variants) were genotyped in the replication cohort 
and tested for associations. Variants for replication testing were selected based on significant 
genotype-phenotype associations (p≤0.05) observed in the discovery cohort. All patients in 
225 
the replication cohort were White, and therefore only the previously genotyped White 
patients comprised the discovery cohort (n=67).16  
 
A2.3.2 Patient characteristics 
In the discovery cohort, advanced solid tumor patients were treated at the University 
of Chicago (Chicago, USA) with a 90-min infusion of single-agent irinotecan every three 
weeks at 300 mg/m2 (n=18) or 350 mg/m2 (n=49). Eligibility criteria included adequate 
hematopoietic function (white blood cell count >3,500/µL, ANC >1,500/µL, platelets 
≥100,000/µL), normal renal and hepatic function (creatinine <1.5 mg/dL, total bilirubin 
<1.25 x upper limit of normal (ULN), and AST/ALT <5 x ULN), and adequate performance 
status (Karnofsky score >70%). Plasma pharmacokinetic parameters of irinotecan and 
metabolites were measured during and after the first cycle infusion of irinotecan. Forty-two 
genetic variants in 12 candidate genes of the irinotecan pathway were previously genotyped 
and tested for association with irinotecan pharmacokinetics and ANC nadir, measured during 
cycle 1.  
In the replication cohort, 108 White advanced solid tumor patients were treated at the 
Erasmus University Medical Center, Erasmus MC Cancer Institute (Rotterdam, The 
Netherlands).19-21 Patients received a 90-min infusion of single-agent irinotecan every three 
weeks at 600 mg (flat dose, n=58), 350 mg/m2 (n=31), or 380-1060 mg (flat dose calculated 
according to an algorithm,19 n=19).  Eligibility criteria included adequate hematopoietic 
function (ANC >2,000/µL, platelets >100,000/µL), and normal renal and hepatic function 
(creatinine clearance >60 mL/min, total bilirubin <1.25 x ULN, and AST/ALT <3 x ULN). 
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Plasma pharmacokinetics of irinotecan and metabolites were measured during and after the 
first cycle infusion. 
  All patients in the discovery and replication cohorts provided written informed 
consent and the local institutional review boards approved the clinical protocols.  Patient 
characteristics from the discovery and replication cohorts are provided in Table A2.1. 
 
A2.3.3 Patient phenotyping: pharmacokinetic parameters and ANC nadir 
In both cohorts, pharmacokinetic parameters included: irinotecan area under the 
concentration-time curve to the last time of sampling (AUC0-24), AUC0-24 of the active SN-38 
metabolite, AUC0-24 of the inactive SN-38 glucuronide (SN-38G), and the ratio of SN-38G 
AUC0-24 to SN-38 AUC0-24 (glucuronidation ratio). 
For the discovery cohort, samples were collected on day 1 of cycle 1 at baseline prior 
to irinotecan infusion, during the infusion (30, 60, and 90 min), and after the infusion (10, 20, 
30 and 45 min, 1, 1.5, 2, 4, 6, 8, 12 and 24 h). Plasma concentrations of irinotecan and 
metabolites were measured, as previously reported.10 Pharmacokinetic parameters were 
calculated by non-compartmental analysis (WinNonlin®, Pharsight Corp., Cary, NC, USA).  
For the replication cohort, samples were collected on day 1 of cycle 1 at baseline 
prior to infusion, during the infusion (30 and 90 min) and after the infusion (10, 20 and 30 
min, and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 and 24 h). Plasma concentrations of irinotecan and 
metabolites were measured, as previously reported.20, 22, 23 Pharmacokinetic parameters were 
calculated by non-compartmental analysis (PK Solutions v2.0, Summit Research Services, 
Montrose, CO, USA).  
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In both cohorts, complete blood counts were taken at baseline, weekly throughout 
cycle 1, and then prior to the start of cycle 2 to obtain the measurements of the ANC nadir.   
 
A2.3.4 Genotype data 
Nine common variants, previously associated with irinotecan pharmacokinetics and 
ANC nadir in the discovery cohort, were genotyped in the replication cohort: ABCB1 IVS9 
44A>G, ABCC1 1684T>C, ABCC1 IVS11 -48C>T, ABCC2 3972C>T, ABCC2 -24C>T, 
SLCO1B1*1b, SLCO1B1*5, UGT1A1*28, and UGT1A1*93.  DNA isolated from peripheral 
blood was used for genotyping. All genotyping assays were performed on an Applied 
Biosystems TaqMan 7500 (Life Technologies, Grand Island, NY, USA). UGT1A1*93 was 
genotyped by restriction fragment length polymorphism PCR, using 5’-
ACCTCTAGTTACATAACCTGAA-3’ as the forward primer sequence and 5’-
ATAAACCCGACCTCACCAC-3’ as the reverse primer sequence. UGT1A1*28 genotyping 
methods for the replication cohort have been previously described.20 All other variants were 
genotyped using TaqMan SNP genotyping assays (Life Technologies, Grand Island, NY, 
USA) as per the manufacturer’s instructions. Positive controls of known genotypes were used 
in the assays.  
 
A2.3.5 Statistics 
Data for all phenotypes for both cohorts were log10 transformed. Hardy-Weinberg 
Equilibrium was evaluated for all nine variants genotyped in both the discovery and 
replication cohorts (Table A2.S1). In the discovery cohort, associations between genetic 
variants and clinical phenotypes were analyzed using linear regression, and were adjusted for 
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sex, age, and irinotecan dose (300 or 350 mg/m2). All ANC nadir analyses were also adjusted 
for baseline ANC.  
In the replication cohort, we prospectively tested associations between the nine gene 
variants described above and phenotypes of ANC nadir and irinotecan pharmacokinetics.  
The same statistical methodologies employed for the discovery cohort were applied: linear 
regression adjusted for sex, age, and irinotecan dose (350 mg/m2, 600 mg flat dose, or dose 
by an algorithm19), with baseline ANC used to adjust the ANC nadir analysis. Flat doses 
were converted to mg/m2 according to the body-surface area of each patient. The same mode 
of inheritance (dominant, recessive, or additive) used in the discovery cohort was also used in 
the replication cohort.  
No general consensus exists to provide standardized criteria for replication cohort 
analyses. We considered a given variant’s association to be replicated based on direct 
comparison of the observed estimates of effect in the discovery and replication cohorts:  an 
association’s estimate of effect in the replication cohort had to be in the same direction as in 
the discovery cohort (an increased or decreased estimate of phenotype change in both 
cohorts), and lie within the 95% confidence interval (CI) of the discovery cohort’s estimate. 
Two-sided p-values are reported for reference. Since comparisons between discovery and 
replication cohort estimates of effect were pre-specified and rely on 95% CIs from the 
discovery cohort, not on hypothesis testing in the replication cohort, issues related to 
multiplicity are not present. Therefore, no correction for multiple comparisons was 
performed.  
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A2.4 Results 
This study sought to replicate, in an independent, external cohort of White cancer 
patients from the Netherlands, nine variants from five genes that had previously associated 
with ANC nadir or irinotecan pharmacokinetics16. Baseline clinical patient characteristics 
and pharmacokinetic data (Table A2.1), as well as allele and genotype frequencies (Table 
A2.S1) were comparable between the two cohorts. Below we report the replication results of 
each variant for neutropenia and irinotecan pharmacokinetics (Table A2.2).  
 
A2.4.1 Replication of variants previously associated with ANC nadir 
For ANC nadir, four variants that previously associated with ANC nadir in the discovery 
cohort were tested in the replication cohort. In the discovery cohort, UGT1A1*28 (additive 
model), UGT1A1*93 (recessive model), and ABCC1 IVS11 -48C>T (recessive model) were 
associated with decreased ANC nadir; SLCO1B1*1b (dominant model) was associated with 
increased ANC nadir. In the replication cohort, we considered UGT1A1*28, UGT1A1*93 and 
SLCO1B1*1b replicated, since the direction of the estimate of the effect for each variant was 
consistent between both cohorts (decreased ANC nadir for UGT1A1*28 and UGT1A1*93, as 
well as increased ANC nadir for SLCO1B1*1b) and each was within the 95% CIs for its 
respective discovery cohort estimate. ABCC1 IVS11 -48C>T failed to replicate (Table A2.2).  
 
A2.4.2 Replication of variants associated with the pharmacokinetic parameters of irinotecan 
For irinotecan AUC0-24, two variants that were previously associated with irinotecan 
AUC0-24 in the discovery cohort were tested in the replication cohort. In the discovery cohort, 
ABCC2 -24C>T and SLCO1B1*5 (both dominant model) were associated with increased 
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irinotecan AUC0-24. In the replication cohort, we considered ABCC2 -24C>T replicated since 
the direction of the estimate of the effect was consistent between both cohorts (increased 
AUC0-24 for both variants), and was within the 95% CIs for the discovery cohort estimate. 
SLCO1B1*5 failed to replicate (Table A2.2). 
For SN-38 AUC0-24, three variants that were previously associated with SN-38 AUC0-
24 in the discovery cohort were tested in the replication cohort. In the discovery cohort, 
UGT1A1*28 and UGT1A1*93 (both additive model) were associated with increased SN-38 
AUC0-24, while ABCB1 IVS9 -44A>G (dominant model) was associated with decreased SN-
38 AUC0-24. In the replication cohort, we considered UGT1A1*28 and UGT1A1*93 replicated 
since the direction of the estimate of the effect for each variant was consistent between both 
cohorts (increased AUC0-24 for both variants), and each was within the 95% CIs for its 
respective discovery cohort estimate. ABCB1 IVS9 -44A>G failed to replicate (Table A2.2). 
For SN-38G AUC0-24, although ABCC2 3972C>T (recessive model) was associated 
with increased SN-38G AUC0-24 in the discovery cohort, it failed to replicate when tested in 
the replication cohort (Table A2.2).  
For the glucuronidation ratio, three variants that associated with the glucuronidation 
ratio in the discovery cohort were tested in the replication cohort. In the discovery cohort, 
UGT1A1*28 (additive model), UGT1A1*93 (additive model), and ABCC1 1684T>C 
(dominant model) were associated with a decreased glucuronidation ratio. In the replication 
cohort, we considered UGT1A1*28 and UGT1A1*93, replicated, since the direction of the 
estimate of the effect for each variant was consistent between both cohorts (decreased 
glucuronidation ratio for all variants), and each was within the 95% CIs for its respective 
discovery cohort estimate. Although the association between ABCC1 1684T>C (dominant 
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model) and glucuronidation ratio also satisfies our criteria for replication, we are less 
convinced of the association, given the 84% reduction in the magnitude of the estimate as 
compared to that of the discovery cohort (Table A2.2). 
 
A2.5 Discussion 
In this replication study, we validated the clinical effects of new germline genetic 
variants for neutropenia and irinotecan pharmacokinetics using an independent, external 
cohort of White cancer patients treated with single-agent irinotecan.  
The most important result of this study was the clinical validation of SLCO1B1*1b. 
To our knowledge, this provides the first replicated data implicating SLCO1B1*1b as a 
protective marker against irinotecan-induced neutropenia. SLCO1B1 encodes for organic 
anion transporter family member 1B1 (OATP1B1), and mediates hepatic uptake of both 
endogenous24, 25 and xenobiotic compounds.26 OATP1B1 is a hepatic uptake transporter of 
SN-38,27, 28 but not irinotecan.28 In this study, we have replicated results from the discovery 
cohort, and have shown that the variant *1b allele was associated with a higher ANC nadir 
compared to the reference sequence *1a allele (Figure A2.1A). Since SLCO1B1*1b is a non-
synonymous variant (asparagine to aspartate amino acid change), and SLCO1B1 is primarily 
expressed in the liver,29 we postulate this variant might associate with reduced neutropenia 
by altering systemic SN-38 exposure. The effect of SLCO1B1*1b on SN-38 AUC0-24 was -
0.083±0.076 (mean±SE) in the White patients of the discovery cohort (n=67; p=0.278), and 
because the p-value was >0.05, this association was not selected for analysis in the 
replication cohort. However, an exploratory univariate analysis (adjusted for dose (mg/m2), 
age and sex) revealed that SLCO1B1*1b was associated with decreased SN-38 AUC0-24 in 
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the replication cohort (n=84; -0.128±0.055, p=0.023). These results support the hypothesis 
that the protective effect of SLCO1B1*1b against neutropenia could be due to increased 
hepatic uptake of SN-38, resulting in increased SN-38 elimination from the plasma after 
irinotecan infusion.  
While the pharmacokinetic data are supportive of the protective effect of 
SLCO1B1*1b against neutropenia, the functional effect of this variant is less clear. Using 
RNA expression data from human livers,30 SLCO1B1*1b (as well as variants in linkage 
disequilibrium r2 ≥0.8) did not associate with changes in the mRNA expression of SLCO1B1 
(results not shown). In oocyte studies, the uptake of SN-38 was higher for SLCO1B1*1b than 
SLCO1B1*1a (the reference sequence allele), but the observed difference was not 
statistically significant (see Figure 6a of Nozawa et al.28). Our results provide evidence that 
SLCO1B1*1b results in a gain of function, which leads to increased hepatic uptake of SN-38 
from the plasma. Although this seems the most plausible hypothesis, other mechanisms 
related to the widespread functions of this transporter on several endogenous constituents 
cannot be ruled out. 
Another important conclusion of this study is that UGT1A1*93 confers an increased 
risk of irinotecan-induced neutropenia. We replicated results from the discovery cohort, and 
have shown that the *93 variant was associated with a lower ANC nadir compared to the 
reference sequence *1 allele (Figure A2.1B). UGT1A1*93 is a -3156G>A change discovered 
during a resequencing study of the region 5′ to the UGT1A exon 1.31 According to an analysis 
of more than 150 human livers where genome-wide genotyping data were available, 
UGT1A1*93 is a major determinant of decreased levels of the UGT1A1 protein (Pearson’s 
r=-0.46, p=3.5x10-9),30, 32 and additional preliminary data corroborate these findings.33 
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Because UGT1A1*93 is in partial linkage disequilibrium with UGT1A1*28 among White 
patients (r2=0.68),34 our results suggest that UGT1A1*93, based on its greater estimate of 
effect for ANC nadir, may be a more robust marker for neutropenia than UGT1A1*28 (Table 
A2.2). While the UGT1A1*93 variant has not yet been included in the FDA-revised 
irinotecan label, we envision that recommendations supporting UGT1A1*93 genotyping 
could eventually replace UGT1A1*28 in the irinotecan drug label. 
The association between ABCC2 -24C>T and increased irinotecan AUC0-24 was also 
replicated (Figure A2.1C). ABCC2 encodes for the multidrug resistant protein-2 and 
contributes to the biliary clearance of irinotecan, SN-38 and SN-38G.35, 36 The -24 C>T 
variant has been associated with a nearly 20% reduction in promoter activity.37 This 
observation is consistent with our results, where the variant T allele was associated with 
increased irinotecan AUC0-24, likely due to decreased biliary clearance. However the estimate 
of effect size was relatively small (Table A2.2), and additional studies should be conducted 
to elucidate the extent of its clinical relevance. 
Established criteria for conducting pharmacogenetic replication studies do not 
currently exist, but we provide a general framework for conducting such studies. 
Pharmacogenetic replication studies are beset with numerous challenges, including dosing 
and population heterogeneity between the discovery and replication cohorts. In our study, we 
attempted to control for population heterogeneity by comparing patients in the replication 
cohort to only the White patients from the original discovery cohort.16 Dosing heterogeneity 
between the two cohorts may have affected our ability to replicate some variants, but it did 
not confound all associations, as evidenced by the detection of associations serving as 
“positive controls”, such as UGT1A1*28 versus SN-38 AUC0-24 and UGT1A1*28 versus 
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glucuronidation ratio (but not irinotecan AUC0-24). Moreover, we are confident that dosing 
heterogeneity did not significantly confound our replication results because irinotecan has 
been shown to demonstrate dose linear pharmacokinetics over a wide range of doses.38 
Regarding our statistical approach, the assessment of replicated associations is not based on 
hypothesis testing, and therefore using p-values as our main criteria for replication would 
have been inappropriate. Moreover, given the influence of sample size on p-values, 
utilization of p-values as the main criteria for replication could have resulted in false negative 
results. We also cannot exclude the possibility that between-cohort differences limited our 
ability to detect phenotypic differences and replicate several variants.  
This replication study allowed us to demonstrate the clinical validity of associations 
between UGT1A1*93 and SLCO1B1*1b and neutropenia. The effects of these two variants 
on neutropenia should be confirmed in studies where irinotecan is given in combination with 
other anticancer agents that have neutropenic effects (for example with 5-fluorouracil). 
Additionally, the effects of these replicated variants can currently be applied only to White 
patients. Efforts should be made to validate these variants in patients from other races who 
receive irinotecan.  Further validation of their clinical utility will aid in the implementation of 
routine irinotecan pharmacogenetic testing and optimization of personalized treatments for 
cancer patients. 
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TABLES 
Table 1. Baseline patient characteristics and pharmacokinetic data from the discovery 
and the replication cohorts. Flat dosing and dosing by algorithm19  were used only in the 
replication cohort. The distribution of the algorithm-derived doses includes: 380 mg (n=1), 
500 mg (n=1), 520 mg (n=2), 540 mg (n=1), 560 mg (n=1), 620 mg (n=2), 640 mg (n=1), 
660 mg (n=1), 680 mg (n=1), 720 mg (n=2), 740 mg (n=3), 780 mg (n=1), 900 mg (n=1), 
1060 mg (n=1). 
 Discovery Cohort 
(n=67) 
Replication Cohort 
(n=108) 
Dose 
   300 mg/m2 18 (26.9%) - 
   350 mg/m2 49 (73.1%) 31 (29.7%) 
   Flat dose (600 mg) - 58 (53.7%) 
   Dose by algorithm (380-1060 mg) - 19 (17.1%) 
Sex 
   Male 42 (62.7%) 60 (55.6%) 
   Female 25 (37.3%) 48 (44.4%) 
 
 Median Range Median Range 
Age (years) 57 34-85 58 26-75 
BSA (m2) 1.87 1.46-2.55 1.88 1.36-2.50 
Baseline ANC (cells/µL) 5.27 2.18-14.36 5.12 1.30-13.60 
ANC Nadir (cells/µL) 2.21 0.05-7.83 1.79 0.03-7.13 
 
Pharmacokinetic Parameters Mean Range Mean Range 
Irinotecan AUC0-24 (h*ng/mL)  23251 8857-65305 22776 11422-67560 
SN-38 AUC0-24 (h*ng/mL) 385 38-1957 364 79-1776 
SN-38G AUC0-24 (h*ng/mL) 1824 360-8214 2238 396-6912 
SN-38G AUC0-24 to SN-38 AUC0-24 
ratio (glucuronidation ratio) 
5.85 0.78-37.57 7.32 1-24.07 
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Table 2. Univariate analyses of the associations between genetic variants and 
phenotypes. Data were adjusted for age, sex, and dose (mg/m2). ANC nadir was also 
adjusted for baseline ANC. The genotype reference groups were the same for all discovery 
and replication cohort analyses, with the exception of ABCC1 IVS11 -48C>T and ANC nadir. 
For ABCC1 IVS11 -48C>T and ANC nadir in the replication cohort, the reference genotype 
was only CC, as there were no TT genotypes. The estimates of effect of replicated variants 
are denoted in bold. The number of patients genotyped per variant in the replication cohort 
varied due to insufficient DNA quantity. *Although the association between ABCC1 
1684T>C (dominant model) and glucuronidation ratio satisfies our criteria for replication, we 
are less convinced of the association, given the 84% reduction in the magnitude of the 
estimate as compared to that of the discovery cohort. Abbreviation: Ref = Reference.  
 
 Discovery Cohort (n=67) Replication Cohort (n=74-103) 
Variant Ref Estimate±SE 95% CI 
P-
value 
n Estimate±SE P-value 
Log10 ANC Nadir 
ABCC1 IVS11 -
48  
(C>T)  
CC/CT -0.489±0.201 
(-0.095, -
0.883) 
0.018 74 0.053±0.117 0.652 
UGT1A1*28 
(TA6>TA7) 
*1*1=1 
*1*28=2 
*28*28=3 
-0.257±0.061 
(-0.137, -
0.377) 
<0.001 75 -0.139±0.081 0.090 
UGT1A1*93 
(G>A) 
GG/AG -0.607±0.129 
(-0.354, -
0.860) 
<0.001 103 -0.417±0.170 0.016 
SLCO1B1*1b 
(A>G) 
AA 0.240±0.106 (0.032, 0.448) 0.027 84 0.278±0.107 0.012 
Log10 irinotecan AUC0-24 
ABCC2 -24 
(C>T) 
CC 0.090±0.035 (0.021, 0.159) 0.012 94 0.067±0.030 0.040 
SLCO1B1*5 
(T>C) 
 
TT 0.084±0.036 (0.013, 0.155) 0.023 83 -0.010±0.035 0.769 
Log10 SN-38 AUC0-24 
UGT1A1*28 
(TA6>TA7) 
*1*1=1 
*1*28=2 
*28*28=3 
0.140±0.046 (0.050, 0.190) 0.004 75 0.189±0.043 <0.001 
UGT1A1*93 
(G>A) 
GG=1 
AG=2 
AA=3 
0.130±0.047 (0.038, 0.222) 0.007 103 0.171±0.033 <0.001 
ABCB1 IVS9 -44  
(A>G) 
AA -0.180±0.070 
(-0.043, -
0.317) 
0.013 77 0.021±0.054 0.703 
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Log10 SN-38G AUC0-24 
ABCC2 3972  
(C>T) 
CC/CT 0.250±0.100 (0.054, 0.446) 0.019 105 -0.104±0.086 0.232 
Log10 SN-38G AUC0-24 /Log10 SN-38 AUC0-24 
ABCC1 1684  
(T>C) 
TT -0.316±0.153 
(-0.016, -
0.616) 
0.043 95 -0.052±0.059* 0.382 
UGT1A1*28 
(TA6>TA7) 
*1*1=1 
*1*28=2 
*28*28=3 
-0.170±0.048 
(-0.076, -
0.264) 
<0.001 103 -0.243±0.053 <0.001 
UGT1A1*93 
(G>A) 
GG=1 
AG=2 
AA=3 
-0.150±0.051 
(-0.050, -
0.250) 
0.004 75 -0.214±0.042 <0.001 
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Table A2.S1. Allele and genotype frequencies of the nine variants genotyped in both the 
discovery and the replication cohorts. In the replication cohort, DNA was insufficient to 
genotype the nine variants in all patients; therefore, the number of genotyped patients varies 
by variant.  HWE=Hardy Weinberg Equilibrium; MAF=minor allele frequency 
  
 
Discovery Cohort  
(n=67) 
Replication Cohort 
 (n=74-104) 
Gene Variant (rs#) Function N (%) MAF HWE N (%) MAF HWE 
ABCB1 
IVS9 -44 A>G 
(rs10276036) 
Intronic  0.46 0.01 77 0.35 0.82 
AA   25 (37)   32 (41)   
AG   23 (34)   36 (47)   
GG   19 (28)   9 (12)   
ABCC1 
IVS11 -48 C>T 
(rs3765129) 
Intronic  0.17 0.08 74 0.17 0.08 
CC   48 (72)   49 (66)   
CT   15 (22)   25 (34)   
TT   4 (6)   0 (0)   
ABCC1 
1684 T>C 
(rs35605) 
Synonymous,  
Exon 13 
 0.23 0.78 95 0.22 0.03 
TT   40 (60)   54 (57)   
TC   23 (34)   40 (42)   
CC   4 (6)   1 (1)   
ABCC2 
-24 C>T 
(rs717620) 
5’ UTR  0.18 0.34 94 0.17 0.21 
CC   44 (66)   63 (67)   
CT   22 (33)   30 (32)   
TT   1 (1)   1 (1)   
ABCC2 
3972C>T 
(rs3740066) 
Synonymous,  
Exon 28 
 0.34 0.81 104 0.36 0.84 
CC   30 (45)   43 (41)   
CT   29 (43)   47 (45)   
TT   8 (12)   14 (14)   
SLCO1B1*1
b 
388 A>G 
(rs2306283) 
Nonsynonymous, 
Exon 5 (N130D) 
 0.46 0.58 84 0.40 0.73 
AA   21 (31)   29 (35)   
AG   31 (46)   42 (50)   
GG   15 (22)   13 (15)   
SLCO1B1*5 
521 T>C 
(rs4149056) 
Nonsynonymous, 
Exon 6 (V174A) 
 0.19 0.79 83 0.13 0.74 
TT   44 (66)   63 (76)   
TC   21 (31)   19 (23)   
CC   2 (3)   1 (1)   
UGT1A1*93 
-3156 G>A 
(rs10929302) 
Intronic  0.32 0.24 103 0.28 0.57 
GG   33 (49)   52 (50)   
GA   25 (37)   44 (43)   
AA   9 (13)   7 (7)   
UGT1A1*28 
TA6>TA7 
(rs8175347) 
TA repeat,  
Promoter 
 0.34 0.25 75 0.33 0.11 
*1/*1   31 (46)   31 (41)   
*1/*28   26 (39)   39 (52)   
*28/*28   10 (15)   5 (7)   
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FIGURES 
Figure A2.1.  Associations between SLCO1B1*1b and ANC nadir (A), UGT1A1*93 and 
ANC nadir (B), and ABCC2 -24C>T and log10 irinotecan AUC0-24 (C) in the replication 
cohort. For the purpose of illustrating the replicated genetic associations, the data are not 
adjusted for the same factors used in the univariate analyses, and the differences among 
genotypes might not be the same as the ones reported in Table A2.2. ANC nadir is 
normalized to the baseline pretreatment ANC. Data are expressed as medians, 25th and 75th 
percentiles, minimums and maximums.  
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